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DESIGN OF INORGANIC PEPTIDE BONDED FUSION BIOMOLECULES 
FOR TRACKING DISEASE RELATED PROTEINS 
SUMMARY 
Detecting disease-related antigens could save lives; Therefore, researchers are 
constantly in an urgency to find ways for increasing sensitivity as well as speeding 
up detection. First, the substrates used for colorimetric reaction were replaced with 
the chemiluminescent ones allowing a more sensitive detection in a shorter time. 
Next, the reducing the number of detection steps was targeted.  Simulatenously, 
single step detection strategies were developed by introducing covalent coupling of 
the fluorescent molecules or by bioconjugating fluorescence proteins to the antibody. 
Due to the restricted orientation control in these approaches, novel protocols are 
constantly being searched to improve the diagnostic systems. 
Surface Plasmon Resonance (SPR) spectroscopy is a label-free technique offering 
real-time monitoring of noncovalent interactions of protein-protein, protein-DNA 
and many other biomacromolecules in relatively short times. The principle relies on 
an electron charge density that arises at the surface of a metallic film, e.g. gold and 
silver, when the collective oscillation of the electrons is stimulated by incident light. 
The adsorption of the molecules detected as a refractive index change at the metal 
film surface. Since the interactions followed by the variation of plasmon resonance 
on the sensing surface of the chip, no label such as enzyme or fluorescent molecules 
are necessary.  
Despite the success of SPR based detection systems, they have several drawbacks. 
Proteins or antibodies, which are used as capture agents, must be covalently coupled 
to the gold surface via chemical reactions. And the second drawback which is also 
present in ELISA-based detection systems is the coating of the capture molecules 
without any orientation control. In biological systems, molecular structure is the key 
to the functionality, any obstruction due to disorientation may affect the detection 
efficiency immensely. 
This study focuses on developing a novel approach to enhance the adsorption of the 
antibodies by controlling their binding on SPR chips. This approach eliminates the 
covalently coupling of the capture molecules. Furthermore, it provides the capture 
molecules to be biologically self-assembled to the sensing surface in an oriented 
manner. As a case study, we used Hepatitis B virus surface antigen as the disease-
tracking target to create self-assembled sensing surface. 
Hepatitis B virus (HBV) is one of the major causes of chronic Hepatitis, cirrhosis and 
liver cancer (hepatocellular carcinoma, HCC). According to World Health 
Organization (WHO) the number of infected people is about 2 billion. From these 
infected people approximately 240 million are chronically infected, and about 
600,000 people die  every year due to the consequences of HBV. HBV infects human 
hepatocytes, which results in the release of infectious virions and excessive hepatitis 
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B surface antigens (HBsAg) to the blood stream. Therefore, the presence of HBsAg 
in circulating blood is an indicator of HBV infection. The HBsAg specific ELISA 
kits are routinely used throughout the world for the detection of HBV infection. 
Nevertheless, this method requires a second anti-HBsAg antibody, which is different 
from the HBsAg capture antibody, and it requires approximately 3 hours for the 
detection of HBsAg. Consequently, HBsAg detection was selected as a model to 
develop our novel SPR based biosensor strategy.  
For this purpose, an anti-HBsAg single chain variable fragment (scFv) recombinant 
antibody was first developed by the Immunogenetics Laboratory (Genetic 
Engineering and Biotechnology Institute, Marmara Research Center)  This antibody 
was then genetically fused with a gold binding peptides (GBP1) characterized by 
Tamerler’s group. The bifunctional recombinant antibody contains both gold 
bindings as well as anti-HBsAg was successfully generated and used as a biosensing 
probe. The probe molecule was demonstrated to biologically self-assemble on the 
surface in a single step process. With this probe, we detected HBsAg  using and SPR 
spectroscopy, resulting an equilibrium dissociation constant of 0,6 nM.  
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HASTALIKLA İLİŞKİLİ PROTEİNLERİN İZLENMESİNDE ANORGANİK 
PEPTİT BAĞLARLA FÜZYON BİYOMOLEKÜLLERİN TASARIMI 
ÖZET 
Hastalıklarla ilişki antijenlerin belirlenebilmesi hayat kurtarır. Bu nedenle 
araştırmacılar sürekli olarak daha hassas ve hızlı tanı sistemleri geliştirmek için 
çalışmaktadırlar. İlk olarak, ELISA yöntemi gibi tanı sistemlerinde standart olarak 
kullanılan kolorimetrik substratlar daha hassas ve hızlı görüntüleme sağlayan 
kemilüminesan subtratlar ile değiştirilmeye başlanmıştır. Bazı çalışmalar ise tanı 
sistemlerindeki aşamaların azaltılması konusuna yönelmiştir. Algılayıcı moleküller 
olan antikorlara kovalent olarak bağlanmış kuantum dot’lar gibi floresan moleküller 
veya genetik füzyon olarak bağlanmış yeşil floresans protein (GFP) aracılığıyla tek 
aşamalı tanı sistemleri geliştirilmiştir. Günümüzde ise farklı tanı stratejilerin ile yeni 
cihazların geliştirilmesi söz konusu olmaktadır. 
Yüzey plazmon rezonans (SPR) spektrometreleri protein-protein etkileşimlerini 
gerçek zamanda takip etmeyi sağlayan cihazlardır. Bu cihazlar sayesinde protein-
protein etkileşimlerinin kinetik hesaplamalarının yapılması dışında ayrıca daha kesin 
sonuçlar elde edilmesini sağlanmaktadır. SPR cihazların temeli SPR çipi yüzeyinde 
bulanan ince altın tabakasının yaydığı yüzey plazmon rezonanslarına dayanmaktadır. 
SPR çipinin alt tarafında bulunan bir prizmanın içerisinden geçen bir ışık süzmesi 
gönderilmektedir. Işık süzmesinin altın tabakaya çarptıktan sonra ışık süzmesinin 
yansıma açısı ölçülmektedir. SPR çipi üzerinde proteinlerin geçişi sağlandığı zaman 
çip yüzeyine bağlanan proteinler altın tabakanın yaydığı yüzey plazmon rezonansını 
etkileyerek ışık süzmesinin yansıma açısını değiştirmektedir. Ölçülen yansıma 
açısındaki değişiklik çip yüzeyinde bağlanan protein miktarı ile doğru orantıda 
olmasından dolayı çip yüzeyinde etkileşime giren protein miktarı 
belirlenebilmektedir. Protein-protein etkileşimleri,  SPR çipi yüzeyinde oluşan yüzey 
plazmon rezonans değişimine dayalı olması nedeniyle diğer tanı sistemlerinde 
gereken enzim veya floresans molekül gibi işaretleyici moleküller ihtiyaç 
duyulmaması SPR’a dayalı tanı sistemlerinin en büyük avantajıdır. 
SPR temelli tanı sistemleri umut vaat edici olmalarına karşın birkaç dezavantajları 
bulunmaktadır. Protein-protein etkileşimlerinin incelenebilmesi için öncelikle bir 
proteinin altın kaplı çip yüzeyine bağlanması gerekmektedir. Bu bağlama işlemi, 
öncelikle çip yüzeyinde bulunan altın tabakasının kullanım türüne göre farklı 
kimyasal kaplama molekülleri ile protein bağlaması için aktif hale getirilmesi 
gerekmektedir. Daha sonra da proteinlerin amino veya karboksi gruplarından 
bağlamak için ayrıca kimyasal reaksiyonlar gerekmektedir. Uygulanan bu kimyasal 
reaksiyonların bağlanacak proteinler üzerinde olumsuz etki gösterebileceği göz ardı 
edilemez. Diğer dezavantaj ise ELISA için de geçerli olmakla birlikte çip yüzeyine 
bağlanan proteinlerin yönlendirilmemiş olmasıdır. Bu nedenle bazı proteinlerin diğer 
proteinlere bağlanma bölgeleri, oluşturulan bağ nedenliyle perdelenmiş olur ve hedef 
molekülün tanısında veri kaybına neden olabilmektedir. 
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Bu çalışma, kimyasal reaksiyonlar kullanmadan ve kendilerini yönlendirmiş bir 
şekilde SPR çipi yüzeyine bağlayabilen antikor yapıların geliştirilmesine 
odaklanarak SPR’a dayalı tanı sistemlerinde bir iyileştirilmeye gidilmesini 
hedeflemektedir. Hastalıklarla ilişkili proteinlerin takibinin yapılması için 
tasarlanacak sistem için model olarak Hepatit B virüsü yüzey antijenine bağlama 
özelliği olan bir rekombinant bir antikor kullanılacaktır. 
Hepatit B virüsü (HBV), Kronik Hepatit, siroz ve karaciğer kanserinin (hepatoselüler 
karsinoma, HCC) başlıca sebeplerindendir. Dünya sağlık örgütüne göre yaklaşık 2 
milyar kişi HBV tarafından enfekte edilmiş ve enfekte edilen kişilerden 240 
milyonunun enfeksiyonu kronikleşmiş durumdadır. Her yıl yaklaşık 600.000 kişi 
HBV’ye dayalı hastalıklardan hayatını kaybetmektedir. 
HBV, insan hepatositlerini enfekte ederek enfeksiyöz virionların ve yoğun miktarda 
hepatit B yüzey S antijeninin (HBsAg) kan dolaşım sistemine bırakılmasına neden 
olmaktadır. Bu nedenle dolaşım sisteminde HBsAg’nin varlığı HBV enfeksiyonu 
belirtecidir. 
HBV enfeksiyonu rutin olarak HBsAg’ye spesifik ELISA kitleri ile belirlenmektedir. 
Bu kitler dünya çapında yaygın olarak kullanılmaktadır. Fakat, bu kitler kullanılarak 
HBsAg varlığı ancak 3 saat gibi bir sürede tespit edilebilmektedir. Daha da önemlisi 
bu tür tanı sistemlerinde  algılayıcı bir anti-HBsAg dışında bir de işaretleme için 
farklı bir anti-HBsAg antikoru gerekmektedir. Bu sebepten dolayı kitlerin maliyetini 
artırmaktadır. Bu nedenlerden dolayı oluşturulmak istenen yeni SPR temelli 
biyosensör stratejisi için HBV enfeksiyonu tanısı model olarak seçilmiştir.  
Bu kapsamda, öncelikle HBsAg’ye bağlanma özelliği olan rekombinant antikor 
geliştirmek amacıyla Faj gösterim teknolojisi kullanılmıştır. Faj gösterim teknolojisi 
ile rekombinant antikor geliştirmek için standart olarak deney farelerinin saf hedef 
antijen ile bağışıklanması gerekmektedir. Bu çalışmada ise, ilk yenilikçi yaklaşım 
olarak maliyeti yüksek olabilecek saf antijenlerin kullanılmasından ziyade 
bağışıklamalar için yüzeyinde HBsAg’yi sunan bakteriyofajlar kullanarak farelerin 
bağışıklanmasını sağlamak olmuştur. Fajların, hayvan bağışıklama çalışmalarında 
adjüvan olarak kullanıldığı bilinmektedir. TÜBİTAK Hayvan Deneyleri Yerel Etik 
Kurulundan onay alındıktan sonra Hepatit B yüzey antijeni geni polimeraz zincir 
reaksiyonu (PZR) ile çoğaltılmış ve bir fajmit vektöre klonlanmıştır.  Sonrasında E. 
coli TG1 suşuna rekombinant vektör kimyasal transformasyon ile aktarılmıştır. Daha 
sonra HBsAg’nin faj yüzeyinde expresyonu sağlanmış ve bu fajlar fare 
bağışıklamasında kullanılmıştır. Ardı ardına yüzeyinde HBsAg sunan fajlar ile 
yapılan üç enjeksiyon sonrasında farelerin oluşturduğu anti-HBsAg immün yanıta 
ELISA (Enzyme-linked immunosorbant assay) yöntemi ile bakılmıştır. Yapılan 
enjeksiyonlar sonucunda farelerde immün yanıt oluştuğu gösterilmiştir. Bu 
çalışmalar Uluslararası atıf endeksine giren “Advances in Biosciences and 
Biotechnology” dergisinde yayınlanmıştır.  
Bağışıklama sürecinden sonra immün yanıt gösteren farelerin dalağı alınmış ve  
antikor üreten B lenfositlerinden RNA izolasyonu yapılmıştır. RNA’ların cDNA’ya 
çevrilmesiyle bir cDNA kütüphanesi oluşturulmuştur.  PZR yöntemi ile cDNA 
kütüphanesinden antikor ağır ve hafif değişken bölgeleri çoğaltılmış ve tek zincir 
rekombinant antikor (single chain variable fragment, scFv) gen kütüphanesi 
oluşturulmuştur. Elde edilen kütüphane fajmit vektöre klonlanmış ve E. coli TG1 
bakterilerine kimyasal transformasyon ile aktarılmıştır. Daha sonra yüzeylerinde 
antikor kütüphanesi sunan fajlar elde edilmiş ve bu kütüphane HBsAg’ye karşı 
xxvii 
 
taranmıştır (Biopanning). HBsAg’ye bağlanan fajlar seçilmiş ve tekrar bir 
biopanning aşamasından geçilerek kütüphanesinin zenginleşmesi sağlanmıştır. Üç 
zenginleştirme aşamasından sonra faj klonlarının ayrı ayrı HBsAg’ye bağlanmaları 
ELISA ile kontrol edilmiştir. HBsAg’ye bağlanma özelliği olan antikorlar seçilmiş 
olmasına karşın TÜBİTAK Marmara Araştırma Merkezi Gen Mühendisliği ve 
Biyoteknoloji Enstitüsü immünogenetik Laboratuarında daha önceden 
oluşturduğumuz Lig7 anti-HBsAg rekombinant antikoru kadar iyi bağlanma 
göstermediklerinden biyosensör çalışmalarına Lig7 antikoru ile devam edilmesine 
karar verilmiştir. 
Lig7 antikoru PZR ile çoğaltıldıktan sonra pQE2 bakteriyel ekspresyon vektörüne 
klonlanmıştır. Bu ekspresyon vektörünün özelliği, protein saflaştırma çalışmalarında 
kolaylık sağlayan Histidin kuyruğunun (His-Tag) daha sonra Histidin kuyruğu ile 
protein arasına yerleştirilmiş proteaz kesim bölgesi sayesinde Histidin kuyruğunun 
çıkarılabilmesidir. Bu sayede üretilen proteinin orijinal yapısına en yakın olabilecek 
şekli elde edilebilmektedir. Lig7 geni pQE2 vektörüne klonlandıktan sonra genetik 
füzyon olacak şekilde Prof. Dr. Candan TAMERLER ve grubunun (Moleküler 
Biyoloji- Genetik ve Biyoteknoloji Araştırma Merkezi, İstanbul Teknik Üniversitesi) 
karakterize etmiş olduğu altına bağlanma özelliği olan GBP1’yi (Gold Binding 
Peptide-1) kodlayan gen rekombinant vektöre klonlanmıştır. Klonlamalar sonrasında 
genetik füzyon yapı DNA dizi analizi ile kontrol edilmiş ve üç farklı füzyon yapı 
belirlenmiştir. Bu genetik füzyonların, Lig7 ile birleşmiş farklı GBP1 tekrarlarından 
(tek GBP1, 3’lü tekrar ve 5’li tekrar) olduğu tespit edilmiştir. Lig7 antikoru ile üç 
Lig7 GBP1 füzyon yapıları eksprese edilmiş ve His-tag aracılığı ile saflaştırılmıştır. 
Saflaştırılan altına bağlanma özelliği kazandırılmış anti-HBsAg bifonksiyonel 
rekombinant antikorların altın kaplı SPR çiplerine bağlanmaları Reichert SPR 
spektrometresiyle kontrol edilmiş ve bağlanmaları teyit edilmiştir. Daha sonra, çip 
yüzeyine yönlendirilmiş şekilde bağlanmış bifonksiyonel antikorların HBsAg’yi 
bağlama özellikleri yine SPR spektrometresiyle kontrol edilmiş ve HBsAg’nin çip 
yüzeyine tutulduğu gösterilmiştir. 
SPR spektrometresi ile yapılan kinetic çalışmalar sonucunda Lig7-GBP1, Lig7-
3GBP ve Lig7-5GBP füzyon antikorlarının altına bağlanma kinetiği çok farklılık 
göstermemesine karşın GBP1 tekrar sayısının HBsAg’nin bağlanması açısından 
kayda değer farklılıklar gösterdiği tespit edilmiştir. Füzyon antikor yapılarının 
HBsAg için denge ayrışma sabitleri Lig7-GBP1, Lig7-GBP3 ve Lig7-5GBP için 
sırasıyla 315 nM, 30 nM ve 0,6 nM olarak belirlenmiştir. Bu değerlere bakıldığında 
GBP1 tekrarının artmasıyla antikorun HBsAg’ye olan “afinitesinin” arttığı 
görülmüştür.  Ancak anti-HBsAg Lig7 antikoru her bir füzyon yapı için aynı 
olduğundan bağlanmadaki bu farkın antikorun HBsAg’nin bağlanmasına ne kadar 
elverişli olduğunun bir göstergesi olarak kabul edilmiştir. Bu nedenle altın çip 
yüzeyine yönlendirilmiş şekilde adsorbe edilmiş Lig7-5GBP bifonksiyonel antikorun 
konformasyonel olarak diğer iki antikora göre HBsAg’yi bağlamak için daha uygun 
olduğu görülmüştür. Antikorların altına bağlanma kinetiklerinin yaklaşık aynı olduğu 
düşünülürse tekrar sayınının altına bağlanma özelliğini arttırmasından çok, anti-
HBsAg Lig7 antikorunun uygun konformasyonda sunulmasında etkili olduğu 
gözlemlenmiştir. Kimyasal bağlar oluşturarak SPR çipi üzerine bağlanmış Lig7’nin 
HBsAg’yi bağlama denge ayrışma sabitinin 31,4 nM olduğu hesaplanmıştır. Bu 
değerin, Lig7-3GBP’nin HBsAg için olan denge ayrışma sabiti ile yaklaşık aynı 
olduğu, Lig7-GBP ile karşılaştırıldığında ise daha düşük olduğu görülmüştür. Fakat 
Lig7-5GBP’nin HBsAg’ye olan afinitesinin kimyasal olarak bağlanmış Lig7’den de 
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yaklaşık 50 kat daha iyi olduğu görülmüştür. Bu sonuçlar da, tez çalışmalarının 
dayandığı, bifonksiyonel rekombinant antikorların yönlendirilmiş şekilde altın kaplı 
SPR çiplerinin üzerine kaplanarak SPR sistemlerinde biyosensör uygulamalarının 
iyileştirilmesi hipotezinin doğruluğunu göstermiştir. 
Sonuç olarak bu çalışmada, genetik olarak altına bağlanma özelliği kazandırılmış bir 
rekombinant antikorun yönlendirilmiş bir şekilde altın kaplı SPR Çipleri yüzeyine 
bağlandığı gösterilmiş, ve bu antikorun SPR spektrometresine dayalı tanı 
sistemlerinde kullanılabileceği ve hatta bir iyileştirme sağladığı gösterilmiştir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
1.  INTRODUCTION 
The detection of disease-related proteins can save lives. Tracking these proteins is 
crucial for the diagnosis and the prognosis of the diseases. There is a race between 
companies for the development of more sensitive, selective and cost-effective 
detection systems than the gold standard; the Enzyme-linked Immunosorbent Assay 
(ELISA). ELISA is a well-established detection method widely used all around the 
world since its development (Van Weemen, 1971). Since technology evolves rapidly, 
especially in the microfluidic field, new detection systems with higher performance 
are expected from the field. Therefore, the development of  new cost and time 
effective devices with higher selectivity has a great importance. The interface 
between the sensor device and the target molecule is one of the key element for 
improving the detection systems.  
Here, will be discussed the two components of immunosensors, the transducers, the 
biosensing probes and the interface between transducers and biosensing probes, the 
most important and challenging part.   
Then a new way of thinking for attaching biomolecules on solid surfaces by self-
assembly for tracking disease related proteins will be defined. The hypothesis will be 
transposed to the development a new biosensing interface for the surface antigen 
detection of the Hepatitis B virus (HBV), the major cause of chronic hepatitis, 
cirrhosis and liver cancer.  
1.1 Immunosensors 
Immunosensors correspond to a small section of  the biosensors family which are 
devices developed for the detection of a variety of molecules in a defined 
environment (Morgan, 1996). In a general view, biosensors are composed of two 
elements, the bioreceptor, the recognition element and the transducer which converts 
the recognition event into a measurable signal (Morgan, 1996). A wide variety of 
transducer technology is used in biosensor systems, such as electrochemical 
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biosensors (potentiometric, amperometric or conductometric), piezoelectric 
biosensors (crystal resonance frequency, surface transverse wave or surface acoustic 
wave), optical biosensors (surface plasmon resonance, fiber optic, light addressable 
potentiometric, bioluminescent or resonant mirror) and thermistor biosensors. 
Bioreceptors are biological entities able to detect, sense different type of molecules 
such as glucose, antigens, antibodies, proteins, toxins. Some examples of 
bioreceptors from many others can be given. Enzymes can catalyze an analyte into a 
detectable product, or they can be inhibited by the catalyst. Nucleic acids (aptamers) 
can be used as a sensing probe for the detection of ligands, also whole cells can be 
used for monitoring the apoptotic or proliferative effects of analytes or proteins on 
cells. Non-enzymatic proteins such as receptor present in cells or proteins implicated 
in different cell signaling  pathways are other examples of bioreceptor. However,  the 
most widely and commonly used recognition molecules are the antibodies or the 
antigens (Homola, 2008). 
Immunosensors are biosensors in which the bioreceptors consist of an antigen or an 
antibody. Depending on the detection purpose, a wide variety of antibodies or 
antigens are present on the market. Medical diagnostic markers (hormones, steroids), 
drugs (therapeutic and abused), bacteria, environmental pollutants (pesticides)  can 
be detected by using an appropriate antibodies (Elliott, 2001; Murugaiyan, 2014; 
Yanez-Sedeno, 2014). Antibodies and antigens are used for the detection of their 
complementary partners for many years for immunological detection systems 
(Immunoassays); they are the key elements for the sensitivity and the selectivity of 
these detection systems. ELISA is the predominant analytical technique for 
quantitative measurement and is considered as “gold standard” for most of the 
detection systems (de la Rica, 2012; Zhao, 2013). However,  other methods such as 
immunoblotting and immunochromatography base detection systems are commonly 
used for detection (Gopinath, 2014). These immunoassay methods have high 
specificity and selectivity and have a broad biological matrices panel owning these 
properties to the chemical binding and the spatial conformation of antibodies (Van 
Weemen, 1971; Gopinath, 2014). These methods are also easy to interpret with a 
minimum training which is one of the most desired property for detection systems.  
Unfortunately, these immunoassay have some drawbacks such as the necessity of 
many antibodies, a time-consuming experimental process (except for the 
immunochromatography) and the lack of multiplex detection possibility. Some 
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improvement in immunoassay methods have been performed with the technological 
development in the field of fluorescence, chemiluminescence emissions detections 
systems. They have allowed the increase of sensitivity of the immunoassays such as 
the detection of prostate specific antigen or cardiac biomarkers (Oh, 2009; Kim, 
2014; Wang 2013).  Improvements regarding immunoassays are still going on, 
recently a microfluidic immunoblotting method was developed for profiling 
inflammatory responses. Also, a plasmonic ELISA system allowing ultrasensitive 
detection with the naked eyes of prostate serum albumin (PSA) and HIV-1 capsid 
antigen p24 was developed (de la Rica, 2012).  
The fundamental principal of immunoassay consists about the immobilization of 
antibodies or antigens to be detected on a Solid phase matrice which facilitates the 
separation and washing steps during the experiments.  Then,  the complementary 
antigen or the antibody conjugated with a wide range of labels, such as radioisotopes, 
fluorescent and luminescent molecules, light scattering molecules, enzymes are 
detected (Gopinath, 2014). Sandwich ELISA and immunochromatography systems 
have an extra layer of a second bioreceptor allowing the immobilization of the target 
molecules on a solid support thus increasing the selectivity and sensitivity of the 
detection (Pei, 2012).   
Immunosensors, like immunoassays, detect antibody – antigen interactions. 
However, in contrary to immunoassays the detection of the binding is directly 
intercepted by the transducer integrated with the device. Therefore, allowing a real-
time monitoring of the binding interactions. This real-time monitoring is supported 
by means of the development of fluidics systems. Real-time monitoring of antibody- 
antigen interactions makes possible the determination of the binding kinetics. 
Immunosensors have also, other advantages such as the possibility of multiplexing 
the detection molecules. They offer the opportunity of regenerating the sensor 
surface enabling the its reuse the for several times (Vaisocherova, 2009). 
Various immunosensors with different transducer systems have been developed and 
are used for different purposes. Electrochemical immunosensors are based on the 
recognition of electrochemical signal variations generated between the electrodes 
during the interaction the antibody and antigen interaction. The advantages of 
electrochemical immunosensors are the possibility of easily miniaturizing the 
electrodes and the possibility of their mass production. Four groups of 
electrochemical immunosensor can be sited such as potentiometric, impedimetric, 
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conductometric  and amperometric immunosensors, the later being the most to be 
used. Most of the electrochemical immunosensors applications are focused on the 
detection of small molecules especially in the fields of environmental pollution due 
the portability, the direct identification and quantification of compounds of this kind 
of sensors. Recently, an electrochemical immunosensor intended to determine 
alcohol consumption was developed. The Ethyl glucuronide molecule, a biomarker 
for alcohol consumption, produced by the nonoxidative ethanol metabolism was 
detected by an anti-Ethyl glucuronide antibody immobilized on gold electrodes. 
Besides the detection of small molecules electrochemical immunosensors are 
recently being used for the detection of mouse or goat antibodies from sera or 
microorganisms such Francisella, Salmonella, Escherichia and Bacillus (Skladal, 
2013). 
Another immunosensor type using different transducer systems is the piezoelectric 
immunosensor such as quartz crystal microbalance. The first piezoelectric sensors 
were used as gas phase sensors then the system was adapted to the detection in the 
liquid phase enlarging its properties to the detection of biomolecules. The system 
consists on the detection of mass transfer on the gold electrodes by monitoring the 
frequency of its quartz crystal resonator. Briefly, an alternating current between the 
piezoelectric sensor causes the oscillation of the quartz crystal which is detected as a 
frequency signal. Once a molecule such as a bioreceptor is conjugated to the gold 
electrodes the change in the frequency allows the determination of mass density of 
the bioreceptor. Overflown analytes on  bioreceptors conjugated electrodes cause the 
binding of these analytes to their receptor causing again a frequency variation allow 
to determine this time the quantity of analytes bound to the bioreceptor. The 
monitoring of dissipation (QCM-D) offering to the system to give information about 
the viscoelasticity of the samples was integrated in year 1996. Several examples 
regarding the applications of piezoelectric immunosensors were given by Gopinath 
(2014) such as the detection of IgG or the alanine aminotransferase enzyme 
(Gopinath, 2014; Wu, 2011; Zhang, 2008). Recently, a piezoelectric immunosensor 
system was developed for the detection of a mutagenic and carcinogenic molecule 
frequently used in agriculture, the 2,4-dichlorophenoxyacetic acid. The detection of 
this small molecule was monitored by enhancing the response signal by  the use of 
gold nanoparticles. Therefore, researches related to the improvement of piezoelectric 
immunosensors are still going on.  
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The last type and the most commonly used immunosensors are the optical 
immunosensor which will be discussed below in more details.  
1.1.1 Optical immunosensors 
Optical immunosensors uses optical transducers which are designed to detect linear 
optical phenomenon such as adsorption, polarization, rotation, interference, 
bioluminescence and chemiluminescence, but also non-linear phenomena such as 
harmonic generation.  
Early optical systems were based on spectrophotometry measurements. Enzymes 
were immobilized on columns, and the absorbance change generated in the local 
environment caused by the catalysis of the enzymes substrate. Later on, reagent 
phase was immobilized on the sensor surface, and a change in optical properties due 
to the binding of the analytes was monitored (Murugaiyan, 2014). 
The lack of requirement of reference electrode, the increased versatility, the speed 
and the reproducibility of the measurements have made of the optical immunosensor 
systems the most suitable detection systems for clinical applications, in vivo 
monitoring and the measurement of hazardous materials. The main drawback of 
optical immunosensors is the cost and the dimension of the devices, which are under 
investigation for the development of cost-effective devices with smaller dimensions. 
Optical immunosensors can be divided into two groups the one which need labelled 
antibodies or antigens and the one which can perform a label-free detection. 
1.1.1.1 Optical sensors using labels 
Some immunosensors are designed to monitor fluorescence; luminescence such as 
bioluminescence and chemiluminescence generated from labels integrated to the 
detection process (Chen, 2010; Gopinath, 2014). Luminol-peroxidase reaction can be 
shown as one example for chemiluminescence sensing where the oxidation of  
luminol by horseradish peroxidase produces light that is detected by the appropriate 
optical transducer. This chemiluminescence sensor was used for the detection of an 
endocrine disrupting compound with a possible carcinogenic effect, the 17-β 
estradiol molecule, in natural water and human serum. Chemiluminescence sensors 
were also used for the detection of antibodies, estradiol, total IgG and antigens 
(Starodub, 1994; Seia, 2012, Chen, 2011).  
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These optical labels are mainly used for increasing the detection limits of the target 
molecules. Recently a fluorescent based immunosensor was developed for the 
serodiagnosis of canine Leishmaniasis combining immunomagnetic separation and 
Flow Cytometry. The immunosensor with increased sensitivity was even able to 
detect pathogen-specific antibodies in asymptomatic animals  (Sousa, 2013). 
Even if high sensitivity is acquired with optical labels the indirect optical 
immunosensors have some drawbacks like the replenishment of the luminescence or 
fluorescence during long-term measurement. The necessity of having luminescent 
compound in excess is another drawback regarding the increase of the detection cost 
(Sun; 2014). Moreover,  finally the narrow excitation bands and the broad emission 
bands with red spectral tails of the fluorescent molecules limit the possibility of 
multiplex detection. Quantum dots conjugated to antibodies overcome some of these 
problems. Quantum dots are nanoparticles with stable and intense fluorescence 
allowing multiplex detection; these nanoparticles have been used in different 
diagnostic systems such as carbohydrate or toxins detection. However, the major 
problems of quantum dots are their hydrophobic properties and their toxicity. 
Therefore, an intense optimization of surface functionalisation is necessary for 
stabilizing the particles in a hydrophilic environment and for preventing their toxic 
effects. These restrictions have pushed the researchers to improve label-free 
immunosensor systems already discovered in the 90’s, but under-exploited until the 
years 2000 (Morgan, 1996). Since year 2000, label-free, direct optical sensing 
systems have gained tremendous importance in biomolecular interaction 
characterisation and quantification (Homola, 2008). 
1.1.1.2 Label free optical immunosensors 
Label-free optical immunosensors are based on the monitoring of refractive index 
changes which corresponds to the changes in the dielectric permittivity on the sensor 
surface. Biological molecules such proteins, DNA, cells have a dielectric permittivity 
superior to the air and water causing a reduction of the propagation velocity while 
the electromagnetic fields pass through them. Briefly, a light (a laser, light emitting 
diode, incandescent light bulb) is directed towards the sensing surface and then the 
light beam is either reflected or transmitted through the sensor. The light emerging 
from the device is then monitored. Direct optical sensors have the advantage of  
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being less sophisticated in instrumentation compared to indirect optical sensors 
where in addition to the transducer a fluorescence excitation systems are necessary. 
Therefore, label-free optical immunosensors can be fabricated at lower cost in a 
smaller size compared to the other type of optical immunosensors. 
There is a variety of direct optical sensors such as resonance wave grafting which 
employ the evanescent wave generated by the resonant coupling of light.  
Ellipsometric and oblique incidence reflectivity difference sensors are based on the 
monitoring of changes in phase and magnitude of the reflectivities of polarized  
monochromatic light due to the physical and chemical changes on the sensor chip 
surface.  Reflectometric interference spectroscopy is an other example for label-free 
optical immunosensors. The sensor determines the change in thickness and refractive 
index of the dielectric layer by the interference of the incident light caused by double 
reflection at the surface (Sun, 2014). The last and most commonly used label-free 
optical detection system is the surface plasmon resonance (SPR). The SPR 
immunosensors are discussed in more details in the next section. All these detection 
techniques have several strengths and weaknesses which are described in Table 1.1. 
 
Table 1.1 : Comparison of Label-Free optical immunosensors (Sun, 2014). 
 
 
Techniques 
 
Strengths (Application Suitability) 
 
Weaknesses Max. Throughput 
Surface Plasmon 
Resonance 
 
 Real-time measurements 
 End-point measurements (in 
imaging) 
 Sensitive to conformational 
changes 
Restricted to gold-coated 
surfaces 
 
~400 features 
 
Ellipsometry based OI-
RD 
 
 Real-time measurements 
 End-point measurements (in 
imaging) 
 Not restricted to gold-coated 
surfaces 
 Simple instrumentation 
 Large field of view 
Insensitive to 
conformational changes 
 
Up to tens of 
thousands of features 
 
Reflectometric 
Interference 
Spectroscopy 
 
 Real-time measurements 
 Very high sensitivity 
 Fast determination of binding 
kinetics 
Commercial instruments 
are expensive and 
complex 
 
Compatible with 384-
well microplates 
 
Resonant Cavity  Real-time measurements 
 End-point measurements (in 
imaging) 
Low sensitivity  ~tens of features 
 
Resonant Waveguide 
Grating 
 
 Real-time measurements 
 Fast determination of binding 
kinetics 
Commercial instruments 
are expensive and 
complex 
Compatible with 384-
well microplates 
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1.1.2 SPR spectrometer 
SPR was developed in the early 1990s as a technique for biomolecular interaction 
analysis (Malmqvist, 1993). Since then this technology is continually improving in 
the term of technology and its applications. The variety of molecules that can be 
immobilized on the sensor surface of SPR has allow the device to be used in different 
purposes such as affinity analysis, kinetic analysis, concentration assays, binding 
stoichiometry determination, thermodynamic analysis, study of interaction 
mechanism, routine screening and epitope mapping of peptides, virus particles and 
antibodies. Therefore, SPR biosensors have become key system for the 
characterization and the quantification of biomolecular interactions (Homola, 2008; 
Kim, 2006). Consequently, many publications have been made regarding the 
applications of SPR in the fields of medical diagnostics, environmental monitoring 
and food safety (Sun, 2014; Gopinath, 2014; Xia, 2010). Within all the biosensor 
systems, SPR spectrometers were the first biosensor to be commercialized 
(Englebienne, 2003; Van der Merwe, 2001). The main reason for the great interest in 
SPR is that SPR is a label-free system with very high sensitivity, which provides 
extensive information about the kinetics between two interacting molecules. 
1.1.2.1 Principle 
The SPR technology is based on the excitation ability of surface plasmons present in 
the metal film (Figure 1.1). Surface plasmons can be defined as electrons at the 
surface of a metal that behave differently from those in the bulk of the metal. Even if 
the physical aspect of SPR is quite complicated the principal is quite simple 
(Englebienne, 2003; Homola, 2008). The SPR spectrometer consists of a light 
source, a detector, a transduction surface (usually gold-film), a prism and a flow 
system (Xu, 2010). Briefly a light beam is directed through the layer of higher 
refractive index (prism) to the interface between the high and low (sample) refractive 
index media (Figure 1.1). When the angle of the incident beam exceeds the critical 
angle, the light is totally internally reflected back out of the device. In the material of 
lower refractive index (sample), a high-frequency electromagnetic field is generated, 
known as an evanescent wave. This wave penetrates into the sample medium for a 
short distance with exponentially decreasing amplitude. At the resonance angle (σ), 
the absorption of light energy by the surface plasmons during resonance causes a 
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sharp decrease in the intensity of the reflected light which implies biomolecular 
interactions. The resonance angle is determined by the wavelength and polarization 
state of the incident light, as well as by the refractive indices of the prism, the metal 
and the sample layers of the system. When all factors are maintained constant the 
resonance angle measures the refractive index at the surface of SPR system. 
 
Figure 1.1 : SPR principle (Morgan, 1996). 
Biomolecules which interact, at the gold interface, with the evanescent wave cause a 
reduction in intensity of the reflected light beam. This decrease reflects the changes 
in mass caused by biomolecules adsorbed on the gold layer. Therefore, SPR is a 
noninvasive method which allows real-time monitoring of interactions between 
injected analytes and immobilized biomolecules (Figure 1.2)(Xu, 2010). 
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Figure 1.2 : SPR angle shift caused by antigen binding to antibodies (Xu, 2010). 
1.1.2.2 Real-time monitoring 
Once the sensor slides are ready for the detection, the sample to be analysed is 
injected into the instrument and flow over the sensor surface. When the antigens 
present in the sample bind to the immobilized antibodies (association) (Figure 1.3), 
there is an increase in the refractive index unit (RIU) which can be monitored from 
the computer. In the same way, dissociation of the antigens is monitored, the 
difference of RIU before and after dissociation indicates the presence of  antigen in 
the sample. The slides are then regenerated for further analysis. The data collected 
from the SPR sensograms can be easily transferred to SPR data analysis software 
where the binding kinetics are calculated according to the association and 
dissociation curves. 
 
Figure 1.3 : SPR sensongram (Url-1). 
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1.1.3 Biointerface 
Since many years material sciences, electronics and  biotechnology have evolved in 
their areas and have reached a quite significant level. Unfortunately, it becomes more 
and more difficult to develop a cutting edge discovery in these fields. Then appeared 
the idea of integrating the properties of biological materials to inorganic materials for 
the development of a new generation of materials:  biomaterials.  Even if this concept 
was actually applied for many years in the diagnosis systems, like ELISA, where the 
antibodies or antigens are attached to plastic based ELISA plates, biomaterial field 
has found its place with the development of detection systems and nanotechnology. 
Suddenly, an increasing interest in the biomaterial field has emerged bringing with it 
an immense area to be elucidated, biointerface.  
Biointerface:  A surface forming a common boundary between a cell, a 
biological material and another material. 
An ideal immunosensor is a mobile, cost effective sensor with high sensitivity, high 
accuracy, high selectivity. The development regarding the detection devices was 
cited above, but the manufacturing of a viable immunosensor necessitates correct 
choice of a solid surface and the development of an appropriate surface chemistry for 
the attachment of proteins. The critical part of immunosensors is to preserve the 
integrity, the native conformation and the biological function of the protein to be 
immobilized on the surface. A well orientation immobilized protein would increase 
the efficiency of the immunosensors (Goddard, 2007) as a non-oriented immobilized 
protein would decrease the efficiency. 
Adsorption is the first method for protein immobilization. Adsorption can be done 
physically, physisorption, or chemically, chemisorption, rearrangement of electron 
density between the proteins and the sensor surface. Physisorption consists on the 
formation of weak interactions such as Van der Walls, non-selective ionic, 
electrostatic and hydrophobic interactions. Even if these interactions are enough to 
immobilize the proteins easily on the surface, the immobilization process is 
uncontrolled causing an inhomogeneous orientation of immobilized proteins. Also, 
with time these proteins might unfold for minimizing interfacial interaction energy 
by rearranging hydrophobic domains.  The uncontrolled immobilization process is 
also prone to the immobilization of undesired protein contaminants on the 
immunosensor surface decreasing the sensors efficiency.  
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The immobilization of proteins by covalent bonds is a second approach. This 
approach is the most commonly used method. However,  specific care must be taken 
for a successful immobilization. First of all, proteins functional groups (-COOH, -
NH2, -SH), suitable for immobilization, must be defined. Secondly, an appropriate 
surface functionalization molecule  (spacer) must be determined to preserve the 
integrity of the protein without disturbing its function. Therefore, the amount of 
functionalization molecule must be optimized. Insufficient quantity of 
functionalization molecule might cause a loss of protein activity by placing proteins 
in direct contact with the hydrophobic layer causing uncontrolled adsorption of the 
protein or protein contaminants. Overloaded functional groups might cause steric 
repulsion causing proteins deactivation (Goddard, 2007). The length of the spacer is 
another factor influencing the conformation of the protein. The longer the spacer is, 
the higher is the protein load on the immunosensor surface and the better is the 
conformational integrity; Therefore, the better is the immunosensor sensitivity 
(Hosseini, 2014). 
Other surface functionalization methods such as sol-gel method, a relatively mild 
procedure consisting of entrapping protein in the swelling gel network can be cited. 
Even if this method confers an improved resistance of proteins toward chemical and 
thermal denaturation, and have a high protein loading capacity, the method have also 
many disadvantages.  For example, the possibility of a direct contact of the protein 
with the sensor surface can cause protein deactivation because of the surface 
hydrophobicity.  Another problem is that there is no intermolecular interaction 
between the gel and the surface, therefore, a good functionalization in necessary 
(Prashar, 2012). The protein immobilization is uncontrolled, therefore, the proteins 
are not oriented, and contaminant proteins might be co-entrapped with the target 
protein. Finally, sol-gel method produces toxic wastes that might cause an 
environmental problem on an industrial scale.  
Plasma treatment compared to sol-gel is not toxic, and no corrosive solvents are 
needed. This method allows the deposition of an extra thin uniform functional 
coating of different shapes, surface charges, surface hydrophylicities allowing 
efficient protein immobilization on sensor surfaces.Many biological applications. 
However, this method has some drawbacks such as the loss or re-orientation of 
functional groups,  and surface ageing related to storage conditions. The method 
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based on vacuum technology requires a strict process control regarding the risk of 
contamination the reproducibility problems (Prashar, 2012). 
Surface functionalization with self-assembling monolayers (SAMs) 
SAMs consist on the spontaneous organization of chemical molecules into a highly 
ordered larger functional structure. They are used as intermediate molecules for 
functionalizing metal surfaces such as gold, platinum, palladium, silver, copper but 
also polymer surfaces such as polystyrene, polydimethylsiloxane (PDMS), 
Polymethacrylate (PMMA), by covalent bonding  (Hosseini, 2014; Arya, 2009). 
SAMs are excellent systems to study interfacial reactions due to the one molecule 
thick layer. Therefore, they are widely used in biotechnology, drug discovery, 
material sciences, polymer synthesis, surface science from full homogeneous 
functionalisation to gradual variation of physicochemical properties (Koepsel, 2012; 
Arya 2009; Nicosia, 2014).  
The formation of ordered films depends on the geometry, the electrostatic and the 
dipole-dipole interactions of the alkane and the tail groups such as acids (-COOH) or 
amines (-NH2) within the monolayer and the affinity of the head functional group 
(Thiols, silanes) to the substrate (Chechik, 2000).  
SAMs are characterized by several methods allowing the detection of surface 
coverage defects. The characterization is made by physical measurement such as 
contact angle and wettability that permit a fast evaluation of the hydrophilicity of the 
SAM, which is necessary for correct protein immobilization. Also, several more 
sophisticated instruments are used for deeper characterization regarding the binding 
efficiency and the surface topology of functionalized immunosensor chip. These 
devices are ellipsometry, X-Ray photon spectroscopy, infrared spectroscopy, QCM, 
surface enhanced Raman spectroscopy, Atomic force microscopy, scanning 
tunneling microscopy, fluorescence spectrometry, SPR (Prashar, 2012). 
Alkanethiol (organosulfur molecule) monolayers on the gold surface are the most 
studied assembling reactions (Prashar, 2012; Nicisia, 2014). Because they form a 
strong bond with gold but thiol SAMs can also be used for other metallic surfaces 
such as platinum, copper, palladium and silver (Arya, 2009).  
Alkanethiolates have an –SH functional head group allowing a strong binding with 
gold. The stability of the thiol SAM depends tremendously with the length of the 
alkane group. Highest organization in SAM was observed with thiol SAM containing 
10 to 20 Carbon atoms (Prashar, 2012). 
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SAMs tail groups give some properties like biocompatibility, corrosion, wettability, 
adhesion, friction, resistance to the interfacial surface (Nicosia, 2014). Three 
functional groups are mainly utilized at the tail terminal. Alkanethiolates containing 
an amino group tail such as the 11-amino-1-undecanethiol  molecule are widely used 
for redox studies The terminal amino group can be activated with acylating reagents 
such as active esters, acid chlorides or quinones. Carboxylalkanethiols are used for 
the immobilization of proteins by forming amide bonds by using carbodiimides such 
as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide (EDC) (Chechik, 2000). Hydroxylalkanethiols are mostly used as 
dilution or blocking reagents to prevent unspecific protein  adsorption for 
immunosensor applications (Prashar, 2012). 
Silane monolayers are used for the  functionalization of glass, silica (SiO2) surface. 
Single Alkylsilane molecules form less perfect layer than thiols, but trifunctional 
silanes have a better SAM formation property, but there is a risk of 3-dimensional 
structure formations. Organosilane SAMs have importance in the photoresist 
industry and the silicon technology. 
SAM looks to have many advantages that make them suiTable for surface 
functionalisation, but they have some considerable drawbacks.  
First of all, SAM fabrication can be labor intense because it forms a stable layer. 
Therefore, contaminant molecules, unwanted by-products or unreacted molecules 
cannot be removed selectively from the surface, causing severe surface impurity 
problems, Therefore, changing the homogeneity of the SAM. This problem is even 
more critical when successive reactions are performed  (Chechik 2000; Koepsel, 
2012). It has been also demonstrated that  sulfur can induce corrosion of Au (111). 
The strong interaction between gold (Au) atoms and sulfur weakened the Au-Au 
interactions. This causes the removal of some Au atoms from the surface and which 
incorporates into the growing 2D phase producing etch pits and irregular shaped au-
Sulfur islands. The stability of SAM is another point to consider, SAMs undergo 
photooxidation during exposure to ultraviolet light that causes the desorption of the 
thiol groups from the surface. The final stability of monolayers for short temperature 
excursions are small compared to typical microfabrication processing conditions 
(Celestin, 2014).  
Also, thiol SAMs on the gold surface are well packed and have a quasi-crystalline 
structure when the tail group has a long alkane chain. However, if bulky and charged 
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groups are incorporated to SAMs disruption of the molecules from the surface due to 
the steric effect and electrostatic repulsion is possible (Chechik, 2000). Another 
problem is the time necessary for the formation of accepTable SAMs. Even if the 
binding of alkanethiols on gold surface is very fast, the time necessary to obtained a 
highly organized compact SAM vary between 12 -18 hours. This can increase up to 
48 hours for 11-mercaptoundecanoic acid (Prashar, 2012; Marques de Oliveira, 
2011). Finally, the most important drawback is that proteins are immobilized on the 
surface in a non-oriented manner causing a severe reduction in the availability of 
proteins functional groups such as the recognition sites of antibodies. In 
consequence, a decrease in the immunosensor efficiency is expected. 
Considering all the defects regarding chemically based material surfaces 
functionalization processes, there is an urge for new functionalization strategies. Bio-
functionalization offers an enormous potential in the functionalization area with its 
easy to handle single-step self-assembling protein immobilization process. Biological 
self-assembling layers offered highly ordered, stable and oriented homogenous 
biocompatible structures by using green technology (Yazici, 2013; Hnilova, 2012).  
1.2 Inorganic binding peptides 
Proteins are the fundamental elements for life. These proteins have very broad 
functions that may consist of structural integrity of tissues (collagen) and enzymatic 
activity for cell survival or gene expression regulation.  Therefore, they can interact 
with various organic molecules such as other proteins, DNA, carbohydrates, lipids. 
But there is the other aspect of proteins that is  forgotten. Living organism are 
producing biological hard tissues such as bones, teeth, hairs, nails but also nacre or 
spicules with the intervention of proteins. Therefore, these inorganic binding proteins 
inspired from nature or their molecular derivatives might help to develop new high-
tech organic-inorganic hybrid materials by using molecular biology, bioinformatics 
for the nanotechnology industry. 
1.2.1 Roles of proteins in biological materials 
Biological hard tissues are complexes structures composed of sensitively balanced 
mixture between organic and inorganic molecules. These structures can even be 
found in single cell organism such as bacteria. Aquasprillum magnetotacticum is one 
16 
of the possible examples (Figure 1.4A). This bacteria has organelles containing 
magnetite (Fe3O4) nanoparticles which help the bacteria navigation through the 
sensing of earth’s magnetic field (Frankel, 1991). This phenomenon is called 
magnetotaxis. The extraordinary facts are that these biologically produced 
nanoparticle have equivalent size (50 nm) and same cubo-octahedral shape allowing 
the maximum sensing ability of the earth’s magnetic field (Tamerler, 2010). 
The protective shell of mollusks is another example for the structural perfection of 
biological hard tissues (Figure 1.4B). The layered shell structure of mollusks 
composed of aragonite (orthorhombic CaCO3) and the biopolymer mixture of 
proteins and polysaccharides gives the shell the unique toughness and fracture 
strength among all ceramic based materials (Fong, 2003; Sarikaya, 1992). 
 
Figure 1.4 : Biological material examples (Tamerler, 2010). 
Sponges (Rosella racovitzea) also are producing inorganic materials such as spicules 
(Figure 1.5). These silica-based fibers with star-shaped tips are collecting the light 
and transfer it into the inner part of the sponge allowing sponges survival (Sarikaya, 
2001). 
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Figure 1.5 : Cross section of Sponge spicule of Rosella by SEM (Sarikaya, 2001). 
The last example is mammalian tooth (Figure 1.4C) that is one of the most complex 
structure comprising layers of different tissues. Enamel is the protective outer layer 
of the tooth that is the hardest material in the body. Enamel has a very particular 
woven-like fiber structure, composed of tightly controlled shape and size of 
hydroxyapatite crystallites. Enamel is integrated to dentin, the later is the softer 
bone-like tissue involved in absorbing external physical stress. All these inorganic 
tissues are generated by a panel of proteins. Some of these proteins are involved in 
nucleation, others are implicated in growth and assembly.  
Therefore, if proteins are highly involved in the production of various inorganic 
materials by controlling the shape, the size and the strength of produced crystallites, 
then why not mimicking their activity? So the term of “molecular biomimetics” has 
arisen (Sarikaya, 2003). Since then, mechanism involved in the formation of biologic 
inorganic materials are investigated and especially, at the first step, proteins or 
peptides implicated in the recognition of inorganic compounds. 
1.2.2 Inorganic binding peptides 
The first term of metal recognition polypeptides was employed in year 1997 by 
Stanley Brown regarding the selection of polypeptides able to bind gold and 
chromium (Brown, 1997). Brown has generated a repeating peptides library and 
displayed the library on the surface of Escherichia coli. Then the cell surface 
displayed library was screened either against gold or chromium and cells adhering to 
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gold or chromium surfaces were selected. The library was enriched with several 
enrichment cycles, and the polypeptides encoding inserts were amplified by PCR. 
The PCR amplified inserts were recloned into an alkaline phosphatase (AP) vector 
for facilitating the soluble expression of the polypeptides. The gold binding property 
of the peptides fused with AP was analyzed by a modified Scatchard method. Later 
on, new cell surface displayed polypeptides libraries were constructed for the 
selection of polypeptides which have an effect on gold crystals formation (Brown, 
2000). They have found that two different peptides with some commons sequences 
were accelerating colloid appearance of gold. Referring to these experiments, the 
authors have suggested a mechanism in the formation of the crystalline phases of 
hard tissue. 
Cell surface display method was the pioneer for the selection of genetically 
engineered polypeptide for inorganic (GEPI). Up to now, cell surface display has 
been used to identify peptides recognizing zinc oxide, cuprous oxide, iron oxide and 
zeolites. New inorganic binding peptides were discovered by M13 phage-displayed 
peptide libraries. Metal binders such as silver (Ag), platinum (Pt) and palladium (Pd) 
binding GEPI’s were selected by using 12-mer or disulphide-constrained 7-mer 
peptide libraries (Naik, 2002; Sarikaya, 2003). But also peptides specific to Titanium 
oxide (Sano, 2003; Sano, 2005), semiconductors (GaN, ZnS, CdS ( Lee, 2002), 
minerals (hydroxyapatite, graphite, calcite, sapphire (Krauland, 2007) were selected 
from peptide libraries (Gaskin, 2000; M. Gungormus, 2008; So, 2012; Whaley, 
2000). The most important and critical point for the selection of inorganic peptides is 
the composition or the structure of the target material during the selection process. 
Because of inorganic material heterogeneity at atomic and crystallographic level, 
several peptides with different sequences might be selected, each of them specifically 
binding different state or size of the inorganic compounds (Sarikaya, 2003). 
Most of the selected inorganics binding  peptides were used as it is. But some 
peptides were further engineered by computational biomimetics approaches. Amino 
acid sequences of peptides might be a very effective data for understanding the 
binding mechanism of inorganics binding peptides. The inspection of the sequence of 
the noble-metal binders showed that the serine and the threonine amino acids were 
important for binding, possibly by their aliphatic hydroxyl groups. Interestingly two 
amino acids which are known to bind to transition metal ions, cysteine and histidine, 
were mostly absent in these sequences  (Slocik, 2002). The same inspection was 
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made for non-metal binding sequences Therefore, the phage display or cell surface 
display technologies have given the opportunity to predict which amino acids were 
important for binding to metals or non-metals (Sarikaya, 2003). This knowledge was 
useful for molecular modelling studies. The structure of the 3-repeat gold-binding 
peptide GBP1 was determined in silico and then this structure was placed on gold 
atomic lattices (Au 111) for visualisation the potential interaction between them 
(Braun, 2002). In consequence, second generation of peptides with higher binding 
ability and specificity were selected with the help of bioinformatics tools and/or 
experimental mutagenesis (Tamerler, 2010). Material-specific scoring matrices were 
produced by combining sequence alignment techniques (Oren, 2007; Tamerler, 
2009). These matrices were used to develop a bioinformatics method allowing the 
design of new peptides with a high affinity and specificity. This methodology was 
validated by the design of new peptides with high affinity to quartz (Oren, 2007).  
Even if molecular modelling and bioinformatics might help to understand binding 
interactions, more precise structural analysis are required such as nuclear magnetic 
resonance spectroscopy. But also other characterization methods are necessary for 
determining the affinity (quartz crystal microbalance (QCM) and surface plasmon 
resonance spectroscopy (SPR)) and selectivity (fluorescence microscopy, atomic 
force microscopy (AFM)).  Such that the binding properties of GBP1, platinum 
binding (PtBP1) and silica binding (QBP) peptides to respectively gold, platinum and 
silica were determined by SPR (Seker, 2007; Seker, 2009; Tamerler, 2006a; 
Tamerler, 2006b). The binding of GBP1 was also confirmed by QCM was 
determined with SPR (Tamerler, 2006a; Tamerler, 2006b).  
1.2.3 Genetically engineered peptide-based applications 
GEPI have been widely used for a wide range of applications, mainly on the 
biofunctionalization of materials (Seker, 2011; Tamerler, 2010). GEPI were used for 
the immobilisation of anti-fouling polymer such as poly(ethylene glycol), integrin-
binding RGD, enzymes (alkaline phosphatase, L-lactate dehydrogenase), 
fluorescence protein (Green fluorescence protein) on different solid surfaces such as 
gold, titanium or silica. GEPI fused with DNA binding proteins were also used for 
targeting nanoparticles to DNA by this way  demonstrating that complex 
nanoarchitecture through DNA-protein-nanoparticle can be constructed (Cetinel, 
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2013; Sedlak, 2010; Khatayevich, 2010; Tamerler, 2010). Some of these applications 
are explained in more details further. 
An enzyme, such as Alkaline phosphatase (AP) was successfully immobilised on the 
gold surface through Gold binding peptide (Kacar, 2009). Several alkaline 
phosphatase fusion construct with different copy number of GBP were expressed and 
purified. These fusion enzymes were then immobilized on a pattern by adsorption 
with the use of microcontact printing (Figure 1.6), and the enzymatic activity of AP 
was demonstrated. 
 
 
Figure 1.6 : Two-dimensional array of immobilized 5GBP1-AP (Kacar, 2009). 
GEPI against hydroxyapatite was selected with phage display technology. One strong 
hydroxyapatite binder peptide (HABP1) was selected, and the effect of this peptide 
on biomineralisation of hydroxyapatite was observed with SEM for 28h. HABP1 
significantly influenced hydroxyapatite crystal formation by generating larger 
crystals. Consequently, genetically engineered peptides for inorganics have the 
potential to be used in tissue regeneration (Gungormus, 2008). Then a fusion peptide 
(MDG1, Mineral Directing Gelator), wherein the HABP1 peptide and a peptide 
implicated in hydrogel formation, was synthesized. It was shown that MDG1 gels 
were capable of directing the formation of hydroxyapatite (Gungormus, 2010). 
Yuca (2011) have engineered a hydroxyapatite binding fluorescent protein for 
monitoring biomineralisation. They have genetically linked the DNA encoding the 
HABP1, hydroxyapatite-binding peptide, with green fluorescence proteins gene and 
expressed the fusion protein in E.coli. The fluorescence of the construct was verified 
under a fluorescence microscopy, and the affinity of the engineered protein to 
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hydroxyapatite was determined by quartz crystal microbalance spectroscopy (Figure 
1.7). 
 
Figure 1.7 : Fluorescence labeling of teeth with GFPuv-HAPB1 (Yuca, 2011).  
Quartz binding peptide (QBP) was used as molecular linker (Kacar, 2009). The 
quartz binding peptide was conjugated with fluorescein or biotin and then printed by 
microcontact on quartz surface. The immobilized QBP-fluorescein fusion protein 
was directly monitored by fluorescence microscopy. The QBP-biotin  fusion 
construct was monitored with the help of streptavidin conjugate fluorescent 
quantum-dot. By this way, it was demonstrated that inorganic solid-binding peptides 
could be used as ink for microcontact printing as well as linker for self-assembly.  
Hnilova  (2012) have developed a gold and quartz binding bifunctional peptide by 
the fusion of the QBP with AUBP1, a gold binding peptide. This bifunctional peptide 
was able to assemble gold nanoparticles on a silica surface. The group has also 
succeeded to synthesize nano-metallic particles in situ on the peptide pattern 
(Hnilova, 2012).  
The same group has also demonstrated a bio-enable self-assembly technique by using 
a gold binding peptide (AuBP1) tag (Hnilova, 2012).  They have used this technique 
for multi-layered protein formation and nanometallic assembly. For this purpose, 
they have fused the AuBP1 gold binding peptide with maltose binding protein 
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(MBP) using different linkers. Then they have measured the binding affinity of the 
construct to gold. The equilibrium dissociation constant  (KD) of the AuBP1-MBP 
fusion protein was determined between 0,02 and 0,04 µM, differing because of the 
detection method used (SPR and localised SPR (LSPR)) and the linker sequence 
inserted. They have immobilized the gold and quartz binding bifunctional peptide on 
a silica surface, then gold nanoparticles successively. As the third layer, they have 
immobilized the gold binding AuBP1-MBP construct and finally, they have 
immobilized an Alexa-488 conjugated anti-MBP antibody as a monitoring agent. 
Therefore, they have successfully immobilized a combination of organic and 
inorganic layers on the surface of silica, demonstrating as a matter of fact a new 
layer-by-layer coating method (Figure 1.8).  
 
Figure 1.8 : Immobilized proteins on gold NP arrayed surface (Hnilova, 2012). 
Recently, Yazici (2013) have developed two titanium binding bi-functional peptides 
with an integrin recognizing peptide motif, RGDS. They have shown that the 
functionalization of titanium surface with these peptides significantly enhanced 
osteoblasts and fibroblasts bioactivity. Briefly, they have screened a cell surface 
displayed peptide library against Titanium. They selected 60 unique peptides with 
titanium binding ability. Out of them two strong titanium binding peptides (TiBP1 
and TiBP2) were identified and characterized for their molecular structures by 
circular dichroism spectroscopy and molecular modeling studies. The affinity of the 
peptides to titanium was measured by QCM and dissociation constant (Kd) of 
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0.9±0.12 µM for TiBP1 and 0.18±0.03 µM for TiBP2 was calculated. Then they 
have synthesized new TiBP1 and TiBP2 peptides containing RGDS peptide motif, 
and they have shown the increases of  NIH3T3-E1 preosteoblast cells adherence and 
proliferation on titanium surfaces functionalized with TiBP1-RGDS and TiBP-
RGDS (Figure 1.9).  
 
Figure 1.9 : Cell adhesion mediated by TiBP1-RGDS peptide (Yazici, 2013). 
In conclusion, GEPIs have proven their metal-binding ability and their potential to be 
used as self-assembled linkers between inorganic surfaces and proteins. This 
property is opening a new vision about the immobilization of antibodies on 
biosensors surfaces for the detection of disease-related proteins such as the Hepatitis 
B virus Surface antigen. 
1.3 Hepatitis B virus 
Hepatitis B virus (HBV) is one of the major causes of chronic Hepatitis, cirrhosis and 
liver cancer (hepatocellular carcinoma, HCC) in the World.It is forecasted that it will 
be in higher ranks in the next two decades (World Health Organization, WHO, 
Executive board 126th session EB126/15, 2009). According to WHO (Fact sheet No: 
204, 2013) the number of infected people is about 2 billion. From these infected 
people approximately 240 million are chronically infected, and about 600,000 people 
die  every year due to the consequences of HBV. 
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It is estimated that HBV was present in the Antic times 5th before J.C. but only in 
year 1883 the presence of HBV in blood serum was detected by Bremen Shipyard 
and its colleagues (Lok, 2001). Mac Callum assigned the Hepatitis word in year 
1947, and  this terminology was approved by WHO in year 1973. In year 1965 
Hepatitis B surface Antigen was discovered called at that time Australian antigen 
(Lusebrink, 2009). After this discovery many works have been done on HBV about 
its structure, its replication processes and its infection mechanisms. In year 1992, a 
world vaccination program leaded by WHO was initiated for the vaccination of the 
children’s in the aim of reducing the infection rate of HBV. This program has been 
successful with an overall decrease of HBV infection prevalence (Luo, 2012). 
1.3.1 Epidemiology and virology 
HBV is a virus from Hepadnaviridae virus family, which infects specifically human 
liver cells, but it can also infect experimentally chimpanzees even though it is not 
infectious for them. However, there are different variants of Hepatitis specific for 
another animal such as woodchuck hepatitis virus or duck hepatitis virus. These 
hepatitis models have helped to understand their structure and their mechanism of 
infection liver cells (Lusebrink, 2009).  
HBV is a circular partially double-stranded virus of 3.2 kb length, which the smallest 
genome among viruses. Up to know ten different genotypes has been discovered with 
a 8% genome variation (Hakami, 2013; Harkisoen, 2012). The worldwide 
distribution of the most dominant genotypes is given in Figure 1.10. In Turkey, the 
prevalent genotype was determined by a complete genome sequencing phylogenetic 
analysis of HBV isolates from different regions of Turkey (Bozdayi, 2005; Sunbul, 
2013). Zehender and its colleagues have modeled the spatial and temporal dynamics 
of HBV D spreading. According to their reconstruction the origin of HBV D 
genotype is India, and this genotype arrived in Turkey around years 1960 (Zehender, 
2012). 
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Figure 1.10 : Dominant genotypes of HBV (Harkisoen, 2012). 
The HBV genome consist of a full-length strand is called negative (-) strand and a 
partial non-coding strand called positive strand (+) (Figure 1.11). The HBV genome 
contains four highly condensed and overlapping Open Reading Frames (ORF) on the 
minus strand. This strand encodes 7 proteins which are the surface antigens S, PreS2 
and PreS1, the Hepatitis B e antigen (HBeAg), the Hepatitis B core antigen 
(HBcAg), the polymerase and the HBx protein (Lusebrink, 2009). 
 
Figure 1.11 : HBV genome representation. 
The polymerase protein is expressed from the longest ORF and is covalently bound 
to the minus strand; this polymerase is necessary for the replication of the virus. The 
polymerase has three functions. The first one is the primase activity at the N-
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terminal. The second one is the reverse transcriptase activity for converting the 
pregenomic RNA into DNA and also for the generation of the + strand. It also helps 
the encapsidation of the pregenomic RNA in the core proteins. The last activity is the 
RNAse H activity which helps the degradation of the pregenomic RNA. 
The core protein (183-185 aa) is essential for the formation of the nucleocapsid. The 
core protein is obtained by the cleavage of the peptide signal sequence (propeptide) 
of the precore protein. The core proteins are forming dimers then they self-assemble 
together for forming the HBV nucleocapsid with 90 dimers (30 nm) or 120 dimers 
(34 nm) the major infectious viral particle (Schadler, 2009). 
The HBeAg is a clinical serum marker related with high HBV replication indicating 
disease severity.  HBeAg, establish immune tolerance and chronic infections. HBeAg 
is conserved among all Hepadnaviridae family which suggests that it is evolutionary 
conserved. Therefore, it has an important role in HBV infections (Revill, 2010) 
HBeAg is produced from the same ORF as HBcAg and have a very high sequence 
similarity. The only sequence variation is that, instead of HBcAg, HBeAg carries the 
ten amino acid N-terminal propeptide and that HBeAg is deprived of the Arginine 
rich present in HBcAg. These two proteins have differents functional and physical 
properties even their sequence similarity. Recently DiMattia and his colleagues have 
crystallized HBeAg complexed with an HBeAg specific Fab (E6). They have 
discovered that HBeAg was present as a dimer and that this dimerization was due to 
the Cysteine residue present in the propeptide. This residue was forming a disulfide 
bond with the Cys 61 which is implicated in the dimerization of the HBcAg.  
This conformational change was favoring the HBeAg dimerization, changing the 
antigenic property of the dimer drastically. This conformational change explained the 
functional and structural differences between the two similar antigens (Figure 1.12 
and 1.13) (DiMattia, 2013). 
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Figure 1.12 : HBcAg and HBeAg representation (DiMattia et al., 2013). 
 
Figure 1.13 : 3D representation of HBcAg and HBeAg (DiMattia, 2013). 
The X protein (17 kDa) is a highly conserved multifunctional protein acting as a 
transcription activator of host gene promoters required for in vivo viral replication 
and some proto-oncogenes such as c-jun, c-fos and c-myc. It is also regularly 
detected in HBV-associated HCC patients. Therefore, it is believed to be highly 
implicated in Hepatocellular carcinoma (HCC) (Hwang, 2003; Lucifora, 2011; Ng, 
2011). 
The three surface antigens constitute the virus envelope. These antigens are encoded 
from the same ORF with three different start codons. The small HBV surface antigen 
is composed by the S domain (226aa), the PreS2 antigen (334-345 aa) comprised the 
S domain and the PreS2 domain of 55 amino acids. The Large antigen called PreS1 
(389-400aa) is expressed from the full-length ORF. Therefore, it contains the S; 
PreS2 and PreS1 domains (Figure 1.14).  
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Figure 1.14 : Hepatitis B virus surface antigens (Schadler, 2009). 
The position of the surface antigens on the Endoplasmic reticulum (ER) membrane is 
shown in Figure 1.16 where the possible glycosylation sites Asn 4 and Asn 146 are 
indicated. PreS1 antigen is present in two different forms due to a posttranslational 
translocation of the Transmembrane domain 1 (TM1). When the TM1 domain is 
located in the ER membrane then, the PreS1-PreS2 domains are located in the ER 
lumen from where there will be secreted and be found on the external part of the 
virions. This form of the PreS1 antigen will allow the attachment of the virions to the 
corresponding host cell receptor.  However, if the TM1 is not translocated then the 
PreS1 and PreS2 domains are located at the cytoplasmic part of the host cell. Once 
secreted, they will be positioned in the inner part of the virions and interact with the 
nucleocapsid and activate intracellular signal transduction.  
The expression of the HBsAg, which is higher than the required amount for the virus 
production, the reason is not well understood. The over-expressed HBsAg will self-
assemble and form spherical or filament shaped particles of 22 nm. These non-
infectious particles will then be released into the blood circulation (Figure 1.15). One 
hypothesis is that these non-infective particles might help to increase of the 
efficiency of the infection by overwhelming the host immune system. Therefore, 
allowing the immune escape of the infective virions (Dane particles) (Bruns, 1998).   
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Figure 1.15 : HBV life cycle (Rehermann, 2005). 
The detection of HBsAg in the blood is, therefore, a perfect indicator for HBV 
infection.  
1.3.2 Detection of HBsAg 
Molecular based detection is a very sensitive system allowing accurate detection of   
very low copy numbers of HBV DNA or RNA by real-time polymerase chain 
reaction (RT-PCR). Even different sub-genotypes of HBV can be detected and 
quantified by multiplex-PCR reactions making the molecular biology based detection 
methods (Chen, 2007). Therefore, as ELISA is the gold standard for serological tests, 
real time-PCR is the gold standard for all detection methods of HBV (Heiat, 2014). 
However, molecular-based HBV detection have several drawbacks, the systems 
require highly specific instrumentation, clean rooms, qualified personnel to do an 
experiment and to interpret it. Therefore, molecular-based systems are very sensitive 
but not prone to be good biosensors.  
Instead, HBsAg is a very specific biomarker for HBV infection. Its detection in 
blood is of great importance for human health care. Therefore, many researches have 
been made for the development of easy, rapid, sensitive and selective HBsAg 
detecting immunosensing systems. The first detection systems developed which are 
still on the market are the serological tests such ELISA, radioimmunoassay, 
immunochromatographic assay and immuno-chemiluminescence (Lau, 2003). 
Among them radioimmunoassay (RIA) is the first detection system based on a 
competitive  binding assay between a radiolabeled and a label-free HBsAg to an anti-
HBsAg antibody. ELISA-based detection systems are the most widely used among 
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the commercial HBsAg detection kits especially in clinical laboratories. These 
intensively optimized detection kits for several generations became and are still 
becoming faster, more accurate and sensitive. These improvements are not due to the 
development of new antibodies but rather to the decrease of the environmental noise.  
Immunochromatography based detection systems are the most desired detection 
systems because of their very fast response time and their easy result interpretion. 
However,  in a research regarding the detection of HBsAg,  a comparative assay was 
done between immunochromatography based detection kit and a third generation 
ELISA kit. The authors concluded that immunochromatography based detections 
were still not enough for the detection of HBsAg in blood serum. The same fact was 
previously stated by Lin (2008), who tested commercially available 33 HBsAg rapid 
tests. Therefore, even if these detection methods were developed many years ago 
they still need some improvement to meet the requirements of FDA to be approved 
as a rapid test (Lin, 2008). 
With the technological development many new, highly sensitive and selective 
devices are being investigated for the detection of HBsAg. Even so that HBsAg has 
been accepted as a model molecule for many biosensors in the development phase 
(Heiat, 2014).  The detection of HBsAg was investigated  with Piezoelectric 
immunosensors, a detection level in the  range of 0,1-100ng/mL have been measured 
with Piezoelectric Microcantilever. A multiple piezoelectric based detection system 
was able to detect simultaneously HBsAg and α- feto protein, a  tumor marker (Xu, 
2010). HBsAg was also detected by electrochemical immunosensors using sandwich-
type assays a by using gold nanoparticles and horseradish peroxidase (Nourani, 
2013). 
Finally, by using gold nanorods based localised SPR immunosensor, HBsAg was 
able to be detected in blood serum and plasma (Wang, 2010). Recently, the detection 
of HBsAg using plasma-treated parylene-N film on SPR chip was confirmed with a 
1000 fold increase of the SPR sensitivity (Choi, 2014). 
1.4 Detection probes for HBsAg 
The sensitivity and the selectivity of immunosensors are increasing each day with the 
development of the technology. However, all the detection systems have the same 
goal, improving either instrumentation  or the surface functionalisation methods.  
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The aim is to offer the most favorable environment to the bioreceptor so that it can 
binds specifically to its target molecules with high affinity. Even if the sensitivity of 
detection can be increased by using signal enhancing molecules, which might also 
bring some background noise, the selectivity of the immunosensor is limited to the 
specificity of the bioreceptor used. Therefore, the development of a better 
bioreceptors is one of the important and most challenging part for improving 
immunosensors. Many bioreceptors against HBsAg have been produced up to now. 
Starting with polyclonal antibodies produced by animals such as rabbit, goat, horse 
after several  injection steps of the target antigen for which its antibody is expected. 
However,  polyclonal antibodies are not suited for immunosensors because they give 
high cross reactivity with other proteins having the same epitope. Then comes the 
monoclonal antibodies developed by the hybridoma technology developed by Cesar 
Milstein, Georges J. F. Köhler in 1975 and awarded with the Nobel price in 1984. 
With the molecular biology techniques and the knowledge regarding antibodies, the 
development of genetically engineered recombinant antibody production has  been 
boosted. Once the genetic material encoding the antibodies were obtained and 
combined with molecular biology techniques, the development of recombinant 
antibody variants was limited with the imagination. Recombination of antibodies 
started with a simple antibody variable region exchange. It has expanded to the 
modification of CDR’s for increasing affinity, the modification of the frame region 
for increasing antibody solubility.  It has also expanded to the generation of single 
chain variable fragment antibodies,  of dimeric, trimeric, bispecific antibodies, of 
recombinant antibody libraries (Erdag, 2011). 
New,  non-proteic but nucleic acid based bioreceptor molecules are also investigated, 
such as aptamers, peptidic nucleic acids. Recently, an aptamer specific to HBsAg  
was developed for the purification of HBsAg from expression cells (Binning, 2012). 
However, very little is known on the structural and biochemical aspects of aptamers. 
Therefore, until more knowledge is acquired about these nucleic acid based 
recognition molecules,  their use as bioreceptors for biosensor applications would 
add new uncertainties. Below only the hybridoma technology in its basic aspects and 
the phage display technology will be described. Phage display is a  powerful 
technique, allowing the expression of proteins or antibodies on the surface of 
filamentous phages allowing the selection of many of recombinant antibodies against 
a wide range of antigens. 
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1.4.1 Anti-HBsAg monoclonal antibodies with Hybridoma technology 
Hybridoma technology was developed by Cesar Milstein, Georges J. F. Köhler in 
1975. This technology has allowed the production of  large quantities of monoclonal 
antibodies highly specific to a single epitope of antigens. Therefore, monoclonal 
antibodies have found their place in the diagnostic and therapeutic arena rapidly. 
The technology consists on the fusion of two differents cell lines. The B-cells, 
capable of  producing antibodies, are isolated from the spleen of animals immunized 
with the target antigen. The immortal myeloma cell line, which is a B-cell cancer cell 
line. The fusion hybrid cells are called hybridomas. These cells will be able to 
multiply rapidly and indefinitely and also to produce large amounts of antibodies. 
The main difficulty of the hybridoma technology is a necessity to select a single 
hybridoma cell producing full antibody after an extensive screening procedure by 
limiting dilution. The major drawback of this technology is the lack of the genetic 
information regarding the antibody encoding genes. The discovery of polymerase 
chain reaction and Sanger DNA sequencing methods have opened a new area. The 
recombinant antibody engineering area, wherein the genetic material encoding the 
antibodies was isolated and then genetically modified for further antibody properties 
improvement suiTable for  diagnostic and therapeutic applications.  
1.4.2 Recombinant antibodies with phage display technology 
Phage display was first introduced by Smith in year 1985. Smith has expressed a 
polypeptide on the surface of a lysogenic M13 filamentous phage. Since then phage 
display technology have found many applications such as generating recombinant 
antibody or cDNA libraries for diagnostic, therapeutic purposes (Rakonjac, 2011). 
This display technology was then expanded to cell surface display and ribosome 
display (Wittrup, 2001). 
1.4.2.1 M13 Bacteriophage structure 
M13 Filamentous phage was first isolated from wastewater in Munich 1963 
(Hofschneider, 1963). It is a 900 nm long cylindrical shaped E.coli bacteriophage 
with 6-7nm diameter (Makowski, 1997; Webster, 1996). Wezenbeek (1980) have 
sequenced the single-stranded genome of M13 phages, and they have determined the 
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size of the genome as 6407 base pairs length (van Wezenbeek, 1980). The genome 
encodes 11genes, 5 of them being coat proteins (pIII, pVI, pVII, pVIII, pIX) (Figure 
1.16 and 1.17) (Sambrook, 2001; Paschke, 2006). 
 
Figure 1.16 : Genetic map of the Ff phage (Sambrook, 2001).  
 
Figure 1.17 : Surface proteins of M13 phage (Paschke, 2006). 
The pVIII protein (50 amino acids) is the major coat protein with 2700 copies 
covering approximately the whole phage responsible for the encapsulation of the 
DNA (Table 1.2). The pIII (406 aa) and pVI (112aa) proteins with five copies each 
are necessary for the phage stability and infectivity. The remaining two coat proteins 
pVII (33 aa) and pXI (32 aa) are implicated in phage assembly and release (Lopez, 
1983; Sidhu, 2001). 
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Table 1.2 : M13 phages coat proteins (Sidhu, 2001). 
Protein Amino acid number Molecular Weight (Da) Copy number 
PIII 406 42.500 ~5 
PVI 112 12.300 ~5 
PVII 33 3.600 ~5 
PVIII 50 5.200 ~2700 
PIX 32 3.600 ~5 
The structure of PIII has been studied more intensely because of its importance in 
bacteria infection (Kay, 1996). The pIII protein has three distinct domains separated 
with glycine-rich linkers (Figure 1.18) (Russel, 2004). The C-Terminal domain (CT) 
is anchored into the phage particle. Two distinct domains compose the N-terminal 
domain which is necessary for phage infection. These two domains are interacting 
with each other (N1 and N2) which shown by X-Ray Crystallography and NMR 
spectroscopy (Holliger, 1997; Lubkowski, 1998). 
 
Figure 1.18 : pIII protein structure (Russel, 2004).  
1.4.2.2 Infection of M13 Bacteriophage   
The infection of E. coli by M13 phage is made with the strong interaction of bacterial 
F pili with the N2 domain of the phage  (Deng, 2002). This interaction causes the 
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separation of the N1 domain making it accessible for interactions. With the retraction 
of the bacterial pilus (Jacobson, 1972; Maier, 2005; Marvin, 1969) the phage gets 
closer to the surface of the bacteria. This approach allows the interaction of the N1 
domain of pIII protein interacts with the host TolA co-receptor (Figure 1.19). 
 
Figure 1.19 : Infection of E. Coli by Ff bacteriophage (Russel, 2004). 
Even though, the interaction of the pIII proteins with the E. Coli pili is known the 
mechanism of phage DNA entry into the host cytoplasm is unclear.  A speculative 
DNA entry model where the CT domain of pIII is “opened” allowing the 
hydrophobic helix region of CT to interact with the inner membrane of the host cell 
was represented (Rakonjac, 2011).  
Once the phage is in contact with the host inner membrane, the phage DNA is 
injected in the cytoplasm, and the pVIII coat proteins are integrated into the inner 
membrane (Figure 1.20). 
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Figure 1.20 : Infection mechanism of E. Coli by Ff phage (Russel, 2004)  
Once the single strand phage DNA (+ strand) is injected into the host cytoplasm, 
synthesis of the negative strand starts. Replication is initiated after   the binding of 
the host RNA polymerase to the negative strand origin of replication. RNA 
polymerase generates an RNA primer which will be used as a template for the 
synthesis of the negative strand by the host polymerase III. Once the second strand is 
synthesized the DNA is called as double-strand (ds) DNA replicative form (RF). PII 
protein binds to the positive strand origin of replication of the RF and nick the + 
strand where after rolling circle replication of the + strand is initiated. At the initial 
step of the viral infection the newly synthesized + strands are used for the synthesis 
of – strand in the aim of increasing the copy number until about 50 copies of the RF 
DNA per host cell. Then phage proteins are expressed. The expressed PII, pV and pX 
proteins are stay in the cytoplasm for assisting to the genome replication and the 
virus packaging. Proteins pI, pIV and pXI form a transport complex in between the 
inner and the outer membrane of the host cell. The phages coat proteins pIII, pVI, 
pVII, pVIII and IX are transported to the inner membrane of the host cell. In the later 
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step of infection when the amount of pV in dimeric form got sufficient for coating 
the + strand DNA. The pV coated + strand DNA is brought to the cell membrane 
wherein the phage is packaged and exported out of the host cell (Figure 1.21) 
(Rakonjac, 2011; Russel, 2004). 
 
Figure 1.21 : The life cycle of the Ff phage (Rakonjac, 2011). 
1.4.2.3 Displaying proteins on the phage surface 
Various phages have been used for phage display such as T4  and λ phages (but 
filamentous bacteriophages are far more beyond because of their stability in a broad 
range of pH and temperature. 
Different coats proteins have been used for displaying proteins and peptides. A 
heterodimeric protein was expressed on the surface of phage by the fusion of each 
monomer with either pVII or pIX (Gao, 1999). Also, pVI coat protein served as a 
display tool as C-terminal fusion system (Jespers, 1996). However, the major coat 
proteins used for phage display are the pIII and pVIII proteins. These two coat 
proteins, differing from their copy number, and their size have allowed to display 
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many peptides and proteins and had open the way for the commercialization of phage 
display-based systems.  
For a proper display of the proteins, a signal sequence which targets the proteins to 
the inner membrane of the host cell is necessary. This signal sequence is cleaved by a 
signal peptidase allowing the release of the mature protein into the periplasm. 
Variable display strategies have been developed. The most commonly used one is the 
insertion of the protein coding region in between of the signal peptide sequence and 
the pIII or pVIII N-terminal region (Figure 1.22). The recombinant DNA insert has 
been also successfully inserted in between of the N- and C- terminal domain of pIII 
protein without disturbing the infectivity of the phage (Figure 1.22).  
Cytosolic proteins have been also displayed on the phage surface. Because these 
proteins are folded in the cytoplasm, the gene encoding these proteins have been 
fused either at the c-terminal region of pIII or a Tat signal sequence. The c-terminal 
region of pIII is in the cytoplasm of host cell during phage propagation. The Tat 
signal sequence allowsthe  translocation of folded proteins trough the inner 
membrane (Fuh, 2000; Velappan, 2010). 
 
Figure 1.22 : Peptide display strategies (Smith, 1997). 
1.4.2.4 Phage display systems 
Since phage display technology has appeared, the display methods have changed and 
evolved according to the need of the protein to be displayed. The major coat proteins 
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used for displaying are the pIII or pVIII proteins. These two proteins have different 
advantages or disadvantages related to their copy number and size. The pIII coat 
protein having three to five copies per phage allows the selection of high-affinity 
molecules due to its low avidity. However,  this stringency in the selection comes out 
during the selection steps with the loss of some proteins that might have lower 
binding property but better blocking ability or catalytic activity. In contrary pVIII 
with its high copy number allows the selection of molecules with lower affinity but 
increasing the chance of selecting a larger protein panel from the library. The size of 
the protein to be displayed is another factor to be considered. Due to the steric effects 
of large molecules, the latter ones cannot be displayed with pVIII proteins. 
Therefore, pVIII is used for displaying peptides and pIII is used for displaying larger 
molecules such as Fab or viral proteins such as Hepatitis B virus core antigen 
(Barbas, 1992; Ozdemir-Bahadir, 2011). 
The way that the fusion proteins will be displayed depends according to the strategy 
used. One of the strategies is to insert the recombinant DNA into the phage genome. 
Therefore, the protein to be display is expressed theoretically in all the pIII or pVIII 
copies (Type 3 or type 8) (Figure 1.25) (Smith, 1993). This strategy allows 
maximum load of the protein to be displayed. However, the size of the filamentous 
phage particle depends on its genome size, Therefore, the length of the phage 
increases with the insertion recombinant DNA. If the insert size is too large then, it 
might destabilize the phage particle or even obstruct the formation of phage particles. 
However, even displaying peptides on all the 2700 pVIII copies might generate steric 
effect problem. Therefore, other strategies have been developed such as the 33 or the 
88 systems (Figure 1.25). These systems consist on the insertion of a second copy of 
the pIII or pVIII encoding genes fused with the coding region of the protein to be 
displayed. The expression of wild-type coat proteins is favorited during the phage 
infection resulting in a fewer copy of recombinant pIII or pVIII displayed on phage 
particles.  
The systems 3+3 and 8+8 consist of (Figure 1.23) using two copies of the pIII or 
pVIII genes. One of the genes, is in the wild-type phage (helper phage) genome 
while the recombinant one is inserted in a “phagemid” (Cesareni, 1988; Mead, 1988). 
Phagemid carries the origin of replication of E.coli, but also the filamentous phage 
replication origin allowing it to replicate either as a plasmid in or “a phage” when 
helper phage infects the phagemid carrying E.coli cell. Two progeny virions are 
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obtained after infection of helper phage. The first one is a phage particle carrying the 
wild-type, and the second progeny contains the phagemid both displaying a mixture 
of wild-type or recombinant coat proteins with a preference to wild-type pIII or 
pVIII.  
Phagemid system, because of its smaller genetic material compared to phage 
genome, allows better transformation efficiency which is a great problem limiting the 
diversity of phage display libraries.  However, this system has a major drawback due 
to the very low average of recombinant pIII or pVIII displayed on the phage surface, 
which is less than one per phage. 
Therefore, to increase the copy number of recombinant proteins several 
modifications have been made. Oh (2007) has inserted an amber mutation into the 
gene III of helper phage decreasing the expression of wild-type pIII in a suppressor 
E.coli strains, Therefore, increasing the integration of recombinant pIII. Helper 
phages with complete deletion of the gene III was also done by several research 
groups (de Wildt, 2002; Griffiths, 1993). Moreover, recently a helper plasmid has 
been constructed eliminating the need of helper phage (Chasteen, 2006). 
 
Figure 1.23 : Phage display types (Smith, 1997). 
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1.4.2.5 Phage display applications 
Phage display has been successfully used for the display of different kind of proteins 
such as Enzymes (Alkaline Phosphatase (Light, 1992; McCafferty, 1991), trypsin 
(Wang, 1996); glutathione transferase (Widersten, 1995); hormones (human growth 
hormone (Lowman, 1991; Lowman, 1993); angiotensin (McConnell, 1994); 
inhibitors (plasminogen activator inhibitor (Pannekoek, 1993; van Meijer, 1996); 
receptors, (IgE receptor, T cell receptor (Onda, 1995; Scarselli, 1993); ligands, 
(neurokinin A 53); epitopes and antigens (epitope of malaria parasite Plasmodium 
falciparum, Hepatitis B virus core antigen (Greenwood, 1991; Ozdemir-Bahadir, 
2011); DNA and RNA binding proteins, (zinc finger (Rebar, 1994); enzyme 
substrates, (protease substrates (Matthews, 1993); cytokines, (interleukin-6 (Cabibbo 
et al., 1995).  
However, the breakthrough of phage display was the display of antibody libraries. 
The first antibodies displayed on the surface of phages were Fab (Barbas, 1991; 
Kang, 1991) and single chain Fv fragments (Clackson, 1991). These recombinant 
antibody structures were generated from B cell mRNA of immunized animals or 
volunteers and displayed as a fusion with the pIII protein. This technology has 
allowed the selection of different recombinant antibodies for diagnostic such as 
ELISA, immunostaining, in vitro and vivo imaging or for therapeutic purposes 
(Erdag, 2011; Melancon, 2008). Human anti-Human antibodies have been selected 
by using a pre-immune library (nonimmunized) and used for the development of 
therapeutic recombinant antibodies (Griffiths, 1993; Zhu, 1998). Human pre-immune 
antibody libraries have a great advantage because no immunization is necessary. 
Therefore, a large antigen panel such as toxins, receptors, cytokines enzymes can be 
screened in-vitro. However, the selected antibodies have low affinity. Various 
strategies have been applied for increasing the affinity of these antibodies by random 
mutagenesis or by shuffling variable regions of low-affinity antibodies (Schier, 1996; 
Thompson, 1996). 
Protein-protein interactions are essential for life. Therefore, it is important to 
determine these interactions. Yeast two-hybrid is the most commonly used technique 
(Fields, 1989). Phage display technology has been used for the detection of protein-
protein interactions by generating cDNA libraries. The main advantage of  phage 
displayed cDNA libraries is the in vitro screening process whereas yeast two-hybrid 
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is made in vivo. Therefore, the protein panel is restricted with their toxicity to the 
cells.  
In the last few years, phage display technology has been used for the development of 
vaccines. It is known that phages particles are highly immunogenic. Therefore, 
phages displaying viral antigens have been used for immunizing various animals 
wherein phages were used as haptens (Ozdemir-Bahadir, 2011; van Houten, 2010). 
1.4.2.6 Random peptide libraries 
Antibodies are binding specifically with high affinity to their antigens. The binding is 
inbetween the Complementary determining regions (CDR) of the antibody and the 
epitopes of the antigens. Therefore, it has been hypothesized that only few amino 
acids might be sufficient for binding. Since then random peptide libraries have been 
attracted the researchers. The greatest impact to the use of random peptide libraries 
was realized once these libraries have been displayed on phages or cells surfaces 
(Lee, 2003; Scott, 1990). 
The first phage display random peptide library, generated by Scott and Smith (1990), 
was linear but then disulphide bond constrained peptide libraries have immerged 
(Vispo, 1993). Since then many different random peptide libraries with various 
peptide length varying from 4 to 40 amino acids have been generated (Giebel, 1995; 
McConnell, 1996; Rickles, 1995). 
Phage or cell surface displayed random peptides libraries have been used for many 
different applications. Two Vascular endothelial Growth Factor (VEGF) binding 7-
mer peptides with Human umbilical vein endothelial cells proliferation (HUVEC) 
inhibition ability have been selected from a phage display random peptide library 
(Erdag, 2007). Also, cancer tissue-specific peptides have been selected by in situ 
screening of the phage display peptides libraries for targeting the cancer drug 
doxorubicin to xenotransplanted human breast cancer tissue (Pasqualini, 1996). 
Peptides specific for cell internalization were identified for in vitro and vivo imaging 
(Maguire, 2013) but also for targeted gene delivery  (Tannous, 2005). 
Also, peptides with inorganic material binding ability have been selected from phage 
display and cell surface display random peptide libraries. These peptides have 
opened a new vision new in the bionanotechnology field. 
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1.5 “Self-Assembling Biosensing HBsAg Probes” 
ELISA based Hepatitis B virus diagnostic kits are widely used in the world. They 
consist on recognizing HBsAg, HBcAg, HBeAg and the antibodies generated against 
these antigens from the blood by using antibodies developed against all of these 
protein structures. Even if ELISA is a very sensitive assay it has some disadvantages 
such as ELISA needs two antibodies that recognize the same antigen, but different 
none overlaying epitopes and in addition of these antibodies must be labeled. 
Therefore two different antibodies must be developed, and one of them must be 
labeled which increases the production cost of the kits.  
Nowadays, researches are focused on the generation of faster and cheaper diagnosis 
systems. Studies on Surface Plasmon Resonance (SPR) based diagnosis systems are 
increasing and the results are getting closer and closer to ELISA results which make 
SPR based diagnosis systems a rival to ELISA (Elliott, 2001; Vaisocherova, 2009). 
The main advantages of SPR based systems are the need of developing only one 
antibody against the target antigen and secondly, SPR is a label-free system which 
decreases the production cost thus makes this system suitable for diagnosis. In 
addition,  the other advantages are that this system is faster than ELISA, and the 
binding reaction can be monitored in real time.  
SPR sensor technology has become as alternative to ELISA since the improvement 
in the last decade in terms of surface chemistry, resolution, sampling and data 
analysis (Homola, 2006). The most important factor to be aware for the development 
of SPR based biosensors is the binding of biomolecules on the surface of SPR sensor 
chip. Different immobilization methods for binding proteins on gold coated SPR 
chips, are used but binding by adsorption or chemical cross-linking for the generation 
of covalently bonded molecules are the most commonly used methods. Chemical 
binding consists on coating the gold layer of SPR chips with carboxy-terminated 
thiol then activating these carboxyl group by using cross-linking agents and binding 
proteins from their amino groups to the activated carboxyl groups. However, recently 
some studies have shown that carboxy-terminated thiol molecules are being oxidized 
which decreases their stability over time. Chemically formed covalent bonds are 
much stronger bonds compared to the interactions implicated in adsorption, but both 
methods might cause loss of biological activity of the immobilized proteins due to 
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unwanted bond formation or adsorption at the active site of the immobilized protein. 
Therefore, in both cases the orientation of the proteins to be coated can not be 
controlled. A system allowing the orientation of the coated proteins so that all the 
binding sites are accessible is, therefore, of key importance. There are some 
strategies for orienting antibodies like adding a cysteine residue at the very beginning 
or the very end of proteins in the aim of generating an active site for covalent 
coupling (Jung, 2007). Also, 11-mercaptoundecanoic acid monolayer coupled G-
proteins was used for immobilization (Kausaite-Minkstimiene, 2010). Even tough 
because of the presence of other Carboxy- or amino- groups within the proteins, the 
immobilization of the proteins is not very effective. 
Phage display (Hoess, 2001; Smith, 1985) and cell surface display (Wittrup, 2001) 
technologies are two powerful protein or peptide selection methods against an 
antigen. By using these methods polypeptides able to bind inorganic molecules have 
been developed. Peptides such as iron oxide (Brown, 1992), zinc oxide (Kjaergaard, 
2000), silica (Naik, 2002) binding peptides or peptides binding to noble metals such 
as gold (Brown, 1997; Sarikaya, 2003), palladium, platinum (Sarikaya,  2004), silver 
(Naik, 2002) were described in previous studies.  
Among noble metals, gold has great advantages for medical nanotechnology 
purposes. SPR chips can be easily coated with gold, and gold can be linked easily 
with biomolecules. Furthermore, gold has no toxic effect on cells and for the human 
body. Finally, gold has unique as Plasmon resonance and light scattering properties. 
All of these advantages make gold suitable material for in-vitro and in-vivo diagnosis 
and the tracking of diseases related proteins by conjugating antibodies to gold 
nanoparticles. Therefore, peptides binding plain gold have a great potential for being 
used as an immobilizing molecule on gold coated sensor chips. A peptide with gold 
binding ability (GBP1) was selected by cell display technology  (Brown, 1997). 
GBP1 was composed of 14 amino acids (MHGKTQATSGTIQS) with no cysteine 
amino in it, which is known to make thiol bonds with gold. It was demonstrated by 
Brown and its co-worker in year 2000 that a polypeptide composed by the three-time 
repeat of GBP1 (3R-GBP1) was binding better than GBP1 itself. The binding 
specificity of 3R-GBP1 to gold and not to the other noble metal was demonstrated, 
and its binding affinity was calculated by Quartz-Crystal Microbalance (QCM) 
(Tamerler, 2006). 
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Phage display was also used as a carrier for eliciting an immune response in animal 
models because of their high immunogenic and their naturally immuno-stimulatory 
properties (Irving, 2002; Wang, 2004; Willis, 1993). In addition, it was used for the 
selection of recombinant antibodies such as Fab or single chain variable fragment or 
the selection of peptides (Benhar, 2001; Erdag, 2003; Erdag, 2007; Rosander, 2002; 
Smith, 1997). Recombinant antibodies, such as Fab and scFv, were developed 
against HBsAg in different works (Ayala, 1995; Barbas, 1991).  
In this study, an accurate label-free HBsAg detecting system was foreseen. 
According to the information given above, an SPR based biosensor was chosen as 
the most appropriate device for this purpose. A recombinant antibody (scFv) 
developed against HBsAg was selected as the most appropriate biosensing probe 
because of its smaller size compared to a whole antibody and also because the 
genetic material encoding the scFv is easily accessible. The immobilization strategy 
was chosen according to three criteria; strong immobilization on gold, no need of any 
chemical coupling and correct orientation of the scFv on the sensor chip. Therefore, 
an adequate system was to use a fusion protein with a scFv as biosensing probe and a 
gold binding peptides as an immobilization structure (Figure 1.24).  
 
Figure 1.24 : Chemically immobilized (A) and self-assembled oriented (B) scFv. 
For this purpose, a scFv against HBsAg will be developed by using phage display 
technology. First, a scFv library will be generated from the spleen mRNA of mice 
immunized with HBsAg displaying phages. The scFv with HBsAg binding ability 
will be selected by biopanning. Then the scFv encoding gene will be fused with 
GBP1 encoding gene and the fusion construct will be cloned into pQE2 expression 
vector.  The gold binding bifunctional scFv will be expressed and tested using SPR 
for its potential as a biosensing probe. 
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2.  MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Strains 
2.1.1.1 Bacterial strains genotype 
- Escherichia coli DH5α strain: (F- 80dlacZ M15 (lacZYA-argF) U169 recA1 
endA1hsdR17(rk
-
, mk
+
) phoAsupE44 
-
thi-1 gyrA96 relA1) 
- Escherichia coli TG1 strain: K12 Δ(lac-pro) supE thi hsdΔ5/F' [traD36 
proAB LacI
q
 lacZΔM15], Amersham Biosciences Cat. No. 
- Escherichia coli HB2151 strain: K12 Δ(lac-pro) ara nalr thi/F’ [proAB lacIq 
lacZΔM15], Amersham Biosciences Cat. No. 
- Escherichia coli BL21 StarTM (DE3) strain: F- ompT hsdSB (rB-mB-) gal 
dcm rne131 (DE3), Invitrogen Cat. No. C6010-03. 
- Escherichia coli M15[pREP4] strain:  , Qiagen Cat. No. 34210. 
2.1.1.2 Mouse strain 
BALB/cJ mice were obtained from the Animal Genetics and Reproduction Biology 
Laboratory of the TUBITAK Marmara Research Center, Genetic Engineering and 
Biotechnology Institute, Turkey. Animal studies were approved by the Ethics 
Committee of the Genetic Engineering and Biotechnology Institute, TUBITAK 
Marmara Research Center. 
2.1.1.3 Mammalian cell lines 
HeLa, Hek293 Trex, HepG2 and COS7 cells lines were provided from ATCC. 
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2.1.2 Vectors 
The information regarding the vectors   pCANTAB5E, pQE2 and pDUCK1 is given 
in appendix A. 
2.1.3 Primers 
The primer list is given in appendix B. The design of the primers was performed with 
the help of the San Diego Supercomputer Center (SDSC) Biology Workbench 
Internet website. 
2.2 Methods 
2.2.1 Development of an anti-HBsAg single chain Fv recombinant antibody 
2.2.1.1 Cloning of HBsAg in phagemid vector 
The plasmid construct containing the HBsAg coding gene was kindly provided by 
Assoc. Prof. Mehmet Yapar of the Virology Department from Gulhane Military 
Medical Faculty, Gulhane Military Medical Faculty (GATA) (Kubar, 1988). 
Hepatitis B Surface antigen gene was amplified by PCR using primers 
HBsAg_SfiI_For and HBsAg_NotI_Rev containing Sfi I and Not I restriction 
enzyme sites, respectively. The PCR reaction was prepared as following (Table 2.1): 
Table 2.1 : PCR reaction for HBsAg amplification. 
Reagents Volume Final 
concentration 
dH2O  34µL  
10X reaction buffer (Roche) 5 µL 1X 
25 mM MgCl2 3 µL 2.5mM 
10 mM dNTP each  1 µL 10 pmol 
10 pmol HBsAg for. primer 2 µL 20 pmol 
10 pmol HBsAg rev. primer 2 µL 20 pmol 
HBsAg gene containing plasmid  2 µL 100ng 
1U Taq DNA polymerase (Roche) 1 µL 1U 
TOTAL 50 µL  
The PCR reaction was run as following  94 ºC, 1min, 55 ºC, 2min,, 72 ºC, 2 min for 
30 cycles, with an elongation step of 10 min at 72ºC in Biometra T3000 
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Thermocycler (Germany). The PCR products were run on 1,2 % Agarose gel at 80V. 
An agarose gel of 1.2% was prepared by melting 0.6 gr of agarose (Sigma, Katalog 
no: A5304) in 50 mL of 0.5X TAE buffer (24,2gr Tris Base, 5.7 mL Glacial Acetic 
acid, 5mM EDTA, pH 8.3) in the microwave and 1.3 μL of 10 mg/mL Ethidium 
bromide (Sigma E7637) was added in the melted Agarose. The electrophoresis was 
performed in 0.5X TAE Buffer for 40 minutes at 80V (BioRad, Power Pac 300). The 
PCR bands were visualized with the Gel Doc 2000 system under UV light. PCR 
products were cut from the agarose gel and purified according to the instruction 
manual of the agarose gel DNA extraction kit (Roche, Cat. No. 1 696 505). 
The PCR products and the pCANTAB5E vector were first digested with Sfi I at 50ºC 
in the heat block (Techne, DB-2D) for 3 hours (Table 2.2). 
Table 2.2 : SfiI digestion reaction. 
Reagents PCR 
product 
Vector Final 
concentration 
dH2O  16μL 16μL - 
10X reaction buffer M  (Takara) 3 µL 3 µL 1X 
DNA (100ng/μL) 10μL 10μL 10 μg 
10U/μL Sfi I enzyme (Roche) 1 µL 1µL 10 U 
TOTAL 30 µL 30µL - 
The digestion products were loaded on 1,2 % agarose gel and electrophoresis was 
performed at 80 V.  The digestion products were extracted with the agarose gel DNA 
extraction kit (Roche, Cat. No. 1 696 505) according to the manufacturer 
instructions. The purified SfiI digestion products were then subjected to NotI 
digestion (Table 2.3). The NotI digestion was incubated 3 hours at 37Cº. The 
digestion products were agarose gel extracted (Roche, Cat. No. 1 696 505). 
Table 2.3 : NotI digestion reaction. 
Reagents PCR 
product 
Vector Final 
concentration 
dH2O  1μL 1μL - 
10X reaction buffer H  (Takara) 3 µL 3 µL 1X 
Sfi I digestion product 25μL 25μL - 
10U/μL Not I enzyme (Roche) 1 µL 1µL 10U 
TOTAL 30 µL 30µL - 
50 
SfiI/NotI digested HBsAg PCR product, and the pCANTAB5E phagemid vector 
were ligated with T4 DNA ligase (Fermentas) at 16ºC overnight, the enzyme was 
heat inactivated at 72ºC for 5 minutes. The reaction mixture was prepared as 
mentioned below (Table 2.4). 
Table 2.4 : Ligation reaction. 
Reagents 1:3 ratio 1:6 ratio 
dH2O  38µL 38µL 
10X ligation buffer  (Fermentas) 5 µL 5 µL 
Sfi I/ Not I digested PCR product 1µL (100 ng) 1µL (200 ng) 
Sfi I/ Not I digested vector (200ng) 5µL 5µL 
T4 DNA ligase (2,5U/μL) 1 µL 1µL 
TOTAL 50 µL 50µL 
The ligation product was transferred by Calcium chloride method into chemically 
competent E.coli TG1 cells (Pharmacia, The Netherlands). The transformation 
reaction was performed according to Maniatis (1982). Ligation product completed to 
50 μL with 50mM Tris pH 7.2 was mixed with 300 μL of E.coli TG1 competent cells 
in glass culture tube and incubated for 1 hour on ice. Then the mixture was incubated 
for 3 minutes at 42ºC followed by 10 minutes of incubation at room temperature. LB 
medium (1mL) was added to the transformation product and bacteria were incubated 
at 37ºC for 1 hour at 220 rpm in an incubator shaker (Innova, 4230 Refrigerated 
incubator shaker). After that time, 200μL of the transformation product was taken 
and spread on LB/Agar/Ampicillin (100g/mL) plate. The plate was incubated 
overnight at 37ºC (Innova). The remaining transformation product was poured in 50 
mL of LB containing Ampicillin (100g/mL) and incubated overnight at 37ºC at 220 
rpm (Innova, 4230 Refrigerated incubator shaker). 
The presence of HBsAg coding gene in bacteria colonies was controlled by colony 
PCR. Cells  picked from colonies were suspended in 15 l distilled water. Tubes 
were incubated at 95C for 3 minutes and centrifuged; the upper fluid was used as a 
template for polymerase chain reaction. Primers specific to the cloning region of 
pCANTAB5E vector were used as forward and reverse primers. The PCR reaction 
was prepared as following (Table 2.5). 
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Table 2.5 : Colony PCR reaction for HBsAg. 
Reagents Volume Final 
concentration 
dH2O  34µL  
10X reaction buffer (Roche) 5 µL 1X 
25 mM MgCl2 3 µL 2.5mM 
10 mM dNTP each  1 µL 10 pmol 
10 pmol pCANTAB5E For 2 µL 20 pmol 
10 pmol pCANTAB5E Rev 2 µL 20 pmol 
Supernatant of bacterial lysates  2 µL - 
1U Taq DNA polymerase (Roche) 1 µL 1U 
TOTAL 50 µL  
The PCR reaction was run as following  94ºC, 1min, 55ºC, 2min, 72ºC, 2 min for 30 
cycles, with an elongation step of 10 min at 72ºC in Biometra T3000 Thermocycler 
(Germany). The PCR products were run on 1.2% Agarose gel at 80V. 
One E.coli colony containing the plasmid of interest was selected for further DNA 
sequencing. For this purpose the selected colony was inoculated in 5 mL LB medium 
containing 100 µg/mL Ampicillin and incubated overnight at 37ºC, then plasmid 
isolation was performed by using Roche High pure plasmid isolation kit (Cat. No. 
11754777 001). The purified plasmids were used as a template for DNA sequencing. 
Sequencing reactions were done according to the Beckman coulter Genome Lab 
DTCS quick start kit protocol (Beckman Coulter, Cat. No. 608120). Primers HBsAg 
sequencing primer For and HBsAg sequencing primer Rev were used respectively 
for forward and reverse sequencing. The reactions were prepared in thin wall 0,2mL 
tubes as mentioned in Table 2.6.  
Table 2.6 : DNA sequencing reaction. 
Reagents PCR product 
DTCS  8 μL 
Template (400ng) 4 µL 
Primer (1,6pmol/μL) 2 μL 
Distilled water 6 μL 
TOTAL 20 µL 
The 30 cycles DNA sequencing PCR reaction was run as following  96C for 20 sec, 
50C for 2 min and 60C for 4 min in Biometra T3000 Thermocycler (Germany). 
The reactions were terminated by adding 5 μL of stop solution (2 μL of 3M Sodium 
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Acetate (pH 5.2), 2 μL of 100 mM Na2-EDTA (pH 8.0) and 1 μL of 20 mg/mL of 
glycogen) to each reaction tubes. The sequencing reaction products were then 
purified by alcohol precipitation. The air dried pellets were dissolved in 40 μL of 
Sample Loading Solution (Beckman Coulter) and loaded to Dye Terminator cycle 
sequencing automated sequencing system CEQ8800. The reaction program used for 
sequencing was lfr-a program (Capillary: 50ºC, Denaturation: 90ºC for 2 minutes, 
Injection: 2.0 kV for 15 seconds, Separation: 4.0 kV for 110 minutes). The DNA 
sequences were then uploaded to the SDCD Biology Workbench Internet website 
(Url-2), where multiple alignments, database searches and protein translations were 
conducted. 
2.2.1.2 Production of HBsAg displaying phages and phage ELISA 
Wild-type phages and phage-displayed HBsAg were produced by M13K07 helper 
phage infection. For this purpose a single transformant E. Coli TG1 colony 
containing the wild-type phagemid or the correct HBsAg gene insertion were 
selected and were cultured overnight at 37°C at 220 rpm in 2xTY (16.0 gr bacto-
tryptone, 10.0 gr yeast extract, 5.0 gr NaCl) containing 100 μg/mL ampicillin and 2% 
glucose. The next day overnight cultures were inoculated in 50 mL of 2xTY 
containing 100 μg/mL ampicillin and 2% glucose and cells were grown at 37°C at 
220 rpm until the OD600 reached 0.5. Then 10 mL of the culture was added into 50 
mL fresh 2xTY medium containing 100 μg/mL ampicillin and 2% glucose, and 
finally 10
10
 M13KO7 helper phages were added to the culture. After 45 min of 
incubation at 37°C without agitation and 45 min at 37°C with agitation (220rpm), 
cells were harvested for 10 min at 3,000×g. The cells were resuspended in the same 
volume of 2xTY containing 100 μg/mL ampicillin and 50 μg/mL kanamycin and 
grown at 30°C overnight with agitation (220 rpm). The next day cells were harvested 
at 8,000g and the supernatants containing either the  recombinant or the wild-type 
infective phages were precipitated at 4°C by adding ¼ of the supernatant volume of 
polyethylene glycol-6000 (1M PEG 6000, 2.5M NaCl). After 2 hours of incubation 
on ice phages were centrifuged at 12000 rpm for 40 minutes. The pellet containing 
phage particles were resuspended in 1 mL of phosphate buffer saline (PBS; 3.2 mM 
Na2HPO4 × 2H2O, 1.4 mM KH2PO4, 2.7 mM KCl and 137 mM NaCl) and the 
suspension was centrifuged for 10 minutes at 4000 rpm for pelleting residual cells. 
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The supernatant containing the phages was transferred into a new tube. The purified 
phage particles were then filter sterilized with Millex-HV (Millipore) for further 
experiments. The number of infective phages produced was determined by the phage 
plaque counting assay. A single colony of E. coli TG1 was inoculated into 5mL of 
2xTY and grown overnight at 37°C at 220 rpm. The next day overnight culture was 
inoculated (50μL) in 5mL of 2xTY and bacteria were grown at 37°C until mid-log 
phase (OD600 of 0.5-0.8). Then 100 µL of culture was infected with 10μL of serial 
phage dilutions (10
-6
, 10
-8
 and 10
-10) for 30 min at 37°C. Infected bacteria were 
spread on 2xTY agar plates containing 100µg/mL Ampicillin and incubated 
overnight at 37°C. The next day colonies were counted and translated to colony 
forming units (CFU) per mL. 
The binding property of HBsAg displayed on the phage surface was tested by Phage 
ELISA. Two different ELISA methods have been used to detect the HBsAg 
displayed on phage particles. Each assay was conducted in triplicate. In the first 
method, ELISA well plates were coated overnight at +4°C with either 1010 HBsAg 
displaying or wild-type phage particles. The next, day the wells were washed 6 times 
with TPBS (PBS containing 0.1% Tween 20) and then blocked for 2 hours at room 
temperature with TPBS containing 1% BSA. The wells were washed 6 times with 
TPBS. Polyclonal anti-HBsAg rabbit antibody (1/200), as primary antibody, was 
incubated for 1 hour at room temperature. The wells were then washed again 6 times 
with TPBS and goat anti-rabbit alkaline phosphatase (Thermo Scientific) conjugate 
(1/1000) was used as secondary antibody. After one hour of incubation at room 
temperature the wells were washed 6 times with TPBS and para-nitrophenyl 
phosphate substrate (PNPP) solution (1 mg/mL of pNPP in substrate buffer (0,1 M 
glycine, 1mM ZnCl2, 1mM MgCl2, pH: 10,4) was used as a chromogen. The 
absorbance was measured one hour later at 405 nm using an ELISA reader (Bio-Rad) 
after stopping the reaction with 1 M NaOH.  
In the second method, ELISA well plates were coated overnight at 4ºC with anti-
HBsAg polyclonal antibody (1/200). The next day wells were washed 6 times with 
TPBS and then blocked with TPBS containing %1 BSA. Wells were washed 6 times 
with TPBS, phage particles (10
10
) displaying HBsAg, or wild-type phage was then 
added to each well. After one hour of incubation at room temperature wells were 
washed 6 times with TPBS and mouse anti-M13 horseradish peroxidase (GE 
Healthcare) conjugate (1/1000) was used as secondary antibody. The absorbance was 
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measured at 410nm using a microplate reader (Bio-Rad) after a 2,2’- azino-bis (3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate solution (1 mg ABTS in 
4.5 mL 50mM citric acid (pH=4) containing %0.05 H2O2). 
2.2.1.3 Mouse Immunization and ELISA from immunized mice sera 
Immunization assays were conducted with 8-week-old male immunocompetent 
BALB/cJ mice. Six different mice groups containing 3 mice each were subjected to 
different injections without any adjuvant. The first 3 groups received 300 μL of 
different concentrations of phage displaying HBsAg (10
10
, 10
11
 and 10
12 
phage 
particles diluted in PBS). The fourth and fifth groups received 10
11
 or 10
12
 phage 
particles without HBsAg in 300 μL of PBS. The mice in group 6 received 300 μL of 
PBS as control. Each group was constituted of 2 mice except group five and six 
where only one mouse was used. All the immunizations were performed in triplicate 
at 3-week intervals. Intradermal injections were conducted using 50 μL under each 
front leg and 100 μL under each back leg pit). Blood samples were collected from the 
tail of each mouse before each injection; the last bleed was performed 4 days after 
the last injection. Blood samples were centrifuged, and the supernatants were used 
for ELISA assays. 
ELISA plates were coated overnight with 200 ng of HBsAg (Ad/Ay, 100 ng each) 
(Fitzgerald Industries International) in coating solution (0.1N NaHCO3). Wells were 
washed 6 times with TPBS (0,1 % PBS-Tween 20) and then blocked with TPBS 
containing %1 BSA. The wells were washed 6 times with TPBS, mice sera (1/50) 
were then incubated for 1 hour at room temperature. Wells were washed 6 times with 
TPBS and goat anti-mouse HRP conjugate (1/1000) (Thermo Scientific) was added 
and incubated for 1 hour at room temperature. Following 6 times of washing with 
TPBS, ABTS substrate solution was added then the absorbance was measured at 410 
nm after 1 hour of incubation with an ELISA Reader (Bio-rad). 
2.2.1.4 Statistical analysis 
The IBM SPSS Statistics (SPSS), version 17 for Windows was used for statistical 
analysis. The differences in BALB/cJ mice humoral immune response between 
groups were analyzed using mixed model ANOVA with Tukey post hoc test. A 
significant difference between groups and within groups at different injection periods 
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was analyzed using univariate General Linear Model with Tukey post hoc test. P 
values of <0.05 were considered statistically significant. 
2.2.1.5 Construction of a recombinant antibody library 
The construction of a single chain variable fragment (ScFv) recombinant antibody 
library necessitate B cells mRNA extracted the spleen of  immunized mouse. 
Therefore, the spleen of mice immunized with HBsAg were collected and were 
homogenized (Janke & Kunkel Ika Werk RW20) according to the EZ-RNA Total 
RNA Isolation Kit (Biological Industries, Israel) protocol. The purified total RNA 
was dissolved in 100μL of DEPC treated dH2O at 55°C for 15 min. The RNA quality 
was controlled according to the OD260 / OD280 ratio. 
After the isolation of total RNA, Hexamer primer based standard method 
(Samsbrook, Cold Spring Harbor Laboratory Press 1989, second edition) was used to 
generate a cDNA library from mRNA. The cDNA library was used as a template for 
the amplification of immunoglobulin heavy and light chain variable regions by PCR.  
Heavy chain variable region (VH)  amplification was performed in  a  total volume of 
50µL containing 5 µL Taq polymerase buffer (10X); 3 µL MgCl2 (25 mM); 1 l 
dNTP/10 mM of each, 2 l of each heavy chain primers (primer 701 and 702), 2 l 
of template cDNA, 1 μL of Taq polymerase enzyme (1U /l) (Fermentas). A similar 
PCR reaction was made for the amplification of the Light chain variable region (VL) 
and the linker region except that the primers used were different, primers 703 and 
704 for VL and primers 422 and 423 for the linker region. The PCR program for the 
amplifications was set to 5 minutes of incubation at 94°C and 30 cycles, each cycle 
corresponding to 1 min at 94°C, 2 minutes at 55°C and 2 minutes at 72°C with an 
elongation step at 72C for 10 minutes. PCR products were controlled on 1.5% 
agarose gel then extracted from the gel with the agarose gel DNA extraction kit 
(Roche, Cat. No. 1 696 505) according to the manufacturer instructions. 
The construction of the scFv library was carried out with two successive PCR 
reactions. The first stage consisted of the assembly of variable light and heavy chain 
PCR products via the linker coding region. The 50 µL reaction was set up with 5 µL 
of Taq polymerase buffer (10X); 3 µL of MgCl2 (25 mM); 1 l of dNTP/10 mM 
from each, 3 l VH PCR product (100ng/l),  3 l VL PCR product (100 ng/l), 1 l 
linker PCR product (100ng/μL) , 1 μL of Taq polymerase enzyme (1U/l) 
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(Fermentas). The reaction was performed as follows: 1 min at 94 °C, 4 min at 63 °C 
for a total of 7 cycles. The second PCR reaction was run as soon as the first reaction 
was terminated by adding to the first reaction tube 50 l of mixture containing 5 l 
Taq polymerase buffer (10X), 3 l MgCl2 (25 mM), 1 l dNTP/10 mM from each , 2 
l of primers 702  and 704, 1 μL of Taq polymerase enzyme (1U /l) (Fermentas). 
The second reaction was set up to 25 cycles of 1 min at 94°C, 2 min at 55°C,  2min 
at 72 °C with an elongation step of 10 min at 72°C. The scFv library was controlled 
on 1.2 % agarose gel. 
Once the scFv library was obtained, SfiI and NotI restriction enzymes sites were 
integrated respectively at the 5’ and 3’ ends of the scFv library by PCR. The 
integration reaction was performed in 50µL total volume containing 5 µL Taq 
polymerase buffer (10X); 3 µL MgCl2 (25 mM); 1 l of dNTP/10 mM of each, 2 l 
of 702 primer with SfiI restriction enzyme site and 704 primer with NotI restriction 
enzyme site, 2 l of template cDNA, 1 μL of Taq polymerase enzyme (1U /l) 
(Fermentas). Then the reaction was set up to 30 cycles of 1 min. at 94°C, 2 min at 
55°C, 2 min at 72°C with an elongation step of 10 min at 72°C. The PCR products 
were controlled on 1.2 % agarose gel. 
The scFv library cloning procedure was the same as the cloning of HBsAg described 
previously.  The PCR product and the pDUCK1 phagemid vector were first digested 
with Sfi I and NotI, the digestion products were extracted from agarose gel with the 
agarose gel DNA extraction kit (Roche, Cat.No. 1 696 505) then ligated to each other 
with T4 DNA ligase (Fermentas). The ligation products were transferred into 
chemically competent E.coli TG1 cells (Pharmacia, The Netherlands) by calcium 
chloride transformation (Maniatis et al., 1982). The presence of scFv library was 
controlled by colony PCR using the same primers as pCANTAB5E vector.  
2.2.1.6 Selection of an anti-HBsAg scFv from the library 
The scFv phage library was produced as mentioned in section 2.2.1.2. Briefly, the 
scFv library containing cell mixture was grown overnight at 37°C at 220 rpm in 
2xTY (16.0 gr bacto-tryptone, 10.0 gr yeast extract, 5.0 gr NaCl) containing 100 
μg/mL ampicillin and 2% glucose. The next day overnight cultures were inoculated 
in 50 mL of 2xTY containing 100 μg/mL ampicillin and 2% glucose and cells were 
grown at 37°C at 220 rpm until the OD600 reached 0.5. Then 10 mL of the culture 
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was added into 50 mL fresh 2xTY medium containing 100 μg/mL ampicillin and 2% 
glucose and finally 10
10
 M13KO7 helper phages (New England Biolabs) were added 
to the culture. After 45 min of incubation at 37°C without agitation and 45 min at 
37°C with agitation (220rpm), cells were harvested for 10 min at 3,000×g. The cells 
were resuspended in the same volume of 2xTY containing 100 μg/mL ampicillin and 
50 μg/mL kanamycin and grown at 30°C overnight with agitation (220 rpm). The 
next day cells were harvested at 8,000g and the supernatants containing either the  
recombinant or the wild-type infective phages were precipitated at 4°C by adding ¼ 
of the supernatant volume of polyethylene glycol-6000 (1M PEG 6000, 2.5M NaCl). 
After 2 hours of incubation on ice phages were centrifuged at 12000 rpm for 40 
minutes. The pellet containing phage particles were resuspended in 1 mL of 
phosphate buffer saline (PBS; 3.2 mM Na2HPO4 × 2H2O, 1.4 mM KH2PO4, 2.7 
mM KCl and 137 mM NaCl) and the suspension was centrifuged for 10 minutes at 
4000 rpm for pelleting residual cells. The supernatant containing the phages was 
transferred into a new tube. The purified phage particles were then filter sterilized 
with Millex-HV (Millipore) for further experiments. The concentration of phage 
particles in the developed phage-displayed library was determined by the phage 
plaque counting assay. A single colony of E. coli TG1 was inoculated into 5mL of 
2xTY and grown overnight at 37°C at 220 rpm. The next day overnight culture was 
inoculate (50μL) in 5mL of 2xTY and bacteria were grown at 37°C until mid-log 
phase (OD600 of 0.5-0.8). Then 100 µL of culture was infected with 10μL of serial 
phage dilutions (10-6, 10-8 and 10-10) for 30 min at 37°C. Infected bacteria were 
spread on 2xTY agar plates containing 100µg/mL Ampicillin and incubated 
overnight at 37°C. The next day colonies were counted and translated to colony 
forming units (CFU) per mL. 
The selection of anti-HBsAg antibody from the phage-displayed library was done by 
Biopanning. Immunomaxisorb tube was coated with 500 ng of HBsAg (Ad/Ay, 250 
ng each, Fitzgerald Industries International) in coating solution (0.1N NaHCO3) 
overnight at 4°C. The next day the tube was washed 3 times with PBS containing 
0.1% Tween (TPBS) then blocked with TPBS containing 1%BSA for 2 hours at 
room temperature. The tube was then washed 3 times with TPBS. The phage-
displayed  library (500µl containing 1011 phage particles) was added to the tube and 
incubated 2 hours at room temperature. After the incubation, the tube was washed 30 
times with PBS then 30 times with TPBS. The phages bound to the tube were then 
58 
incubated for 30 min at 37°C with 500 µl of E.coli TG1 cells (OD600 0.5) for 
infection. The infected cells (100µl) were spread on LB agar plates containing 
ampicillin (100 μg/mL) and incubated overnight at 37°C. The next day all the 
colonies were counted  then collected in one tube with a scrapper. The cell mixture 
was used for the generation of a new phage library enriched against HBsAg by the  
same phage amplification procedure as mentioned at the beginning of this section. 
The new phage-displayed titer was calculated then used for a second round of 
biopanning. After 2 biopanning rounds, each colony from the infection plate were 
separately subjected to phage amplification then their titer was calculated. 
The binding property of each clone to HBsAg was tested by Phage ELISA. ELISA 
well plates were coated overnight at 4ºC with HBsAg (Ad/Ay, 100 ng each, 
Fitzgerald Industries International). The next day wells were washed 6 times with 
TPBS and then blocked with TPBS containing %1 BSA. Wells were washed 6 times 
with TPBS, phage particles (10
10
) were then added to each well. After one hour of 
incubation at room temperature wells were washed 6 times with TPBS and mouse 
anti-M13 horseradish peroxidase (GE Healthcare) conjugate (1/1000) was used as 
secondary antibody. The absorbance was measured at 410nm using a microplate 
reader (Bio-Rad) after a 2,2’- azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) 
(ABTS) substrate solution (1 mg ABTS in 4.5 mL 50mM citric acid (pH=4) 
containing %0.05 H2O2). 
2.2.2 Development and characterization of an anti-HBsAg gold binding 
recombinant antibody 
The strategy selected for cloning experiments are as indicated in Figure 2.1.  The 
pQE2 multiple cloning site is indicated in Figure 2.1 A, the Lig7 scFv will be first 
cloned into the pQE2 vector (Figure 2.1 B) then the GBP-1 and the GBP-1 and the 
repeated GBP-1 sequences will be cloned into the Lig7/pQE2 vector (Figure 2.1 C). 
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Figure 2.1 : Cloning strategy. 
2.2.2.1 Cloning of the anti-HBsAg Lig7 recombinant antibody into pQE2 vector 
The anti-HBsAg Lig7 scFv present in the pDUCK1 phagemid vector was recloned 
into the pQE2 (Qiagen) vector. For this purpose, the Lig7 scFv was amplified by 
PCR using Lig7_Forw_NdeI and Lig7_Rev_NotI  primers including the NdeI and 
NotI restriction enzyme sites. The reaction was set up as following (Table 2.7); 
Table 2.7 : Lig7 PCR amplification reaction. 
Reagents Volume Final 
concentration 
dH2O  34µL  
10X reaction buffer (Roche) 5 µL 1X 
25 mM MgCl2 3 µL 2.5mM 
10 mM dNTP each  1 µL 10 pmol 
10 pmol Lig7_Forw_NdeI 2 µL 20 pmol 
10 pmol Lig7_Rev_NotI 2 µL 20 pmol 
plasmid 100ng/µL 2 µL 200 ng 
1U Taq DNA polymerase (Roche) 1 µL 1U 
TOTAL 50 µL  
The PCR reaction was run as following  94 ºC, 1min, 55 ºC, 2min, 72 ºC, 2 min for 
30 cycles, with an elongation step of 10 min at 72ºC in Biometra T3000 
Thermocycler (Germany). The PCR products were run on 1,2 % Agarose gel at 80V. 
The amplified PCR fragments and the pQE2 vector were first digested with NotI 
(Fermentas) then extracted from agarose gel (1.2%). The digestion products were 
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then digested with NdeI (Fermentas) enzyme. Both digestions were run for 3 hours at 
37ºC, the digestion reactions are indicated below (Table 2.8 and Table 2.9):  
Table 2.8 : NotI digestion of Lig7. 
Reagents for NotI digestion PCR 
product 
Vector Final 
concentration 
dH2O  16μL 16μL - 
10X reaction buffer  3 µL 3 µL 1X 
DNA (100ng/μL) 10μL 10μL 10μg 
10U/μL NotI  1 µL 1µL 10U 
TOTAL 30 µL 30µL - 
Table 2.9 : NdeI digestion of Lig7. 
Reagents for NdeI digestion Digested PCR 
product 
Digested 
Vector 
Final 
concentration 
dH2O  - - - 
10X reaction buffer  3 µL 3 µL 1X 
DNA (100ng/μL) 26μL 26μL - 
10U/μL NdeI  1 µL 1µL 10U 
TOTAL 30 µL 30µL - 
The agarose gel extracted NotI and NdeI double digested products were ligated with 
T4 DNA ligase (Fermentas, Sweden), the 50 µL reaction was prepared (Table 2.10) 
and the reaction mixture was incubated overnight at 16ºC. The ligase was inactivated 
by treating the mixture at 72ºC for 5 minutes.  
Table 2.10 : Ligation of Lig7 into pQE2. 
Reagents 1:3 ratio 1:6 ratio 
dH2O  38µL 37µL 
10X ligation buffer  (Fermentas) 5 µL 5 µL 
Sfi I/ Not I digested PCR product 1µL (100 ng) 2µL (200 ng) 
Sfi I/ Not I digested vector (200ng) 5µL 5µL 
T4 DNA ligase (2,5U/μL) 1 µL 1µL 
TOTAL 50 µL 50µL 
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The ligation products were transferred into chemically competent E.coli DH5α cells 
by calcium chloride method according Maniatis et al. (1982). The transformed cells 
were spread on LB/Agar/Ampicillin (100g/mL) plates and incubated overnight at 
37ºC (Innova). The remaining transformation product was poured in 50 mL of LB 
containing Ampicillin (100g/mL) and incubated overnight at 37ºC at 220 rpm 
(Innova, 4230 Refrigerated incubator shaker). The presence of the Lig7 scFv 
encoding gene was controlled by colony PCR. The reaction was set up as mentioned 
before. Plasmid isolation was made from the colony PCR positive clones by using 
Roche High pure plasmid isolation kit (Cat. No. 11 754 777 001) according the 
manufacturer instructions. The presence of Lig7 scFv in the pQE2 vector was 
confirmed with DNA sequence analysis by using Beckman coulter Genome Lab 
DTCS quick kit. 
2.2.2.2 Insertion of gold binding peptide coding region in the Lig7/pQE2 vector 
The amplification of the gold binding peptide encoding gene was made PCR using 
specific primers with NotI and HindIII restriction enzyme sites (Table 2.11). For this 
purpose GBP_forward_NotI_with tail and  GBP_reverse_HindIII_ with tail primers 
were used. The reaction was set up as following; 
Table 2.11 : PCR reaction for the amplification of GBP. 
Reagents Volume Final 
concentration 
dH2O  34µL  
10X reaction buffer (Qiagen) 5 µL 1X 
10 mM dNTP each  1 µL 10 pmol 
10 pmol GBP_forward_NotI_with_tail 2 µL 20 pmol 
10 pmol GBP_reverse_HindIII_with_tail 2 µL 20 pmol 
plasmid (Lig7/pQE2) 100ng/µL 2 µL 200 ng 
1U HotStart Taq DNA polymerase (Qiagen) 1 µL 1U 
TOTAL 50 µL  
The PCR reaction was run as following  94 ºC, 1min, 55 ºC, 2min, 72 ºC, 2 min for 
30 cycles, with an elongation step of 10 min at 72ºC in Biometra T3000 
Thermocycler (Germany). The PCR products were run on 2 % Agarose gel at 80V. 
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The half of the PCR product was purified with QIAquick PCR purification kit 
(Qiagen, Cat.No. 28106) according to the manufacturer instructions. Briefly, the 
PCR product was mixed with 5 volume of PB buffer, then the mixture was poured 
into the QIAquick column. The column was centrifuged for 1 min. The column was 
then washed with 750µL of PE buffer and centrifuged for 1 min. The flow-through 
was removed, and the column was centrifuged for 1 min for drying the columns 
membrane. The DNA was eluted with 50 µL of Buffer EB (10 mM Tris·Cl, pH 8.5). 
The other half was extracted from agarose gel with the agarose gel DNA extraction 
kit (Roche, Cat.No. 1 696 505). The purified PCR products were quantified with 
nanodrop (Thermo scientific). The PCR products were then double digested with 
NotI and HindIII (Thermo Scientific) for 3 hours at 37ºC (Table 2.12). 
Table 2.12 : NotI and HindIII digestions. 
Reagents for NotI and HindIII digestion PCR product Vector 
dH2O 16μL 16μL 
10X FastDigest  Buffer 3 µL 3 µL 
DNA (100ng/μL) 10μL 10μL 
10U/μL FastDigest NotI  1 µL 1µL 
10U/μL FastDigest HindIII 1 µL 1µL 
TOTAL 30 µL 30µL 
The digestion products were controlled on 1.5% agarose gel and then extracted with 
agarose gel DNA extraction kit (Roche, Cat.No. 1 696 505). The purified DNA 
products were quantified with nanodrop then ligated with T4 DNA ligase 
(Fermentas, Sweden). The 50 µL ligation reaction (Table 2.13) was incubated 
overnight at 16ºC. The ligase was then inactivated by treating the mixture at 72ºC for 
5 minutes.  
Table 2.13 : Ligation reaction of Lig7 and pQE2. 
Reagents 1:3 ratio 1:6 ratio 
dH2O  38µL 37µL 
10X ligation buffer  (Fermentas) 5 µL 5 µL 
NotI/ HindIII digested PCR product 1µL (100 ng) 2µL (200 ng) 
NotI/ HindIII digested vector (200ng) 5µL 5µL 
T4 DNA ligase (2,5U/μL) 1 µL 1µL 
TOTAL 50 µL 50µL 
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The ligation products were transferred into chemically competent E.coli DH5α cells 
by calcium chloride method according Maniatis et al. (1982). The transformed cells 
were spread on LB/Agar/Ampicillin (100g/mL) plates and incubated overnight at 
37ºC (Innova). The remaining transformation product was poured in 50 mL of LB 
containing Ampicillin (100g/mL) and incubated overnight at 37ºC at 220 rpm 
(Innova, 4230 Refrigerated incubator shaker). The presence of the Lig7-GBP fusion 
encoding gene was controlled by colony PCR using 3 sets of primer pairs. The first 
set was  GBP_forward_NotI_with_tail and GBP_reverse_HindIII_with_tail primers; 
the second set was primers specific to Lig7 scFv, Lig7_Forw_NdeI and 
Lig7_Rev_NotI primers. The last set was pQE2 promoter and reverse primers 
specific to the cloning site of the pQE2 vector. The reactions were set up as 
mentioned in Table 2.14. 
Table 2.14 : Colony PCR reaction. 
Reagents Volume 
dH2O  34µL 
10X reaction buffer (Roche) 5 µL 
25 mM MgCl2 3 µL 
10 mM dNTP each  1 µL 
10 pmol Forward primer 2 µL 
10 pmol Reverse primer 2 µL 
Supernatant of bacterial Lysate  2 µL 
1U Taq DNA polymerase (Roche) 1 µL 
TOTAL 50 µL 
Plasmid isolation was made from the colony PCR positive clones by using Roche 
High pure plasmid isolation kit (Cat. No. 11 754 777 001) according the 
manufacturer instructions. The presence of the gold binding peptide encoding 
sequence scFv in the Lig7/pQE2 vector was confirmed with DNA sequence analysis 
by using Beckman coulter Genome Lab DTCS quick kit. 
2.2.2.3 Expression of the bifunctional recombinant antibodies 
To express the bifunctional antibodies first plasmids containing either Lig7 itself or 
Lig7-GBP encoding gene was isolated with QIAprep Spin Miniprep Kit (Qiagen, 
Cat.No. 27106) according to the manufacturer instructions. The plasmids were then 
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transferred into either chemically competent  E.coli BL21(DE3) strain or E. coli 
M15[pREP4] strain by calcium chloride transformation as mentioned in section 
2.2.1.1. Transformant cells were selected on selective medium containing ampicillin 
(100 µg/mL) for E.coli BL21(DE3) strain,  containing ampicillin (100 µg/mL) and 
kanamycin (50 µg/mL) for E. coli M15[pREP4]. One clone for each bifunctional 
construct was selected for protein expression studies. 
The protein expression experiment was started by inoculating 5 mL of LB medium 
containing the appropriate selection agent regarding the cell strain used, and cells 
were grown overnight at 37 °C and 220 rpm. The next, 5 mL of LB medium 
containing the appropriate selection agent were inoculated with the overnight 
cultures. The cells were grown at 37 °C and 220 rpm until OD600 reached 0.5, and an 
aliquot was taken as a time 0 (T0) sample. Then IPTG was added into the culture 
flasks to a final concentration of 1mM. An aliquot was taken after 4 hours as  T4  
induction sample. The remaining cells were harvested at 4000 rpm for 10 min and 
the pellet was stored at -20 °C.  
The T0 and T4 pellet samples were prepared by resuspending the pellets with 30 µL 
of sample buffer (1 % Glycerol, 1 % SDS,  0.1% 2--mercaptoethanol, 0.05 % 
bromophenol blue in 0.5M Tris-HCl, pH:6.8) and denatured at 95 °C for 3 min. The 
samples were loaded (5 µL) on a 12% acrylamide gel and run at 100 V for 10 min 
than at 120 V for 1.5 hours with Miniprotean II system (Bio-Rad). After the 
electrophoresis one gel was stained with Coomassie staining solution (50% 
Methanol, 10% Acetic acid and 0.1% Coomassie Blue R) for 40 min and destained 
with destaining solution (10% Methanol and 7% Acetic acid). The twin gel was 
subjected to western blot by electro-blotting the proteins on nitrocellulose membrane 
using  a semi-dry blotting system (Bio-Rad). The nitrocellulose membrane was then 
blocked for 1.5 hours with a blocking solution (PBS containing 0.1% Tween-20 and 
1% BSA). The membrane was washed 3 times for 5 min. with washing buffer (PBS 
containing 0.1% Tween-20). Mouse monoclonal anti-His HRP conjugate (Sigma) 
diluted in  blocking buffer  (1/16000) was incubated for 1 hour. The membrane was 
washed 3 times with washing buffer then a 4-Chloro-1-Naphthol substrate solution 
was used as chromogen (2 mL of 4-Chloro-1-Naphthol solution (30 mg of 4-Chloro-
1-Naphthol in 10 mL of methanol), 50 µL of 3% H2O2 in 10 mL of triethanolamine 
buffer ( 128 mM NaCl, 0.28 % triethanolamine, pH 7.5). 
65 
2.2.2.4 Purification of bifunctional antibodies from large scale culture and 
removal of His-Tag 
Large scale production of the bifunctional recombinant antibody was made using 
clones in  M15[pREP4] cells. Cells were grown overnight in 50 mL LB medium 
containing ampicillin (100 µg/mL) and kanamycin (50 µg/mL) at 37 °C and 220 
rpm. The next day all the 50 mL of the overnight culture was poured into 500 mL of  
LB medium containing ampicillin (100 µg/mL) and kanamycin (50 µg/mL). The 
cells were grown at 37 °C and 220 rpm until OD600 reached 0.5 and IPTG was added 
into the culture flasks to a final concentration of 0.1 mM. Cells were then harvested 
at 4000 rpm for 10 min and the pellet was resuspended with 20 mL of B-PER 
bacterial protein extraction reagent (Thermo Scientific, Cat. No. 78243) and 
incubated at room temperature and 200 rpm for 10 min. The suspension was 
centrifuged for 15 min at 27000 g and the supernatant was stored. The inclusion body 
pellet was solubilized with inclusion body solubilization reagent (Thermo scientific, 
Cat. No: 78115) according to the manufacturer instructions indicating that 8 mL of 
reagent must be used for 1 g of wet inclusion body pellet. After 2 hours of 
solubilization at room temperature, the suspension was centrifuged for 15 min at 
27000 g and room temperature. The supernatant was collected for metal affinity 
purification step. 
The metal affinity purification was done by mixing the solubilized inclusion body 
solution with HisPur Cobalt resin  (Thermo Scientific, cat. No. 89965) (1/4 volume 
of solubilized inclusion bodies) and incubated for 80 min at 37 °C and 200 rpm.  The 
suspension was then centrifuged for 1 min at room temperature and 700 g. The 
supernatant was collected. The resin was washed by shaking for 10 min (37 °C and 
200 rpm) with 8 mL of Buffer C (100 mM NaH2PO4, 10 mM Tris-Cl, 8M urea, pH 
7.0) then centrifuged for 1 min at 700 rpm. The supernatant was collected, and the 
pellet was washed 2 times with 4 mL of Buffer C (pH 7.0). The supernatants were 
collected after 1 min of centrifugation at 700 rpm. The elution was made 2 times by 
resuspending the resin with 4 mL of  Buffer E (100 mM NaH2PO4, 10 mM Tris-Cl, 
8M urea, pH 4.5) and incubating for 10 min at  37 °C and 200 rpm. The purification 
steps were controlled on 12% SDS-PAGE. The percentage of the purity of the 
antibodies was determined by the 2001 Bioanalyzer instrument (Agilent). 
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The affinity column purified denatured recombinant antibodies were then subjected 
to refolding process by successive 1/2 dilutions (Yang et al., 2011). For this purpose 
successive dilutions of the solubilized recombinant antibodies was done with dilution 
Buffer (100mM NaH2PO4, 10mM Tris.Cl) until Urea concentration  reached 2 M 
Then, for a correct disulphide bonds formation within the antibody structure a red-ox 
environment was generated with reduced and oxidized glutathione (GSH 2mM, 
GSSG 0,4mM). The prevention of recombinant antibody precipitation was planned 
by adding L-Arginine for a final concentration of 400 mM. The same red-ox and L-
Arginine conditions were followed until the Urea concentration was decreased to 0.5 
M. Finally all the additives were removed from the recombinant antibody solution by  
dialysis against Dilution Buffer for 2 days at +4°C. 
Histidine tag removal experiments were done with DAPase enzyme according to the 
manufacturer instructions. Briefly 50 µg of recombinant antibody in 50 µl of buffer 
was digested with 10.5 µL of activated enzyme mixture (2.5 mU of DAPase enzyme, 
5 µL of 2 mM of Cysteamine-HCl and 150 mU of Q-cyclase) for 15, 30 and 45 min. 
at 37 °C. The digestion products, for each time period, were controlled on 12% 
Acrylamide gel. 
2.2.3 The use of the recombinant antibodies as a biosensing probe 
2.2.3.1 Binding studies using Surface Plasmon Resonance spectroscopy (SPR) 
The SPR spectroscopy and SPR slides were obtained from Reichert Instruments 
(Reichert Technologies, Depew, NY, USA).  
Immobilization of gold binding bifunctional antibodies studies was made by 
adsorbing the antibodies to gold coated SPR chips. First the gold coated chips were 
cleaned by UV/Ozon treatment for 15 min. Then the chips were placed on the SPR 
spectrometer and washed for 10 min with dilution buffer (100mM NaH2PO4, 10mM 
Tris.Cl) at 100µL/min rate and 25°C. Once baseline was stabilized, different 
concentrations ( 200 nM, 300 nM, 400 nM and 600 nM) of Lig7-GBP, Lig7-3GBP 
and Lig7-5GBP were flown on the sensor chip for 5 min at 100µL/min rate and 
25°C. After each injections the chips were washed with dilution buffer until the 
stabilization of the chips surface. 
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The binding of HBsAg to the immobilized bifunctional antibodies was monitored 
first immobilizing 300 nM of antibodies on the chip surface. Then various 
concentrations of HBsAg (100 nM, 150 nM and 200 nM) were flown over the chip 
with immobilized recombinant antibodies at 100µL/min rate and 25°C. After each 
injections the chips were washed with dilution buffer until the stabilization of the 
chips surface. 
For chemically immobilization of Lig7 on SPR chips, the SPR chip surfaces were 
functionalized overnight with mercaptoundecanoic acid (Sigma) to form self-
assembled monolayers (SAMs) of COOH-terminated thiols. The functionalized SPR 
surface was activated by injecting 1:1 volume ratio of N-hydroxysulfosuccinimide 
(NHS) and 1-ethyl-3-(-3-dimethiyaminopropyl) carbodiimide (EDC) in a flow cell. 
Lig7 scFv solution was passed across the activated SAM surface at a constant flow 
rate (2 μL/Min) at 25◦C. After immobilization of Lig7 scFv on the surface, loosely 
bound and unbound receptors were removed by extensive washing of the chip 
surface with buffer solution. Ethanolamine was passed across the Lig7 scFv 
decorated SPR chip surface in the aim of blocking  the amine-coupling end of SAM. 
Interaction of the Lig7 scFv with HBsAg was monitored by passing HBsAg over the 
chip surface at 50, 100, and 200 nM.  
All the measurements were analyzed with the BIAevaluation Software 4.1 (Biacore). 
The maximum uptake and adsorption values were plotted on graphs. The adsorption 
kinetics were calculated using 1:1 Langmuir association model represented by the 
equation given below: 
RIttkCkRtR daeq  ))])(*(exp(1[)( 0  (2.1) 
where  
max*)*/(* RkCkCkR daaeq   (2.2) 
R(t) correspond to the SPR signal (µRIU) at time t. The injection start time is t0. The 
association rate (M
-1
s
-1
) constant is represented by (ka) and the dissociation rate (s
-1
) 
constant is represented by (kd). The analyte concentration is C. Rmax corresponds to 
maximum analyte binding capacity (µRIU) and RI corresponds to the bulk refractive 
index contribution (µRIU).  
The equilibrium dissociation constant  (KD) was deduced from adsorption (ka) and 
desorption (kd) rates according to equation 2.3. 
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K   (2.3) 
2.2.3.2 Monitoring HBsAg in in-vitro cell model 
For monitoring HBsAg presence in mammalian cells first HBsAg was cloned into 
mammalian expression vector and transfected into mammalian cells and the 
expression of HBsAg was controlled by ELISA and microscopic observations. The 
cloning experiments were done according to the cloning protocol given in section 
2.2.1.1. Briefly, HBsAg gene was amplified with PCR by using 
HBsAg_Forward_BamHI and HBsAg_Reverse_BamHI primers containing BamHI 
restriction site. The PCR product was extracted from 1.2 % agarose gel by using 
agarose gel DNA extraction kit (Roche, Cat. No. 1 696 505). Then the pCEP4 vector 
and PCR product were digested with BamHI enzyme. The digestion products were 
purified and then ligated with T4 DNA ligase (Fermentas). The ligation product was 
transferred into chemically competent DH5α cells by calciım chloride transformation 
method. The presence of HBsAg in pCEP4 was confirmed by colony PCR and then 
by DNA sequence analysis (Beckman coulter Genome Lab DTCS quick kit). One 
position clone was selected and plasmid was isolated from it with Roche High pure 
plasmid isolation kit (Cat. No. 11754777001).  
High purity HBsAg-pCEP4 plasmid was then transfected into different mammalian 
cell lines such as HeLa, Hek293 Trex, HepG2 and COS7. For this purpose, 1day 
before transfection, 0.5 x 10
5
 cells in 1 mL of DMEM-F12 growth medium 
(containing %10 FBS) were poured in wells. The next day 8 µg HBsAg-pCEP4 
plasmid was gently mixed in 500 μl of DMEM-F12 without serum. In another tube, 
20 µL of Lipofectamine 2000 was gently mixed with 500 μl of DMEM-F12 medium 
and incubate for 4 min. at room temperature. After incubation, the Lipofectamine 
mixture and the diluted plasmid solution were mixed together and incubate for 20 
min. at room temperature. Then,  50 μl of mixture was added  to each cell culture 
well. The cell culture plate was then mixed gently by rocking. The cells were left to 
grow at 37°C in a CO2 incubator. Twenty-four hours after transfection the growth 
medium was replaced with fresh medium containing 200 µg Hygromycin B. The 
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medium was then collected 7 days after transfection for testing the presence of 
HBsAg in the culture media by ELISA.  
ELISA well plates were coated overnight at 4ºC with the 7 days cell culture medium. 
The next day wells were washed 6 times with TPBS (0,1 % PBS-Tween 20) and then 
blocked with TPBS containing %1 BSA for 2 hours. Wells were washed 6 times with 
TPBS and polyclonal anti-HBsAg rabbit antibody (1/200) was used as primary 
antibody. After 1 hour of incubation at room temperature, wells were washed 6 times 
with TPBS. Then, goat anti-rabbit alkaline phosphatase (Thermo Scientific) 
conjugate (1/1000) was used as secondary antibody. After 1 hour of incubation at 
room temperature, wells were washed 6 times with TPBS. 
The absorbance was measured at 405 nm using a microplate reader (Bio-Rad) 1 hour 
after the addition of  para-nitrophenyl phosphate substrate (PNPP) solution (1 
mg/mL of pNPP in substrate buffer (0,1 M glycine, 1mM ZnCl2, 1mM MgCl2, pH: 
10,4). The color reaction was stopped with 1 M NaOH.  
For monitoring the expression of HBsAg directly in HeLa cells.  A new transfection 
was done as mentioned above, but instead of growing cell directly in the wells, the 
cells were grown on steril 12 mm coverslips. Twenty-four hours after transfection the 
growth medium was replaced with fresh medium containing 200 µg Hygromycin B. 
Then previously expressed Lig7 scFv, mcherry (fluorescent protein) or Lig7-mcherry 
fusion construct were added to the wells and cells were incubated for 24 hours. Then 
cells were fixed with ice-cold 100% methanol after aspirating the growth medium. 
Cells were incubated for 20 minutes at -20 C° for fixation. Then the fixative was 
aspirated and the coverslips were rinsed three times with PBS for 5 min. The nucleus 
of the cells were stained with a drop of mounting medium (%50 Glycerol + %50 
PBS) containing Hoechst dye. Coverslips were turned up site down on a lamel and 
cells were analysed with a fluorescence microscope. 
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3.  RESULTS AND DISCUSSION 
3.1 Development of an anti-HBsAg single chain Fv recombinant antibody 
The first scope of the thesis was the development of a recombinant antibody against 
Hepatitis B surface antigen by using phage display technology. For this purpose mice 
immunized with HBsAg was necessary. Commercial HBsAg is available on the 
market but the production and purification processes for HBsAg are expensive and 
time-consuming which is reflected into the price of HBsAg. HBsAg was first 
purified from human plasma in 1980. It was then produced in a recombinant yeast 
system (Valenzuela, 1982), followed by expression in mammalian cells. Several 
years ago, a lower-cost method using phage display for the expression of HBsAg for 
immunization purposes was demonstrated. Tan (2005) fused the 111 - 156 amino 
acid coding DNA region of HBsAg, including the dominant neutralizing epitope “a”, 
with T7 phage capsid proteins. T7 phages expressing the 45 amino acid-length partial 
HBsAg on their surfaces were used as immunization agents in rabbits. Until now, a 
full-length HBsAg was not displayed on the phage surface and hence it was not used 
for immunization of mice with the aim of developing an anti-HBsAg recombinant 
antibody. This approach is facilitated by our group for the first time. This section 
describes the expression of the entire small HBsAg on phage surfaces as a pIII fusion 
protein and use of these recombinant phage nanoparticles as immunization agents in 
immunocompetent BALB/cJ mouse strain based on the paper published in 2014 
(Balcioglu, 2014). 
3.1.1 Cloning of HBsAg in phagemid vector 
In the purpose of cloning the HBsAg gene in the phagemid vector, the gene was first 
amplified by PCR with flanking primer containing appropriate restriction enzyme 
cutting sites. Then restriction enzyme digested gene was inserted into the phagemid 
clone by classical ligation procedure and the transformant vector was transferred into 
competent E. coli cells. The experiments are described below in more details. 
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The HBsAg gene provided by GATA was amplified by polymerase chain reaction 
using primers flanked with SfiI or NotI restriction enzyme sites, the single ~700 bp 
PCR amplified product was confirmed by 1.2% Agarose gel (Figure 3.1).  
 
Figure 3.1 : PCR amplification of HBsAg gene with Sfi I ve Not I restriction 
enzyme site containing primers. Lane 1. M4 marker, Lane 2. ScFv 
marker, Lane 3-10., Lane 11. Control PCR product. 
Multiple PCR reactions were prepared for increasing the amount of amplified 
HBsAg gene after Agarose gel extraction. The purified PCR products were 
controlled by 1.2% Agarose gel electrophoresis (Figure 3.2) and were quantified by 
nanodrop measurements.   
 
Figure 3.2 : Purification of Sfi I and Not I restriction enzyme site containing PCR 
products from agarose gel. Lane 1; M4 Marker, Lane 2-3; Agarose gel 
extracted PCR product. 
The Agarose gel extracted PCR products, and the phagemid pCANTAB5E vector 
were digested first with SfiI I then with NotI restriction enzymes (Figure 3.3) then 
extracted from Agarose gel after each digestion steps.  
 1      2     3      4      5      6      7     8      9     10  11 
~700 bp 
1419 bp  
517 bp  
396 bp  
214 bp  
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Figure 3.3 : Control of pCANTAB5E phagemid vector and PCR products after Sfi I 
and Not I digestion. Lane 1; M4 marker, Lane 2; HBsAg, Lane 3; 
pCANTAB5E. The DNA band size was deduced from  semi-log 
plotting. 
Double digested products of PCR amplified HBsAg gene (~700 bp) and the 
pCANTAB5E phagemid vector (~4522 bp) were ligated with T4 ligase overnight at 
16ºC. The ligation product was transferred into chemically competent TG1 E.coli 
cells with Calcium Chloride transformation method (Maniatis). Transformant 
colonies were picked randomly for control with colony PCR reaction method (Figure 
3.4). 
 
Figure 3.4 : Colony PCR results of transformation colonies. Lane 1; M4 Marker, 
Lane 2; ScFv marker, Lane 3-6; Colony PCR products. 
A Single band of ~850 bp containing the HBsAg encoding gene and the flanking 
regions of the pCANTAB5E gene as drawn in (Figure 3.5) was observed.  
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Figure 3.5 : A schematic representation of the emplacement of the HBsAg and the 
pCANTAB5E primers resulting of a PCR amplification.band of ~700 
bp and ~850 bp, respectively. 
Plasmids bearing the HBsAg gene were isolated with the Roche High pure plasmid 
isolation kit from PCR confirmed transformation colonies. The plasmids were 
controlled  on 1% Agarose gel and quantified with nanodrop. According to the 
Beckman Coulter Genome Lab DTCS kit 400 ng of plasmids was used for DNA 
sequencing. The DNA sequences obtained from duplicated sequencing (Figure 3.6). 
were converted into a protein sequence and the protein sequence was searched in the 
reference sequence viral protein database by using BlastP compared from the San 
Diego Supercomputer Center (SDSC) Biology Workbench Internet website (Url-2). 
 
Figure 3.6 : DNA and protein sequences of the HBsAg gene region cloned into the 
pCANTAB5E vector. The yellow region indicates the vector sequence, 
the underlined sequence correspond to SfiI restriction enzyme site and 
the red star indicates the end of translation. 
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The protein sequence showing the highest homology HBsAg (Hepatitis B virus 
isolate 4436-97 HBsAg protein (S) gene, complete) with the cloned HBsAg was 
compared by CLUSTALW multiple sequence alignment compared from the San 
Diego Supercomputer Center (SDSC) Biology Workbench Internet website (Figure 
3.7). The cloned HBsAg showed ~97% of homology with the HBsAg from the 
database, sufficient to accept that HBsAg was cloned into a phagemid vector. 
 
Figure 3.7 : Sequence alignment of the cloned HBsAg and the HBsAg sequence 
selected from the reference sequence viral protein database (Hepatitis B 
virus isolate 4436-97 HBsAg protein (S) gene, complete) by 
CLUSTALW multiple sequence alignment. The blue color indicates 
total homology; green color indicates similar amino acids. 
3.1.2 Production of HBsAg displaying phages and phage ELISA 
Once HBsAg cloning was confirmed, cells containing the phagemid vector were 
grown for the production of infective phages displaying HBsAg protein on their 
surface as a fusion protein with the PIII minor phage surface protein. For this 
purpose cells containing the recombined pCANTAB5E were mixed with M13K07 
helper phages and incubated for the production of infective phages. Phages were 
purified by PEG precipitations and the titer was calculated by phage titration 
protocol.  
Then two different ELISA methods were used to verify the HBsAg display on the 
phage particles (Figure 3.8). 
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Figure 3.8 : Detection methods of M13 phages displaying HBsAg based on ELISA.  
In the first method, ELISA plate wells were coated either with phage particles 
displaying HBsAg or wild-type phages. Then, a rabbit anti-HBsAg polyclonal 
antibody was used as a primary antibody, and goat anti-rabbit AP conjugate was used 
as the secondary antibody. The ELISA results had a 9-fold higher binding signal for 
HBsAg-displaying phages relative to the wild-type phages (Figure 3.9). In the second 
method, polyclonal rabbit anti-HBsAg antibody was used to coat the wells. In this 
assay, either phage particles displaying HBsAg or wild-type phages were used as the 
primary antibody, and a mouse anti-M13/HRP conjugate was used as the secondary 
antibody. The binding signal for HBsAg-displaying phages was 7.7 times higher than 
the binding signal for the wild-type phages (Figure 3.9). 
 
Figure 3.9 : Phage ELISA results of the first and second ELISA strategies. 
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The goal of this present study was to express the full-length small HBsAg on the 
surface of an M13 filamentous phage as a PIII fusion protein. The gene coding the 
full-length HBsAg was cloned into a pCANTAB5E phagemid vector for this 
purpose. After the gene insertion was confirmed by DNA sequence analysis, 
infective phages displaying HBsAg were obtained. Small HBsAg expression was 
confirmed by two different ELISA methods as illustrated in Figure 3.8. In both 
methods, a binding signal was expected if HBsAg was displayed on phage surfaces, 
and if no HBsAg was displayed (wild-type phages), then no signal was expected. The 
ELISA results from both methods clearly showed a specific binding between phages 
displaying HBsAg and polyclonal anti-HBsAg antibodies. In contrast, no binding for 
the wild-type phages to the polyclonal anti-HBsAg antibodies was detected proving 
the expression of HBsAg on the phage surfaces. 
3.1.3 Mouse immunization and ELISA from immunized mice sera 
Immunizations of 8-week-old male BALB/cJ mice were performed by intradermal 
injections of the phage nanoparticles at different concentrations (10
10
, 10
11
 or 10
12
 
phage particles). The immunizations used either HBsAg-displaying recombinant 
phage nanoparticles, wild-type phage nanoparticles or PBS. Three injections were 
performed at three-week intervals, and mouse blood was collected prior to each 
injection. For determining the immune response developed against HBsAg, an 
ELISA test against anti-HBsAg antibodies in mice sera was conducted. The 
injections gave no signal for mice immunized with 10
10
 and 10
11 
phage particles. 
However, a three-fold increase in absorbance was observed in the sera of mice 
immunized with 10
12
 recombinant phage nanoparticles displaying HBsAg. A mixed 
model ANOVA with Tukey post hoc test was conducted to assess the immune 
response difference between different treatment groups (phage particles displaying 
HBsAg, phage particles without HBsAg and PBS) across different injection periods 
(Before injection, first injection, second injection and third injection). There was a 
statistically significant interaction between the treatment groups and the injections on 
the immune response, F(6,18) = 80.208, p < 0.0005, partial eta squared = 0.964. 
Then univariate General Linear Model with Tukey post hoc analysis were conducted 
to determine the differences of immune responses be-tween groups at each level of 
injection periods. Their immune response was statistically lower in the PBS group 
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(M = 0.39, SE = 0.017, p < 0.0005) and the phage particles without HBsAg group (M 
= 0.38, SE = 0.017, p < 0.0005) compared to the phage particles displaying HBsAg 
group (Figure 3.10). 
 
Figure 3.10 : Immune response results of mice before the injection of phages and 
after each injection of 10
12
 phages. 
The goal of this present study was to express the full-length small HBsAg on the 
surface of an M13 filamentous phage as a PIII fusion protein. The gene coding the 
full-length HBsAg was cloned into a pCANTAB5E phagemid vector for this 
purpose. After the gene insertion had been confirmed by DNA sequence analysis, 
infective phages displaying HBsAg were obtained. Small HBsAg expression was 
confirmed by two different ELISA methods. In both methods, a binding signal was 
expected if HBsAg was displayed on phage surfaces, and if no HBsAg was displayed 
(wild-type phages), then no signal was expected. The ELISA results from both 
methods clearly showed a specific binding between phages displaying HBsAg and 
polyclonal anti-HBsAg antibodies. In contrast, no binding for the wild-type phages to 
the polyclonal anti-HBsAg antibodies was detected as expected. Therefore, the 
expression of HBsAg on the phage surfaces was confirmed. 
The HBsAg-displaying phage nanoparticles were then used for immunization assays. 
The results showed that injections of 10
10
 and 10
11
 phage nanoparticles were not 
sufficient to generate an immune response against HBsAg but were sufficient for 
generating an immune response against an M13 phage (data not shown). A 
significant (p< 0.05) anti-HBsAg immune response was observed in mice immunized 
with 10
12
 recombinant phage nanoparticles after the third immunization. Therefore, 
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our results demonstrated that at least 10
12
 recombinant phage nano-particles are 
necessary to generate an immune response against HBsAg. The present results 
support the concept that M13 phages are good antigen carriers built upon the 
inexpensive and easy phage display method to express HBsAg for immunization. 
Further, the results demonstrate that full-length HBV small surface antigen displayed 
on M13 phage minor pIII coat proteins can activate an anti-HBsAg immune response 
in BALB/cJ mice, even at a very low pIII copy number. 
3.1.4 Construction of a recombinant antibody library 
ScFv antibodies are recombinant antibodies generated from the genetic fusion of the 
light and heavy chain of variable region. Therefore, scFvs’ are six times smaller than 
IgG type antibodies (Figure 3.11).  
 
Figure 3.11 : Schematic representation of an antibody and a single chain Fv. Orange 
color represent the light chain, and the blue color represent the heavy 
chain. Dark color represents the constant region, and light color 
represent the variable region. 
The scFv recombinant antibody is generated by the fusion of the antibody variable 
regions via a linker. The 15 amino acids linker peptide is the optimized amino acid 
number which gives the exact antibody recognition conformation to the scFv. The 
linker sequence may vary for each laboratories but the most commonly used linker is 
the 3 times repeat of  the Gly-Gly-Gly-Gly-Ser (Gly for Glycin and Ser for serine) 
Pentapeptide flanked with short VH and VL homologue sequence necessary for the 
genetic fusion process to generate the scFv (Figure 3.12). 
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Figure 3.12 : Schematic representation of the construction of a single chain Fv from 
variable domains of light  (VL) and heavy (VH) chains and a linker. 
Orange color represent the light chain, and the blue color represent the 
heavy chain variable domain. The linker is represented by purple color 
flanked with short homologue sequences to VL or VH. 
The construction of the scFv library was, Therefore, initiated with a total RNA 
extraction from the spleen of mice immunized with 10
12
 phage particles displaying 
HBsAg. For this purpose total, RNA was extracted from homogenized immunized 
mice spleen with the EZ-RNA Total RNA isolation kit. The RNA quality was 
controlled according to OD260 / OD280 ratio. The RNA was then converted to a cDNA 
library by using random primers (Froussard, 1992). The cDNA library was used as a 
template for the PCR amplification of VH and VL regions (Figure 3.13).  
 
Figure 3.13 : PCR amplification results of VH and VL on 1.5% agarose gel. Lane 1; 
Thermo scientific Mass ruler Low Range DNA ladder (SM0383), Lane 
2-3; Variable Heavy chain PCR, Lane 4-5; Variable Heavy chain PCR, 
Lane 6-7; Linker PCR.PCR amplification bands of  ~350 bp for VH and 
~320 bp for VL were obtained (Figure 3.13). Also, a single band of 
~100 bp was also observed for the PCR amplification of the linker. 
These results confirmed the presence of  a VH and a VL library. 
Primers dimers in the PCR product were purified with an agarose gel 
DNA extraction kit (Roche, Cat. No. 1 696 505) according to the 
manufacturer instructions and controlled on 1.5% agarose gel (Figure 
3.14). 
81 
 
Figure 3.14 : Agarose gel purification results of VH and VL on 1.5% agarose gel 
electrophoresis. Lane 1; Thermo scientific Mass ruler Low Range DNA 
ladder (SM0383), Lane 2; Heavy chain variable region, Lane 3; Light 
chain variable region.  
The VH and VL library was quantified then used as a template for the generation of 
the scFv encoding gene. The genetical fusion reaction was made by mixing the VH 
library, the VL library and the (Gly-Gly-Gly-Gly-Ser)3 linker in an equimolar 
quantity. The fusion product was then amplified by PCR using primers 702 and 704 
specific for scFv (Figure 3.15). 
 
Figure 3.15 : The PCR amplification results after the fusion of the VH and VL 
libraries with the (Gly-Gly-Gly-Gly-Ser)3 linker on a 1.2% agarose gel. 
Lane 1; Thermo scientific Mass ruler Low Range DNA ladder 
(SM0383), Lane 2-4; scFv fusion products. 
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Figure 3.16 : The scFv PCR amplification products after agarose gel extraction. 
Lane 1; Thermo scientific Mass ruler Low Range DNA ladder 
(SM0383), Lane 2-4; Purified scFv fusion products, Lane 5; Purified 
VH-Linker fragment, Lane 6; Purified VL-Linker fragment, Lane 7; 
Purified VH fragment, Lane 8; Purified VL fragment. 
VH and VL fragments and their linker fusion versions and finally, the scFv was 
monitored on 1.2% agarose gel. The scFv library was then amplified with scFv 
specific primers containing SfiI and NotI restriction enzyme sites necessary for the 
cloning of the library into the pDUCK1 phagemid vector. The library PCR amplified  
product, and the pDUCK1 phagemid vector were digested with SfiI then with NotI 
restriction enzymes. The digestion products were then ligated with T4 DNA ligase. 
The ligation product was transferred into E.coli TG1 cells by calcium chloride 
method. The transformant cells were then pooled into one tube, and phage-displayed 
scFv library was produced by phage amplification method. The titration of the library 
was done, and a titer of 3.10
12
 phage particles per mL was calculated.  
3.1.5 Selection of an anti-HBsAg scFv from the library 
The scFv library was then screened against 500ng of HBsAg (Ad/Ay, 100 ng each, 
Fitzgerald Industries International) coated in a maxisorb immunotube. The 
biopanning process was initiated with an equivalent number of the phage particle so 
that the eluted phage particle number could be measured.  
The enrichment of the phage-displayed scFv library, specific to HBsAg after two 
rounds of biopanning is given in Table 3.1. 
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Table 3.1 : Enrichment of HBsAg specific scFv phage-displayed library. 
Biopanning round Starting 
phage 
particle 
number 
Eluted phage 
particle 
number 
Amplification 
rate 
Phage particle 
concentration 
after 
amplification 
(pfu/ml) 
First 10
11
 3.3 x10
4
 - 10
13
 
Second 10
11
 8.9x10
5
 26,97 - 
 
After the second round of biopanning, a ~ 27 fold enrichment against HBsAg was 
observed. Randomly selected 95 differents scFv-displaying phage particles were 
amplified and tested the display of HBsAg on phages surface (Figure 3.17).  
 
Figure 3.17 : ELISA results of HBsAg binding phage particles after two rounds of 
biopanning. The clones indicated in red (G5, K28 and K54) correspond 
to high HBsAg binding and the clones indicated in blue (G2, K2) 
correspond to low HBsAg binding phages. The green color correspond 
to negative control clones. 
Three clones (G5, K28 and K54) with high binding signal (A450>1.3) and two 
clones (G2 and K2) with low binding signal (A450<0.4) were selected for a second 
ELISA experiment for checking cross-reactivity. 
No cross reactivity for clones G5, K28 and K45 were found. Therefore, these clones 
were specific to HBsAg (Figure 3.18).  
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Figure 3.18 : ELISA results of the selected clones for HBsAg and BSA.  
3.2 Development and characterisation of an anti-HBsAg gold binding 
recombinant antibody 
3.2.1 Cloning of the anti-HBsAg Lig7 recombinant antibody into pQE2 vector 
 
An anti-HBsAg scFv recombinant antibody (Lig7), developed and characterized by 
Dr. Berrin Erdağ and her group was used as a template. Because the Lig7 scFv was 
inserted into a pDUCK1 phagemid vector, the Lig7 scFv encoding gene was recloned 
into the pQE2 expression vector (Figure A.2). The pQE2 expression vector is a 
vector allowing the cleavage of the His-tag, which might interfere with the binding 
of the bifunctional antibody to the gold surface.  
Primers specific to Lig7 were designed according to the DNA and protein sequences 
given in the Qiagen TAGzyme handbook  by taking care of not leading a frameshift 
error (Figure 3.19). Also the C-terminal region of Lig7 was modified by adding 
glutamine (Q) between the first methionine (M1) and the alanine (A2) so that the 
cleavage of the His-tag with the TAGzyme enzyme stops after the “HM” amino acid 
sequence (Figure 3.20). Finally, the NdeI and NotI restriction enzyme sites, 
necessary for the recloning of Lig7 scFv into the pQE2 vector were inserted to the 
primers (Lig7_Forw_NdeI and Lig7_Rev_NotI). 
 
Figure 3.19 :    The multiple cloning sites of the pQE2 expression vector (Qiagen). 
,000 
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Figure 3.20 : Modification of the Lig7 C-terminal region. Glutamine (Q) indicated 
in red was added to the Lig7 sequence to stop the cleavage of the 
Tagzyme enzyme. 
The lig7 scFv was amplified by PCR with the designed primers. The agarose gel 
purified PCR amplification purified products and the pQE2 vector were then 
successively digested with NdeI and NotI enzymes. The digestion products were 
ligated and transferred into chemically competent E.coli DH5α cells with calcium 
chloride method. The next day colony PCR was made from randomly selected 14 
transformant colonies (Figure 3.21). 
 
Figure 3.21 : Colony PCR results from 14 randomly selected transformant colonies. 
Lane 1; Thermo scientific Mass ruler Low Range DNA ladder 
(SM0383), Lane 2-14; different transformation colonies, Lane 15; 
Control PCR of Lig7 scFv from the original Lig7/pDUCK1 vector. 
One clone containing the ~750 bp PCR amplification band was randomly selected 
and  was subjected to DNA sequence analysis. Forward and reverse sequencing 
primers specific to the pQE2 vector was used for the dye terminator cycle sequence 
analysis. The resulting sequences were translated using the San Diego 
Supercomputer Center (SDSC) Biology Workbench Internet website. No frameshift 
within the sequence was observed, and the presence of the inserted Glutamine (Q) 
amino necessary for the excision of the His tag was confirmed (Figure 3.22). 
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Figure 3.22 : DNA and protein sequence results retrieved from the San Diego 
Supercomputer Center (SDSC) Biology Workbench Internet website. 
Color code for restriction enzyme site; orange; NdeI, green; NotI, blue; 
HindIII. 
3.2.2 Insertion of gold binding peptide coding region in the Lig7/pQE2 vector 
Following the confirmation of the insertion of the Lig7 scFv, the cloning of the 
GBP1 encoding region at the C-terminal of Lig7 was initiated. The 14 mer GBP1 is 
encoded from a 42bp DNA sequence. Primers specific to the 5’ and 3’ end of GBP1 
containing NotI and HindIII restriction enzyme sites, respectively, GBP1_Not_F and 
GBP1_HindIII_R  were designed using the San Diego Supercomputer Center 
(SDSC) Biology Workbench Internet website. The PCR reaction was realized by 
using the pDrive cloning vector containing the 5-time repeats of GBP1 (5GBP) as 
template, which was kindly provided from Candan Tamerler’s research group.  To 
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increase the resolution of the electrophoretic pattern of the small PCR amplification 
bands an Agarose gel of 2,5% was used (Figure 3.23).  
 
Figure 3.23 : Results of PCR amplification from the pDrive-5GBP vector using 
primers containing NotI and HindIII restriction enzyme sites. Lane 1; 
Thermo scientific Mass ruler Low Range DNA ladder (SM0383), Lane 
2-3; PCR products.  
Five PCR bands with sizes, ~66 bp, ~108 bp, ~150 bp, ~192 bp and ~234 bp  were 
observed. These five bands are corresponding to the amplification of GBP1 repeats. 
Each band were ~ 24 bp higher than the GBP1 nucleotide itself  because of the 
integration of NotI and HindIII restriction enzyme sites. The bands were individually 
extracted from the agarose gel for further cloning experiments. But due to the low 
recovery of the bands after NotI and HindIII digestions the cloning experiments were 
unsuccessful. After several assays with the same results, the cloning strategy was 
changed.  
New primers including the BamHI and EcoRI restriction enzyme from the pDrive-
5GBP vector were designed in the aim of obtaining a single PCR amplification band 
(GBP_forward_NotI_with tail, GBP_reverse_HindIII_ with tail) flanked with NotI 
and HindIII restriction enzyme sites (Figure 3.24). 
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Figure 3.24 : Schematic representation of the GBP_forward_NotI_with_tail and 
GBP_reverse_HindIII_with_tail primers annealing emplacement on 
pDrive-5GBP vector.  
PCR amplification of 5GBP was done with the new  “GBP_forward_NotI_with_tail” 
and “GBP_reverse_HindIII_with_tail” primers using the pDrive-5GBP vector as 
template. Also, a higher quality of Taq polymerase with  high proofreading was used 
for cloning experiments (Qiagen, HotStart Taq DNA polymerase). The PCR results 
are shown in Figure 3.25. 
 
Figure 3.25 : PCR amplification results of 5GBP by using the  
“GBP_forward_NotI_with_tail” and “GBP_reverse_HindIII_with_tail” 
primers. Lane 1; Thermo scientific Mass ruler Low Range DNA ladder 
(SM0383), Lane 2; empty well, Lane 3-12; PCR amplifications. 
A major band which is ~ 260 bp was obtained from the PCR amplifications. The new 
primers set allowed the amplification of 5GBP encoding region in a higher amount. 
All the  PCR amplification reactions were pooled together. Half of the PCR 
amplified products were purified with QIAquick PCR purification kit  (Qiagen), and 
the remaining PCR products were extracted as a single band from agarose gel. The 
purified PCR products were quantified with nanodrop. The DNA concentration 
obtained from the agarose gel extraction was 10ng/mL whereas a better yield was 
obtained with eluted DNA from the PCR purification kit was 36ng/mL.  
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The  purified  5GBP PCR product and the Lig7- pQE2 vector were then double 
digested with NotI and HindIII restriction enzymes for 3 hours. The digestion 
products were controlled on 1.5 % agarose gel (Figure 3.26).  
 
Figure 3.26 : PCR amplification results of 5GBP by using the  
“GBP_forward_NotI_with_tail” and “GBP_reverse_HindIII_with_tail” 
primers. Lane 1; Thermo scientific Mass ruler Low Range DNA ladder 
(SM0383), Lane 2; empty well, Lane 3-12; PCR amplifications. 
The digestion products were quantified with nanodrop after agarose extraction. A 
final concentration of  22.4 ng/μL and  42.5 ng/μL was obtained for the digestion of 
Lig7-pQE2 vector and the 5GBP PCR product, respectively. Ligation ratio selected 
for insertion was 3:1, insert: vector, the ligation reaction was limited to 10 minutes at 
22°C. The recombinant vector was transfered into chemically competent E.coli 
DH5α cells with calciun chloride method. The next day, 16 colonies were randomly 
selected for the colony PCR reaction made with GBP1 specific  primers 
(GBP_forward_NotI_with_tail and GBP_reverse_HindIII_with_tail) (Figure 3.27). 
 
Figure 3.27 : Agarose gel image of the colony PCR made with GBP1 specific 
primers set. Lane 1; Thermo scientific Mass ruler Low Range DNA 
ladder (SM0383), Lane 2-17; transformation colonies from 1 to 16. 
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A major band of ~ 260 bp was observed for the colonies from 1 to 4 and 8 to 16 
corresponding to 5GBP amplification. However, the PCR bands obtained for 
colonies 5; 6 and 7 were unexpected. Because that GBP1 specific primer were used 
for colony PCR, these PCR products suggested that some different GBP1 repeats 
were also cloned individually. To verify this hypothesis, plasmids were isolated from 
clones 1, 5, 6 and 7 and used as a template for PCR amplifications. Three different 
PCR amplifications with different primer set were done for each clone. The first 
primer set contained the GBP_forward_NotI_with_tail and 
GBP_reverse_HindIII_with_tail primers specific to GBP1. The second primer set 
contained primers specific for Lig7 (Lig7_Forw_NdeI and Lig7_Rev_NotI). The last 
primer set contained primers specific for the pQE2 vector, i.e. pQE2 promoter and 
reverse primers.  
The PCR products were controlled on 1.5% agarose gel (Figure 3.28) and the size of 
the PCR bands are given in Table 3.2. 
 
Figure 3.28 : Agarose gel image of the PCR amplification products. Lane 1; Thermo 
scientific Mass ruler Low Range DNA ladder (SM0383), Lane 2, 6, 11; 
clone 7, Lane 3, 7, 11; clone 6, Lane 4, 8, 12; clone 5, Lane 5, 9, 13; 
clone 1, Lane 14; Thermo scientific Mass ruler High Range DNA 
ladder (SM0393). 
Table 3.2 : PCR amplification band size of each clone. 
 GBP primer set ScFv primer set Vector primer set 
Clone 1 ~260 bp ~750 bp ~1150 bp 
Clone 5 ~180 bp ~750 bp ~1050 bp 
Clone 6 ~100 bp ~750 bp ~950 bp 
Clone 7 ~100 bp ~750 bp ~950 bp 
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The Lig7 PCR bands and the GBP bands present for each clone confirmed the 
presence of Lig7 encoding gene (~750 bp) and of the GBP1 sequence. But regarding 
the different sizes of the amplification product specific to GBP1, clone 1, clone 5 and 
clone 6 (or clone 7) were integrating different repeat number of GBP1 encoding 
region. The PCR amplification with the pQE2 primers set shows that Lig7 and the 
GBP1 sequences are within the vectors cloning site, therefore, the fusion of the Lig7 
scFv with the different GBP1 sequences is confirmed. According to an 
approximation regarding the size of bands, clone 6 and 7 were a fusion of Lig7 with 
one GPB1 (Lig7-GBP), clone 5 was the fusion of Lig7 with 3 GBP1 repeats (Lig7-
3GBP) and the clone 1 was the fusion of  lig7 with 5 GBP1 repeats (Lig7-5GBP). 
The DNA sequences obtained from the Beckman Coulter CQE8800 instrument were 
analysed using the San Diego Supercomputer Center (SDSC) Biology Workbench 
Internet website. The DNA and protein sequences of the clones were compared to 
each other (Figure 3.29 and 3.30). 
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Figure 3.29 : DNA sequence alignment of the four clones at the 3’ end. The green and purple colors indicate the GBP1 peptide encoding region. 
 
Figure 3.30 : Protein sequence alignment of the four clones. The green and purple colors indicate the GBP1 encoding region. The stars 
correspond to 100% amino acid homology for each clone at the same amino acid emplacement. 
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The protein and DNA sequences showed that clone 6 and 7 were identical and that  
the other clones were as hypothesis above. No frameshift regarding the protein 
sequences were observed, therefore, clones were suiTable for further protein 
expression works. 
3.2.3 Expression of the bifunctional recombinant antibodies 
Once the DNA sequence was confirmed the Lig7-GBP, Lig7-3GBP and the Lig7-
5GBP containing pQE2 vectors were transferred into chemically competent  E.coli 
BL21(DE3) strain by calcium chloride transformation. The transformation colonies 
were picked and small-scale expression (5 mL of LB medium) of the bifunctional 
gold binding Lig7 recombinant antibodies was done by using 1mM IPTG for 4 
hours. The cells subjected to protein expression were directly loaded on 12% SDS-
PAGE. The expression profile was observed by Coomassie staining (Figure 3.31)  
and western blot (Figure 3.32). 
 
Figure 3.31 : Coomassie staining for bifunctional Lig7 antibodies expression in 
BL21(DE3) cells. T0: before expression, T4: 4 hours of induction. Lane 
1; Fermentas PageRulerTM plus Prestained protein Ladder (SM1811), 
Lane 2; Lig7-5GBP T0, Lane 3, Lig7-5GBP T4, Lane 4; Lig7-3GBP 
T0, Lane 5; Lig7-3GBP T4, Lane 6; Lig7-GBP T0 (clone 6), Lane 7; 
Lig7-GBP T4 (clone 6), Lane 8; Lig7-GBP T0 (clone 7), Lane 9; Lig7-
GBP T4 (clone 7), Lane 10; control scFv T4. 
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Figure 3.32 : Western blot image for bifunctional Lig7 antibodies expression in 
BL21(DE3) cells. T0: before expression, T4: 4 hours of induction. Lane 
1; Fermentas PageRulerTM plus Prestained protein Ladder (SM1811), 
Lane 2; Lig7-5GBP T0, Lane 3, Lig7-5GBP T4, Lane 4; Lig7-3GBP 
T0, Lane 5; Lig7-3GBP T4, Lane 6; Lig7-GBP T0 (clone 6), Lane 7; 
Lig7-GBP T4 (clone 6), Lane 8; Lig7-GBP T0 (clone 7), Lane 9; Lig7-
GBP T4 (clone 7), Lane 10; control scFv T4.  
No significant protein expression profile was visualized with Coomassie staining, but 
protein bands were seen with western blot by using mouse anti-His tag HRP 
conjugate. The bands for Lig7-5GBP and Lig7-3GBP were not as visible as for Lig7-
GBP. The expression bands were ~35 kDa, ~33 kDa and ~30 kDa for Lig7 5GBP, 
Lig7 3GBP and Lig7 GBP clone. The protein expression was not as high as 
expected, therefore, a new bacterial strain was selected for the expression of the 
bifunctional antibody. The E. coli M15[pREP4] strain which have a strong 
expression control was selected according to Qiagen, Qiaexpressionist protocol. The 
plasmid encoding the bifunctional antibodies were transferred into chemically 
competent E. coli M15[pREP4] cell with calcium chloride method. Transformant 
cells were used for protein expression studies in 5 mL of LB medium. The 
expression was made at the same conditions than for the BL21(DE3) cells in the aim 
of comparing expression profiles. The cells were run on 12% SDS-PAGE.  
The expression profile was observed by Coomassie staining (Figure 3.33)  and 
western blot (Figure 3.34). 
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Figure 3.33 : Coomassie staining results for the bifunctional Lig7 antibodies 
expression in M15[pREP4] cells. T0: before expression, T4: 4 hours of 
induction. Lane 1; Fermentas PageRulerTM plus Prestained protein 
Ladder (SM1811), Lane 2; Lig7-5GBP T0, Lane 3, Lig7-5GBP T4, 
Lane 4; Lig7-3GBP T0, Lane 5; Lig7-3GBP T4, Lane 6; Lig7-GBP T0 
(clone 6), Lane 7; Lig7-GBP T4 (clone 6), Lane 8; Lig7-GBP T0 (clone 
7), Lane 9; Lig7-GBP T4 (clone 7), Lane 10; control scFv T4. The 
bands entoured with a black rectangle correspond to protein expression. 
 
Figure 3.34 : Western blot image for the bifunctional Lig7 antibodies expression in 
M15[pREP4] cells. T0: before expression, T4: 4 hours of induction. 
Lane 1; Fermentas PageRulerTM plus Prestained protein Ladder 
(SM1811), Lane 2; Lig7-5GBP T0, Lane 3, Lig7-5GBP T4, Lane 4; 
Lig7-3GBP T0, Lane 5; Lig7-3GBP T4, Lane 6; Lig7-GBP T0 (clone 
6), Lane 7; Lig7-GBP T4 (clone 6), Lane 8; Lig7-GBP T0 (clone 7), 
Lane 9; Lig7-GBP T4 (clone 7), Lane 10; control scFv T4. 
The expression of the bifunctional antibodies was stronger with M15[pREP4] than 
BL21(DE3) cells. Even in Coomassie staining the expression bands were visible 
when compared with the control cells with no expression. Therefore, expression 
studies were continued with M15[pREP4] cells. According to the western blot results 
the bigger is the expression protein the lesser its expression. Therefore, the 
expression of Lig7-5GBP is lesser than Lig7-GBP and Lig7-3GBP. 
Since antibody expression was confirmed, the expression was scaled-up to 50 mL 
than to 500mL LB medium. The scale-up was successful and higher protein 
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expression was observed from SDS-PAGE Coomassie staining and western blot 
analysis (Figure 3.35 and 3.36). 
 
Figure 3.35 : Coomassie staining results for the large scale production of  the 
bifunctional Lig7 antibodies in M15[pREP4] cells. T0: before 
expression, T4: 4 hours of induction. Lane 1; Fermentas PageRulerTM 
plus Prestained protein Ladder (SM1811), Lane 2; M15[pREP4] T0, 
Lane 3, Lig7-GBP T4, Lane 4; Lig7-3GBP T0, Lane 5; Lig7-5GBP T4. 
 
Figure 3.36 : Western blot results for the large scale production of  the bifunctional 
Lig7 antibodies in M15[pREP4] cells. T0: before expression, T4: 4 
hours of induction. Lane 1; Fermentas PageRulerTM plus Prestained 
protein Ladder (SM1811), Lane 2; M15[pREP4] T0, Lane 3, Lig7-GBP 
T4, Lane 4; Lig7-3GBP T0, Lane 5; Lig7-5GBP T4. 
The expression of the bifunctional Lig7-GBP, Lig7-3GBP and Lig7-5GBP 
antibodies were, therefore, confirmed by SDS-PAGE and western blot analysis.  
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Different expression conditions were tested for increasing the protein expression. 
Two parameters, the amount of IPTG (0.1 mM, 0.5 mM and 1 mM) and the 
induction temperature (20°C, 30°C and 37°C) were modified. But no significant 
differences were observed for Lig7 expression. Only, a decrease of protein 
expression was observed for the expression at 20°C with 0,1mM IPTG (data not 
shown). The bacterial pellets from different expression  conditions were treated with 
lysis buffer (50mM Tris-Cl pH 8.0, 200mM NaCl, 1mM EDTA) and the supernatants 
(15 min at 12000 rpm) were controlled with 12% SDS-PAGE and western blot (data 
not shown). The Lig7 extraction profile after lysis buffer treatment showed that the 
best extraction was performed from the pellets induced at 37°C and the best result 
was obtained from the cells induced at 0.1 mM IPTG. 
3.2.4 Purification of bifunctional antibodies from large scale culture and 
removal of His-Tag. 
The bifunctional antibodies were expressed at large scale using the optimum  
established conditions (37°C and 0.1 mM IPTG). After four hours of induction the 
cells were harvested and the pellets were treated with lysis buffer (50mM Tris-Cl pH 
8.0, 200mM NaCl, 1mM EDTA). After centrifugation the supernatants were  run on 
12% SDS-PAGE and controlled with Coomassie Blue and western blot (Figure 
3.37). 
 
Figure 3.37 : Coomassie staining and western blot results of periplasmic extraction 
from large-scale production of the bifunctional antibodies in 
M15[pREP4] cells. Lane 1; Fermentas PageRulerTM plus Prestained 
protein Ladder (SM1811), Lane 2; Lig7 scFv, Lane 3; Lig7-GBP, Lane 
4; Lig7-3GBP, Lane 5; Lig7-5GBP. 
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Single western blot band was observed for each recombinant antibodies. Therefore, a 
non-denaturing Cobalt affinity purification was applied to the lysed cell supernatant 
after a dialysis step against refolding buffer (100mM NaH2PO4, 10mM Tris.Cl). But 
no recovery was obtained (Figure 3.38, Lanes 2 to 5). The remaining pellets 
containing the inclusion bodies were solubilized with the inclusion body 
solubilization reagent (Thermo Scientific, Cat.No. 78115) and the elution products  
are shown in Figure 3.38, Lanes 6 to 9. 
 
Figure 3.38 : Coomassie staining of Cobalt affinity purified periplasmic extraction 
(lane 2-5) and solubilized inclusion bodies (lane 6-9) from large scale 
production of the bifunctional antibodies. Lane 1; Fermentas 
PageRulerTM plus Prestained protein Ladder (SM1811), Lane 2; Lig7 
scFv, Lane 3; Lig7-GBP, Lane 4; Lig7-3GBP, Lane 5; Lig7-5GBP, 
Lane 6; Lig7 scFv, Lane 7; Lig7-GBP, Lane 8; Lig7-3GBP, Lane 9; 
Lig7-5GBP. 
High amount of recombinant antibody having ~90% purity, determined by the 
bioanalyzer instrument, was obtained from the inclusion body solubilization, 
therefore, this method was chosen for further experiments. 
The affinity column purified denatured recombinant antibodies were then subjected 
to refolding process by successive 1/2 dilutions (Yang et al., 2011). For this purpose 
successive dilutions of the solubilized recombinant antibodies was done with dilution 
buffer (DB) (100 mM NaH2PO4, 10 mM Tris-Cl) until Urea concentration  reached 2 
M Then, for a correct disulphide bonds formation within the antibody structure a red-
ox environment was generated with reduced and oxidized glutathione (GSH 2 mM, 
GSSG 0.4 mM). The prevention of recombinant antibody precipitation was planned 
by adding L-Arginine for a final concentration of 400 mM. The same red-ox and L-
Arginine conditions were followed until the Urea concentration was decreased to 
0.5M. Finally all the additives were removed from the recombinant antibody solution 
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by  dialysis against Tagzyme Buffer (20 mM sodium phosphate, pH 7.0; 150 mM 
NaCl) necessary for the TAGZyme digestion (His tag removal). But at that step the 
recombinant antibodies tended to aggregate. Therefore, to prevent aggregation 
several different dialysis conditions were tested. The different conditions are 
indicated in Table 3.3. 
Table 3.3 : Refolding  parameters of Lig7-GBP. 
Buffers 
Original 
Buffer 
pH 
Buffers 
Final pH 
Precipitation 
Volume 
before 
dialysis 
(μL) 
Volume 
after 
dialysis 
(μL) 
Dilution Buffer (DB) 5.65 10.0 No 400 465 
DB + 400 mM L-Arg  10.0 10.0 No 400 395 
DB + 0.5 M Urea  5.9 10.0 No 400 425 
DB+400 mM L-Arg + 
0.4% Triton X100  
10.0 10.0 No 400 475 
DB +0.5 M Urea,+ 
0.4% Triton X100  
5.9 10.0 No 400 525 
DB+0.5 M Urea+ 
400 mM L-Arg  
5.95 8.0 No 400 480 
DB+ 0.5 M Urea+ 
 400 mM L-Arg  
5.95 6.3 No 400 440 
Tagzyme Buffer 4.17 10 Yes 400 - 
 
Because the recombinant antibodies were tending to aggregate in TAGZyme Buffer. 
It was decided to finish first the refolding process in DB than dialysing against 
TAGZyme buffer just before the  His-Tag removal process. 
It is known that L-Arginine, when provided at 400 mM concentration is protecting 
proteins from aggregation. Another reason for aggregation is having lower pH value. 
Therefore, the pH value of the recombinant antibody solution (DB + 0.5 M urea + 
400 mM L-Arg) just before dialysis was measured and a pH of 10.0 was determined. 
According to this measurement, the pH of the different DBs were set at pH 10.0. The 
effect of 0.5 M urea, 400 mM L-Arginine and 0.4% Triton X100. The recombinant 
antibody solution was also dialyzed against the initial DB containing 0.5 M urea, 400 
mM L-Arg but at different pH such as pH 8.0 and pH 6.3. 
After dialysis, no visible aggregation particles were observed for all the dialysis 
except for the TAGZyme buffer. The dialysis tubes were centrifuged for harvesting 
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the aggregate and the supernatant was loaded on 12% Acrylamide gel to control the 
soluble recombinant antibodies. The gel was then stained with Coomassie (Figure 
3.39). 
 
Figure 3.39 : Coomassie staining results of Lig7-GBP after different dialysis 
conditions. Lane 1; Marker, Thermo Scientific 26619, Lane 2; DB + 0.5 
M Urea + 400 mM L-Arg, pH10.0, Lane 3; DB alone, pH10.0, Lane 4; 
DB + 400 mM L-Arg, pH10.0, Lane 5; DB + 0.5 M urea, pH10.0, Lane 
6; DB + 400 mM L-Arg + 0.4% Triton X100, pH10.0, Lane 7; DB + 
0.5 M Urea + 0.4% Triton X100, pH10.0, Lane 8; DB + 0.5 M Urea + 
400 mM L-Arg, pH8.0, Lane 9; DB + 0.5 M Urea + 400 mM L-Arg, 
pH6.3. 
The Coomassie staining results showed that the decrease of pH value to pH8.0 and 
pH6.3 in DB caused also aggregation even if it was not visible with bare eyes. 
Interestingly, the dialysis against DB at pH10.0 showed higher solubilized 
recombinant antibody amount. Therefore, a higher volume of recombinant antibody 
was dialyzed (3 mL) against DB at pH10.0. But this time the precipitation was 
visible. This might be because the amount of protein present in the mediım was 
higher. Even though, the solution was filtered through a 0,22μm filter and controlled 
with SDS-PAGE for determining if soluble recombinant antibodies were present is 
the solution. Unfortunately, no protein was seen on the gel. Then the solution was 74 
fold concentrated and loaded on SDS-PAGE (Figure 3.40). 
 
Figure 3.40 : Coomassie staining of concentrated soluble Lig7 and Lig7-GBP, Lane 
1; Ladder, Thermo scientific, Cat.No. 26619, Lane 2; empty, Lane 3; 
Lig7-GBP, Lane 4; Lig7 scFv. 
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After the concentration process, soluble Lig7 and Lig7 GBP bands were visible on 
SDS-PAGE.  A part of the remaining soluble recombinant antibodies was dialyzed 
against TAGZyme buffer but presipitation occurred again. Therefore, the remaining 
solution was used for His-tag removal, as it is. The pH of the DB containing the  
recombinant proteins was brought to pH6.0-7.0, the optimum pH value for the 
DAPase enzyme according to the manufacturer instructions (TAGZyme handbook, 
Qiagen). Then His-tag digestion was initiated and aliquots were taken after 15, 30 
and 45 minutes. The digestions were controlled on SDS-PAGE (Figure 3.41). 
 
Figure 3.41 : Coomassie staining of DAPase digestion products, 1; Ladder, Thermo 
scientific, Cat.No. 26619, Lane 2; Lig7 scFv, Digestion time: Lane 3; 
15 min, Lane 4; 30 min, Lane 5; 45 min, Lane 6; Lig7-GBP, Digestion 
time: Lane 7; 15 min, Lane 8; 30 min, Lane 9; 45 min, Lane 10; 
DAPase enzyme. 
Unfortunately, not any digestion products were observed with the Coomassie 
staining. This is probably because of the very high sensitivity of DAPase enzyme to 
its environment and a very narrow optimum pH value. Therefore, the use of DB 
buffer instead of the TAGzyme buffer even if the composition was similar was not 
sufficient to provide the optimum environment to the enzyme or maybe the enzyme 
itself was not properly working.  
The cause of stability of the recombinant antibodies was researched, because Lig7 
scFv was expressed and easily purified from the periplasmic region of the HB2151 
E.coli strain by using the pDUCK1 phagemid vector. But the His-Tag present on 
Lig7 scFv expressed from pDUCK1 was at the C-terminal of the scFv. In contrary 
because of the TAGZyme system requirement the His-tag was fused at the N-
terminal  of Lig7 scFv which might have unstabilized the scFv. 
Even if the His-tag was not been able to cut from the recombinant antibodies. Their 
use as biosensing probe was tested. 
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3.3 The use of the recombinant antibodies as a biosensing probe 
3.3.1 Binding studies using Surface Plasmon Resonance spectroscopy 
HBV infects human hepatocytes. HBV infection results in the release of infectious 
virions and excessive hepatitis B surface antigens (HBsAg) from host cells to the 
blood-stream. Therefore, the presence of HBsAg in circulating blood is an indicator 
of HBV infection. ELISA kits are widely used throughout the world to detect 
HBsAg, but it takes approximately 3 hours to have the results and labeled antibodies 
are necessary with these systems. Therefore, the development of new fast diagnosis 
systems are of great interest. Surface plasmon resonance spectroscopy is a method 
allowing a label-free, real-time monitoring of protein-protein interactions (Gopinath 
et al., 2014; J. Homola, 2008; Ladd, Taylor, Piliarik, Homola, & Jiang, 2009). This 
method can be used as diagnostic is also faster compared to ELISA. With all these 
advantages, this method has great potential to be the successor of ELISA-based 
diagnostic methods.  
For the purpose of developing a new biosensor system, the gold binding anti-HBsAg 
recombinant antibody was tested as a biosensing probe on the SPR instrument. The 
binding of the bifunctional antibodies to gold coated sensor chip was monitored at 
various antibody concentrations (0.2 µM, 0.3 µM, 0.4 µM and 0.6 µM) with the 
Reichert SPR instrument. The measurements for all three antibodies were analyzed 
with BIAevaluation Software 4.1 (Biacore) and plotted on graphs (Figure 3.42, 
Figure 3.43 and 3.44).  
 
Figure 3.42 : SPR binding sensograms of Lig7-GBP on gold coated sensor chip. 
Cyan; 0.4 µM, Green; 0.3 µM, Purple; 0.2 µM. 
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Figure 3.43 : SPR binding sensorgrams of Lig7-3GBP on gold coated sensor chip. 
Dark Blue; 0.6 µM, Cyan; 0.4 µM, Green; 0.3 µM, Purple; 0.2 µM. 
 
Figure 3.44 : SPR binding sensorgrams of Lig7-5GBP on gold coated sensor chip. 
Dark Blue; 0.6 µM, Cyan; 0.4 µM, Green; 0.3 µM, Purple; 0.2 µM. 
The sensograms show that all the bifunctional antibodies were adsorption to the gold 
coated SPR sensor chip. But also a strong desorption is observed for higher 
concentration. This desorption might be due to the presence of misfolded or unfolded 
antibodies generated during the antibody purification and refolding step. The 
refractive index unit of the uptake (the maximum µRIU observed during the loading 
of the antibodies) and the adsorption (the lower µRIU observed after the washing of 
the antibody loaded sensor chip) were deduced from the sensograms as indicated in 
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Figure 3.45. The uptake and adsorption values are given in Figure 3.46 and Figure 
3.47. 
 
Figure 3.45 : Figure describing the uptake and the adsorption values of the 
bifunctional antibodies flown on the gold-coated SPR sensor chip. 
 
Figure 3.46 : The uptake of the fusion recombinant antibodies on gold coated SPR 
sensor chip in refractive index unit. 
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Figure 3.47 : The adsorption of the fusion recombinant antibodies on gold coated 
SPR sensor chip in refractive index unit. 
The uptake and the adsorption values obtained from the SPR sensograms show that 
these values are dependent on the antibody concentration. The higher is the 
concentration, the higher is the uptake and the adsorption value. The μRIU ratio 
calculated between 0.2 µM and 0.6 µM for each bifunctional antibody is varying 
from 2.21 to 3.17 for the uptake and from 2.1 to 3.12 for the adsorption was observed 
(Table 3.4). These results show that the μRIU ratio, for 0.6µM/0.2µM antibody ratio, 
between the uptake and the adsorption is conserved. Therefore, the amount of 
antibody adsorbed on the surface of the sensor chip is proportional to the antibody 
flown over the chip. This correlation was expected, and these results showed that the 
sensor chip was still not fully covered with the antibodies at 0.6 µM concentration.  
Since the concentration ratio between 0.2 µM and 0.6 µM is 3 and uptake and 
adsorption ratio of 3 was expected, in the case of the sensor chip not fully covered. 
But the results in Table 3.4 shows that even if the uptake and the adsorption ratios for 
Lig7-GBP are close to 3, the uptake and adsorption ratios are lower than 3 for Lig7-
3GBP and Lig7-5GBP. These results indicate that the higher is the size of the 
antibody flow over the sensor chip the lower is the adsorption rate.One effect for 
such result might be due to the molecular weight increase, as with the increased 
molecule size,  the steric hindrance effect might be increasing. This may result in 
adsorption of fewer antibody on the sensor chip surface. 
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Table 3.4 : The μRIU ratio between 0.2 µM and 0.6 µM antibody concentrations 
(0.6µM/0.2µM) for the uptake and the adsorption. 
 Uptake ratio Adsorption ratio 
Lig7-GBP 3,17 3,12 
Lig7-3GBP 2,78 2,94 
Lig7-5GBP 2,21 2,10 
 
The SPR sensograms showed that the bifunctional antibodies were adsorbed on the 
surface of the gold coated SPR sensor chip. The next step was to control if the 
HBsAg was able to bind to the bifunctional antibodies adsorbed on the sensor chip. 
For this purpose 0.3µM of recombinant antibodies were flown on the sensor chip 
then the chip was washed with PBS (3.2 mM Na2HPO4 × 2H2O, 1.4 mM KH2PO4, 
2.7 mM KCl and 137 mM NaCl). Once the RIU signal became stabilized, HBsAg at 
different concentrations (100 nM, 150 nM and 200 nM) was flown over the chip and 
the binding profile of HBsAg to the bifunctional antibodies  was monitored (Figure 
3.48 and 3.49).  
 
Figure 3.48 : SPR sensorgram of Lig7-GBP (0.3µM) adsorption on the sensor chip 
and the binding of HBsAg binding to Lig7-5GBP.  
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Figure 3.49 : SPR sensorgram of HBsAg binding to Lig7-5GBP adsorbed on the 
sensor chip. The bifunctional Lig7-5GBP at 0.3µM concentration was 
adsorbed on the SPR sensor chip. Three different HBsAg concentration 
was flown over the sensor chip (Blue color; 200 nM, Green color; 150 
nM, Purple color; 100 nM). 
The HBsAg binding SPR sensograms showed that HBsAg was successfully binding 
to the bifunctional antibodies. The sensograms also showed  a very low desorption of 
HBsAg indicating that HBsAg was strongly bound to the antibodies. These results 
demonstrated that the gold binding bifunctional antibodies developed in this work 
were indeed potential biosensing probes.  
The affinity measurements (association rate constant (ka, on), dissociation rate 
constant (kd, off) and equilibrium dissociation constant  KD) of the bifunctional 
antibodies to gold surface and to HBsAg were deduced from the SPR sensograms by 
using BIOevaluation 4.1 software from BIACORE. The calculated ka, kd and KD 
values are indicated in Table 3.5. 
Table 3.5 : Affinity calculations of the bifunctional antibodies. 
Bifunctional antibody ka (M-1s-1) kd (s-1) KD (M) KD 
Lig7-GBP/Gold 1.96 E04 9.03 E-03 4.61 E-07 0.46 µM 
Lig7-3GBP/Gold 1.84 E04 4.31 E-03 2.34 E-07 0.23 µM 
Lig7-5GBP/Gold 1.77 E04 3.46 E-03 1.95 E-07 0.19 µM 
     
Lig7-GBP/HBsAg 7.58 E03 2.39 E-03 3.15 E-07 315 nM 
Lig7-3GBP/HBsAg 4.23 E04 1.29 E-03 3.05 E-08 30 nM 
Lig7-5GBP/HBsAg 1.21 E04 8.01 E-06 6.62 E-10 0.6 nM 
 
According to the SPR based affinity calculations, similar association rate was 
observed for the binding of Lig7-GBP, Lig7-3GBP and Lig7-5GBP to the gold 
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surface. But a higher dissociation rate was observed for Lig7-GBP compared to 
Lig7-3GBP and Lig7-5GBP. Therefore, even if the bifunctional antibodies are 
binding to gold at the same rate, Lig7-GBP dissociates at a higher rate compared to 
the two other antibodies. The equilibrium dissociation constants (KD) show that all 
the bifunctional antibodies have the same affinity to gold at µM range slightly. When 
compared with each other, Lig7-5GBP shows the highest and Lig7-GBP the lowest 
affinity to gold. This difference might be observed because of the higher copy 
number of GBP1  within the recombinant antibody consequently the interaction of 
Lig7-5GBP with a gold surface might be stronger. These results are consistent with 
the results of Tamerler’s group on the characterisation of synthesized 3GBP (Seker, 
2009; Tamerler, 2006; Tamerler, 2006). Tamerler’s group has calculated the Keq 
value of  3GBP with plain gold surface as ~10
7
M-1 (KD of ~10-7M) and the binding 
energy as ~-8.0kcal/mol. The similar equilibrium dissociation constant values 
obtained for each bifunctional antibodies shows that the fusion of the scFv didn’t 
affect the adsorption of GBP to the gold surface.The potential use of the bifunctional 
antibodies as biosensing probe was tested by monitoring the binding of HBsAg to the 
bifunctional antibodies adsorbed on the gold-coated SPR sensor chip. The 
equilibrium dissociation constant KD varied from 3.15 E-07 M for Lig7-GBP to 6.62 
E-10 M for Lig7-5GBP with a KD of 3.05 E-08 M for Lig7-3GBP. These results 
indicate that even if the number of GBP1 repeats has not a very significant effect on 
the adsorption of the bifunctional antibody, it seems that it has a great influence on 
the binding of HBsAg to the Lig7 scFv. The higher is the number of repeats the 
better is the binding of HBsAg to Lig7 scFv. Because Lig7 is the same for all the 
fusion construct the only possible explanation is that the higher is the repeats 
number, the better is the conformation of the recombinant antibody or the 
accessibility to its antigen. These results might also be interpreted such that the 
GBP1 repeats might act as a linker between the scFv and the GBP1 and/or the 
repeats immobilized on the gold surface favoriting the optimal conformation of the 
Lig7 scFv.  
Kacar (2009) have developed alkaline phosphatase (AP) with N-terminally fused 
multiple tandem repeats (n=5, 6, 7 and 9) of GBP1. These gold binding AP fusion 
molecules were immobilized on the gold surface by adsorption. In that work it was 
shown that the best AP activity with the highest gold binding ability was obtained 
with the 5GBP-AP fusion protein and the equilibrium dissociation constant  of 
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5GBP-AP on bare Au gold surface  was determined as ~6 nM (Kacar, 2009) . These 
findings showed that high repeats number (more than 6 repeats)  of GBP1 might also 
have a negative effect on the fusion-protein functions caused by a steric effect 
generated by the large number of GBP1 repeats. Taken together, all these data show 
that a gold binding protein fusion construct comprising 5 repeats of GBP1 might be 
the most appropriate repeats number for an optimal adsorption to gold and a better 
conformation of the fused protein.  
Lig7 was also chemically immobilized on gold coated sensor chip. The affinity of 
chemically immobilized Lig7 was calculated by flowing various concentrations of 
HBsAg (50, 100 and 200 nM) on the sensor chip. According to the SPR 
measurements, an affinity constant (KD) of 31.4 ± 21.4 nM was determined for the 
binding of HBsAg to the Lig7 scFv. This KD value is 10 times lower than the Lig7 
GBP KD value in consequence HBsAg is binding with better affinity to chemically 
immobilized Lig7 than Lig7-GBP adsorbed on the sensor chip. This result 
straightens the hypothesis that one GBP1 copy is not sufficient to bind to the gold 
surface and to maintain the conformation for the fused Lig7 scFv. In the case of 
Lig7-3GBP fusion construct compared with chemically immobilized Lig7, the KD 
values are similar, ~30 nM for Lig7-3GBP and ~31 nM for chemically immobilized 
Lig7. But a 50 times lower KD was observed for Lig7-5GBP compared to 
chemically immobilized Lig7 for HBsAg binding. Therefore, it seems that HBsAg is 
more accessible to the Lig7 immobilized on the gold surface via the 5 repeats of gold 
binding peptide than the chemically immobilized Lig7 scFv. 
These results demonstrate that the gold binding bifunctional Lig7 scFv recombinant 
antibody is adsorbed on plain gold surface and that the number of GPB1 copy does 
not excessively influence the binding affinity of the construct to gold. In contrary the 
number of GBP1 copy number has a great influence on presenting the recombinant 
antibody on the surface of the gold coated sensor chip in the way of favorising the 
conformation of the scFv as the GBP1 copy number increases.  
All these finding are consolidating the hypothesis that the gold binding bifunctional 
recombinant antibody is immobilized on the surface of plain gold coated sensor chip 
allowing the correct orientation of the scFv on the sensor chip. In consequence, this 
construct increases the accessibility of HBsAg to the scFv. Therefore, this self-
assembled  bifunctional antibody allows a more accurate label-free biosensing  probe 
compared to chemically immobilized antibody-based biosensing devices.  
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3.3.2 Monitoring HBsAg in in-vitro model 
In the aim of monitoring HBsAg in mammalian cells. First HBsAg encoding gene 
was cloned into a mammalian expression vector pCEP4. Then the vector was used 
for transfection of 4 different mammalian cells lines (HeLa, Hek293 Trex, HepG2 
and COS7). One week later the culture medium were collected, and the presence of 
HBsAg was checked by ELISA (Figure 3.50).  
 
Figure 3.50 : ELISA results of HBsAg for culture medium of different mammalian 
cells after transfection. 
ELISA results showed that all the transfected cell lines were expressing HBsAg, but 
COS7 cells were expressing the least with an OD405 value of 0.143. THe ELISA 
results show that HeLa and Hek293 Trex cells were expressing the best with an 
OD405 value of 2.894 and 2.567, respectively. Because HeLa cells were expressing 
the best, this cell line was selected for further experiments. 
Once the HBsAg expression in mammalian cells was confirmed a new transfection 
was done into HeLa cells grown on sterile coverslips. Twenty-four hours after 
transfection the growth medium was replaced with fresh medium containing 200 µg 
Hygromycin B. Then previously expressed Lig7 scFv, mcherry (fluorescent protein) 
or Lig7-mcherry fusion construct were added to the wells and cells were incubated 
for 24 hours. The cells were then fixed with methanol, and the nuclei were stained 
with Hoechst dye. The cell preparations were observed under fluorescence 
microscope (Figure 3.51 and 3.52). 
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Figure 3.51 : Fluorescence microscope images (10X) of HeLa cells transfected with 
HBsAg-pCEP4 vector. A; Bright Field, B; A4 filter, C; RFP filter.  
 
Figure 3.52 : Fluorescenct microscope images (40X) of HeLa cells transfected with 
HBsAg-pCEP4 vector. A; Bright Field, B; A4 filter, C; RFP filter. 
The fluorescence microscopy analysis of the transfected HeLa cells incubated with 
either Lig7 scFv or mcherry proteins resulted with no fluorescence signal as 
expected. But the accumulation of the Lig7-mcherry fluorescent recombinant  
antibodies was observed as spots on the surface of some cells (Figure 3.51 and 3.52). 
These results showed that HBsAg expressed from HeLa cells were able to be 
monitored with the Lig7 scFv fused with the fluorescent protein mcherry. These 
results are indicating that the monitoring of HBsAg expression by using the 
bifunctional gold binding recombinant antibodies is a possible issue. 
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4.  CONCLUSIONS AND RECOMMENDATIONS  
The detection of target molecule by using biological sensing probes is well adapted 
over the last decades for medical, military, food and  environmental applications. 
Antibodies,i.e. the main biosensing probes, are widely used due to their high and 
specific affinity to the target molecules. Researches therefore have been mainly 
focused on either the development of antibodies with better or more specific binding 
ability or the development of novel ultrasensitive, reliable and cost effective devices. 
The constant progress in technology leads to the development of new devices but 
brings also high competition between technological companies.  
Regarding the antibody part, the development of new antibodies with higher affinity 
and specificity than the ones already in the market, becomes more and more difficult. 
One of the major area left unsloved needs a high attention and get placed under 
emergent technologies. The coupling methodology of the antibodies on surfaces 
relies on mainly carbodiimide chemistry, which is a chemical coupling method 
focused on amino- or carboxyl- groups present on the proteins. Even if this coupling 
system has great advantages such as covalently coupling antibodies to sensor 
surfaces hence limiting the antibody leakage as well as the chemicals used might 
modify the structure of the antibodies. Moreover, such coupling would lead to 
unoriented coupling of the antibodies.  Because several amino- or carboxy- groups  
might be present on the antibodies, especially at the recognition sites, non specific 
covalent bonds might be generated at the time of coupling, between the antibody 
binding sites and the sensor surface leading to unfunctional antibodies. 
The recombinant antibody technology has allowed to modify amino acid 
composition in the intention of developing self-assembled oriented antibodies by 
adding a cysteine amino acid at the C-terminal end of the antibody heavy chains 
thereby allowing a coupling between SH groups from the antibody and the ones 
coated on the sensor surface (Sukhanova, 2012). Other strategies were also 
successfully done by direct EDC/NHS cross-linking proteins such as protein A or 
protein G with antibody binding ability to the biosensor chip. Or by linking the 
114 
protein G to a single strand DNA and allowing the hybridization with the 
complementary single strand DNA immobilized on the sensor chip (Wang, 2003; 
Song, 2011; Jung, 2011; Lee, 2011) . Even if these methods were successful 
orienting antibodies, they still needed chemical cross-linking steps for immobilizing 
either the proteins A/G or the DNA.  
This thesis provides a new strategy for developing oriented antibody immobilization 
using biological self-assembly approach on SPR chip for biosensor applications. This 
approach offers unique strength to control the orientation of the antibody while using 
a single step surface functionalization under bio-friendly environment without harsh 
chemicals. For this purpose a well characterized Gold binding peptide (GBP-1) by 
Prof. Dr. Candan Tamerler’s group was selected to be used as molecular linker 
between the antibody and the gold coated sensor chip. The GBP-1 peptide has been 
demonstrated  to show its gold binding and assembly property in several studies done 
by the same group or others groups. Up to know GBP-1 was genetically fused with 
alkaline phosphatase enzyme, Huntingtin protein related to Huntington disease and 
the DNA binding protein TraI,  avian influenza surface antigen or a kinase substrate 
(Sedlak, 2010, Kacar, 2009) .However, in designing single biomolecules having 
multifunctional domains, the expected functions might not be present or lost due to 
structural interferences.  
We selected a model antibody having a single chain variable fragment recombinant 
antibody against Hepatitis B virus surface antigen. Hepatitis B virus (HBV) is one of 
the major causes of chronic Hepatitis, cirrhosis and liver cancer (hepatocellular 
carcinoma, HCC). Furthermore an excessive amount of hepatitis B surface antigens 
(HBsAg) is secreted from HBV-infected host cells to the blood-stream, potentially 
making from it a good HBV infection marker for biosensor applications. 
 In this thesis, first an anti-HBsAg scFv was developed by using phage display 
technology. Within the scope of the thesis, a  new cost effective mouse immunization 
procedure was tried out by infecting mice with HBsAg displaying phages. The 
successful immune response obtained with this strategy was published in “Advances 
in bioscience and Biotechnology” journal at the very beginning of year 2014. Then a 
scFv library was constructed from the mRNA encoding antibody light and heavy 
chains and screened against HBsAg in the intention of selecting anti-HBsAg scFvs. 
Several antibodies were selected, but none of them was as good as the previously 
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developed anti-HBsAg Lig7 recombinant antibody. Owing to its better HBsAg 
binding ability, Lig7 scFv was chosen for the further development of the gold 
binding bifunctional recombinant antibody.  
Once the anti-HBsAg Lig7 scFv was selected for further studies. The lig7 scFv 
encoding gene was cloned into the pQE2 expression vector. Then GBP1 encoding 
region was genetically fused with the Lig7 scFv encoding gene. After cloning 
expereiments, three different clones, each containing different repeat number of 
GBP-1 (GBP, 3rGBP and 5r GBP), confirmed by DNA sequence analysis,  were 
obtained and each clone were subjected to protein expression. The SDS-PAGE and 
western blot studies confirmed the successful expression of all the three bifunctional 
antibodies. 
Unfortunately, the expression products were present as inclusion bodies, therefore, 
several extra purification steps were necessary causing a decrease in the functional 
antiobdy yield during the purification steps. Thus, inclusion bodies were solubilized 
then affinity purified with Cobalt affinity columns. The purified recombinant 
antibodies were refolded and used for SPR experiments. The adsorption of the 
antibodies on gold coated sensor chip and the bindnig of HBsAg to the antibodies 
were monitored in real-time. According to the SPR sensograms, the calculated 
equilibrium dissociation constants (KD) show that all the bifunctional antibodies have 
slightly the same affinity with Lig7-5GBP showing the highest and Lig7-GBP 
showing the lowest affinity to gold. When looked at the binding of HBsAg to the 
immobilized recomninant bifunctional antibodies significant changes in the 
equilibrium dissociation constant was observed. The binding of HBsAg to antibodies 
was increasing with the number of GBP-1 peptide repeats to reach a KD of 6.62 E-10 
M for Lig7-5GBP which is also 50 times lower than the affinity of chemically cross-
linked Lig7 to HBsAg.  
Two similar works were published during the thesis, in both studies recombinant 
antibodies were genetically fused  with the GBP-1 peptide. The first group developed 
a bifunctional recombinant antibody comprising of a heavy chain variable  region of 
the human anti-gold antibody as gold immobilizing molecule fused with either scFv 
or variable heavy chain antibodies specific to hen egg lysozyme, prostate specific 
antigen, human chorionic gonadotropin or tumor necrosis factor-R (Ibii, 2010). The 
group has shown as we have done, that using gold binding protein structures fused 
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with antibody were increasing the binding efficiency of the immobilized antibodies 
with its antigen. The group has also measured the gold binding ability of one of their 
antibodies when the antibody was fused with GBP-1 and its repeats (3GBP and 
7GBP). According to their results both three GBP1 based recombinant antibodies 
were binding at lower affinity compared to their gold binding sensor probes. But no 
studies were done with 5GBP which, according to our and Dr. Kacar’s studies, is the 
strongest gold binder (Kacar, 2009). And also no further studies regarding the 
binding ability of the antibody to its antigen were done. 
In the literature, one of the study is similar to our research approach. However, this  
work was based on the genetic fusion of an anti-HBsag scFv fused with a single copy 
of GBP-1 (Zheng, 2010). Interestingly, the use of a gold binding bifunctional 
recombinant antibody as a biosensing probe was also confirmed. But no comparative 
work with different GBP-1 repeats were done and no affinity values were given in 
the publication. 
The results obtained from this work were in correlation with ibii’s and Zheng’s 
publications regarding the great potential of using genetically fused gold binding 
bifunctional antibodies as self-assembled and oriented biosensing probes for the 
detection of disease related proteins.  
The results obtained from this thesis are the first quantitative characterization werre 
completed, i.e. equilibrium dissociation constant data obtained for the binding of an 
anti-HBsAg scFv fused with GBP-1, 3GBP or 5GBP. 
Future directions 
The rapid development of nanotechnology has allowed the generation of 
nanoparticles with various shape and composition. These nanoparticles are currently 
being studied to be utilized in cancer diagnosis and therapy (Agarwal, 2008; Katz, 
2004a). Gold nanoparticles have great advantages compared to other nanoparticles. 
First gold nanoparticles are easy to produce at the determined size and shape; they 
have no toxic effect on cells and they can be coated easily with biomolecules such as 
proteins and DNA. Gold nanoparticles have also great physical properties, which 
make it suitable for imaging systems; gold has light scattering and Plasmon 
resonance properties.  
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Because of these properties, gold nanoparticles are extensively studied for the 
detection of different cell types by combining these particles with detecting agents 
such as antibodies, recombinant antibodies or peptides (El-Sayed, 2005; Katz, 2004b; 
Tkachenko, 2005). Recently, antibody conjugated gold nanoparticles have been used 
for the cancer therapy. Cancer cell targeted gold nanoparticles were heated with 
Infrared laser or radio frequency until the destruction of cancer cells (Gannon, 2008; 
Huang, 2008). According to our knowledge, no study is done regarding targeted in-
vivo diagnostic systems by using self assembled oriented bifunctional recombinant 
antibodies. Therefore, the use of the recombinant antibodies developed during this 
thesis for the development of a new in-vivo imaging or therapeutic systems based on 
gold nanoparticles is intended. For this purpose cell lines such as HeLa and Hek293 
expressing HBsAg, were already developed during the thesis. 
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APPENDIX A: Primer list. 
 
 
HBsAg Forward_SfiI:  
5’-ACTCGCGGCCCAGCCGGCCATGGAGAACATCACATCAGG-3’ 
HBsAg Reverse_NotI:  
5’-CATTCTGCGGCCGCTTTGTTTTGTTAGGGTTTAA-3’ 
HBsAg Forward_BamHI:  
5’-ACTCGCGGATCCATGGAGAACATCACATCAGG-3’ 
HBsAg Reverse_BamHI:  
5’-CATTCTGGATCCTTTGTTTTGTTAGGGTTTAA-3’ 
Light chain primers: 
TUB 703: 5’-TATCGAGCTCACCCAGTCTCCA- 3’ 
TUB 704: 5’- GTTTTATTTCCAACTTTGTCCC- 3’ 
Heavy chain primers: 
TUB 701: 5’- GTGACCGTGGTCCCTTGGCCCC- 3’ 
TUB702: 5’- AGGTGCAGCTGCAGCAGTCAGG- 3’ 
TUB 422: 5’- GGGACCACGGTCACCGTCTCCTCA-3’ 
TUB 423: 5’- TGGAGACTGAGTGAGCTCGATGTC-3’ 
Lig7 scFv primers: 
Lig7_Forw_Ndeİ: 5’- 
TCGCCATATGCAGGCCCAGGTGCAGCTGCAGGAGTCAGG- 3’ 
Lig7RevNotI: 5’- GAGTCATTCTGCGGCCGCCCGTTTGATTTCCAGCTTGG- 3’ 
GBP primers: 
GBP1_Not_F: 5’- CTTAAGCGGCCGCATGCATGGAAAAACTCAGGC- 3’ 
GBP1_HindIII_R:5’- CTTAAAAGCTTGCTCTGGATAGTCCCGCTG- 3’   
3GBP_forward: 5’- GGATCCATGCATGGA-3’   
3GBP_reverse: 5’- TTAGAATTCGCTCTGG-3’ 
3GBP_forward_NotI_with tail: 5’-
ATTCAGGCGGCCGCGGGATCCATGCATGGA-3’ 
3GBP_reverse_HindIII_ with tail: 5’- 
CCATATAAGCTTTTAGAATTCGCTCTGG-3’    
 
Sequencing primers 
pDrive vector-specific sequencing primers: 
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M13 Reverse: 5’ -AACAGCTATGACCATG- 3’ 
Sp6 promotor: 5’ – CATTTAGGTGACACTATAG-3’ 
T7 promotor: 5’-GTAATACGACTCACTATAG-3’ 
PQE2 vector specific sequencing primers: 
PQE promotor:  5’- CCCGAAAAGTGCCACCTG -3’ 
PQE reverse: 5’- GTTCTGAGGTCATTACTGG-3’ 
pCANTAB5E_specific sequencing primers: 
pCANTAB5E_sequencing forward primer: 5’-TATGACCATGATTACGCCAAG-3’ 
pCANTAB5E_sequencing forward primer: 5’- TTTTGTCGTCTTTCCAGACGTT-
3’ 
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APPENDIX B: pCANTAB5E vector. 
 
 
Figure A.1 : pCANTAB5E vector.   
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APPENDIX C: pQE2 expression vector. 
 
Figure A.2 : pQE2 expression vector (TAGzyme handbook, Qiagen). 
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APPENDIX D: Low Range DNA Ladder. 
 
Figure A.3 : MassRuler Low Range, DNA Ladder, ready-to-use, SM0383, Thermo 
Scientific. 
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APPENDIX E: High Range DNA Ladder. 
 
 
Figure A.4 : MassRuler DNA Ladder, High Range, ready-to-use, SM0393, 
Fermentas. 
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APPENDIX F: Prestained Protein Ladder. 
 
 
Figure A.5 : PageRulerTM Plus Prestained Protein Ladder, SM1811, Fermentas. 
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